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Background: Obesity in pregnancy is associated with insulin resistance, which underpins many common
complications including gestational diabetes mellitus (GDM) and fetal macrosomia.
Objectives: To assess the effect of a complex behavioural intervention based on diet and physical activity
(PA) on the risk of GDM and delivery of a large-for-gestational age (LGA) infant.
Design: Three phases: (1) the development phase, (2) the pilot study and (3) a multicentre randomised
controlled trial (RCT) comparing a behavioural intervention to improve glycaemic control with standard
antenatal care in obese pregnant women. A cost–utility analysis was undertaken to estimate the
cost-effectiveness of the health training (intervention) over and above standard care (control).
Setting: Pilot study: antenatal clinics in four inner-city UK hospitals. RCT: eight antenatal clinics in eight UK
inner-city hospitals.
Participants: Women were eligible for inclusion if they had a body mass index of ≥ 30 kg/m2, were
pregnant with a single fetus and at 15+0 to 18+6 weeks’ gestation, were able to give written informed
consent and were without predefined disorders.
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Intervention: The intervention comprised an initial session with a health trainer, followed by eight
weekly sessions. Dietary advice recommended foods with a low dietary glycaemic index, avoidance of
sugar-sweetened beverages and reduced saturated fats. Women were encouraged to increase daily PA.
Main outcome measures: Development phase: intervention development, acceptability and optimal
approach for delivery. Pilot study: change in dietary and PA behaviours at 28 weeks’ gestation. RCT: the
primary outcome of the RCT was, for the mother, GDM [as measured by the International Association of
the Diabetes and Pregnancy Study Groups (IADPSG)’s diagnostic criteria] and, for the infant, LGA delivery
(i.e. customised birthweight ≥ 90th centile for gestational age).
Results: Development phase: following a literature meta-analysis, a study of dietary intention questionnaires
and semistructured interviews, an intervention based on behavioural science was developed that incorporated
optimal and acceptable methods for delivery. Pilot study: the pilot study demonstrated improvement in
dietary behaviours in the intervention compared with the standard care arm but no increase in objectively
measured PA. Process evaluation demonstrated feasibility and general acceptability. RCT: the RCT showed
no effect of the intervention on GDM in obese pregnant women or the number of deliveries of LGA infants.
There was a reduction in dietary glycaemic load (GL) and reduced saturated fat intake, an increase in PA
and a modest reduction in gestational weight gain, all secondary outcomes. Lower than expected was the
number of LGA infant deliveries in all women, which suggested that universal screening for GDM with
IADPSG’s diagnostic criteria, and subsequent treatment, may reduce the number of deliveries of LGA infants.
According to the cost–utility analysis, the estimated probability that the UK Pregnancies Better Eating and
Activity Trial (UPBEAT) behavioural intervention is cost-effective at the £30,000/quality-adjusted life-year
willingness-to-pay threshold was 1%.
Limitations: Included the high refusal rate for participation and self-reported assessment of diet and PA.
Conclusions: The UPBEAT intervention, an intense theoretically based intervention in obese pregnant
women, did not reduce the risk of GDM in women or the number of LGA infant deliveries, despite
successfully reducing the dietary GL. Based on total cost to the NHS provider and health gains, the UPBEAT
intervention provided no supporting evidence to suggest that the intervention represents value for money
based on the National Institute for Health and Care Excellence benchmarks for cost-effectiveness.
Future work: Alternative strategies for reducing the risk of GDM in obese pregnant women and the
number of LGA infant deliveries should be considered, including development of clinically effective
interventions to prevent obesity in women of reproductive age, of clinically effective interventions to
reduce weight retention following pregnancy and of risk stratification tools in early pregnancy.
Trial registration: Current Controlled Trials ISRCTN89971375 and UK Clinical Research Network
Portfolio 5035.
Funding: This project was funded by the NIHR Programme Grant for Applied Research programme and
will be published in full in Programme Grants for Applied Research, Vol. 5, No. 10. See the NIHR journals
library website for further project information. Contributions to funding were also provided by the Chief
Scientist Office CZB/4/680, Scottish Government Health Directorates, Edinburgh; Guys and St Thomas’
Charity, Tommy’s Charity (Lucilla Poston, Annette L Briley, Paul T Seed) and the NIHR Biomedical Research
Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, UK and the Academy
of Finland, Finland. Keith M Godfrey was supported by the National Institute for Health Research through
the NIHR Southampton Biomedical Research Centre. Lucilla Poston and Keith M Godfrey were supported
by the European Union’s Seventh Framework Programme (FP7/2007-2013), project EarlyNutrition under
grant agreement number 289346.
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Plain English summary
One in five UK women of childbearing age is obese. Obese women are more likely to have problems inpregnancy, including gestational diabetes mellitus (GDM), and their babies often grow too large,
leading to complications during labour and delivery. A way to prevent these problems may be for women
to change their diet and to take more exercise. Helped by women who were pregnant and obese, we
developed an individually tailored ‘lifestyle’ programme [the UK Pregnancies Better Eating and Activity Trial
(UPBEAT) intervention]. The advice was aimed at preventing GDM and stopping babies growing too large
by encouraging woment to make specific changes to their diet and taking more physical activity (PA), as
opposed to focusing on reducing pregnancy weight gain, as other studies have done. In a small ‘pilot’
study the programme helped to change the women’s diet but was not very effective in changing PA.
We then tested the programme in 1555 obese pregnant women from UK cities. Half took part in the
programme on top of normal pregnancy care over an 8-week period, and the other half had normal
pregnancy care. All were tested for GDM. Although there was considerable improvement in diet, GDM
was not reduced and there was no benefit in terms of reduced NHS costs. There were fewer large babies
than we expected; this may be because everyone had a diabetes mellitus test and were appropriately
treated if they had developed diabetes mellitus. We conclude that the UPBEAT programme, which was
more intense than previous lifestyle programmes, did not prevent GDM in obese pregnant women or
large-for-gestational-age infants and that other strategies may be more effective.
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Scientific summary
Background
The increasing prevalence of obesity in UK women of reproductive age has implications for obstetric
practice. Obesity in pregnancy is associated with, among other things, heightened risk of gestational
diabetes mellitus (GDM), pre-eclampsia, thromboembolism, dysfunctional labour, delivery by caesarean
section, postcaesarean wound infection and postpartum haemorrhage and lower rates of breastfeeding.
Pregnancy in all women leads to a degree of insulin resistance, which is exaggerated in obese women, in
whom aberrant glucose homeostasis may lead to GDM. Maternal glycaemia, through stimulation of fetal
hyperinsulinaemia, leads to fetal macrosomia even in mothers who are not overtly diabetic, leading to an
increased risk of stillbirth and complications at the time of delivery. The high rates of caesarean section,
increased hospital admissions, greater length of stay and neonatal intensive care are associated with
substantive NHS costs. There is no evidence-based intervention that improves pregnancy outcome in obese
pregnant women. Considerable effort has been directed towards prevention of gestational weight gain
(GWG) through ‘healthy’ dietary advice, but none has been shown to prevent adverse outcomes. The
hypothesis addressed in this study was that a behavioural intervention that focused on reducing maternal
insulin resistance rather than weight gain would lead to prevention of GDM, and that this would reduce
the risk of large-for-gestational-age (LGA) infant deliveries, thereby offering an alternative strategy to
limitation of GWG. The strategy was to use established behavioural change principles adapted for use in
pregnancy to deliver a complex intervention comprising recommendations for a low-glycaemic index diet,
reduced saturated fat intake and increased physical activity (PA), all of which have been associated with
improved insulin sensitivity.
Objectives
The aim of this research programme was to develop, pilot and test in a randomised controlled trial (RCT) a
novel behavioural (diet and PA) intervention in obese pregnant women. The main objectives were:
1. to determine in a development phase, following a review of the relevant literature, the best approach
and delivery for the proposed intervention, develop and standardise the content and delivery method
and assess feasibility and acceptability to women and providers with a view to optimising the
intervention for use in a pilot trial.
2. to undertake a pilot trial to establish the efficacy of the intervention in changing dietary and PA
behaviours, and to evaluate all practical aspects of delivering the intervention.
3. to undertake a RCT to determine whether or not the intervention reduces the risk of GDM in obese
pregnant women and the number of LGA infant deliveries.
Methods
The complex intervention was evaluated in accord with the UK Medical Research Council Framework for the
development and evaluation of complex interventions, delineated by three phases as described in Objectives.
As interventions can be informed by understanding the intentions of pregnant women to change dietary
behaviours a questionnaire-based study was undertaken in 103 pregnant women to appraise their intentions
or perceived barriers to changing their diet in pregnancy to include the foods targeted by the UK Pregnancies
Better Eating and Activity Trial (UPBEAT) intervention. A study was also performed to assess whether or not
pedometers could provide an inexpensive assessment of PA for women in the pilot and main RCT to enable
determination of the effect of the intervention on PA. A multidisciplinary team of a social scientist, a
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psychologist, nutritionists, a physiologist, an obstetrician and a senior midwife developed the intervention,
which was delivered by a health trainer (HT). The UPBEAT intervention comprised an initial one-to-one session
followed by eight weekly sessions delivered in groups or individually, and was informed by psychological
models of health behaviour including control theory and social cognitive theory. Specific, measurable,
achievable, relevant and time-specific (SMART) diet and activity goals were set each week. For those women
unable to attend, the session content was delivered by telephone or e-mail. A pilot trial to assess delivery
and acceptability of the intervention, and to determine whether or not diet and PA were changed by the
intervention, was undertaken in 183 obese pregnant women randomised to standard antenatal care or to
the intervention superimposed on standard antenatal care. Further analyses of the pilot study included a
study of baseline biomarkers and clinical risk factors as potential predictors of GDM, and a study of PA and
pregnancy outcomes. The pilot trial led to a RCT of the intervention in 1555 obese pregnant women from
antenatal populations of eight inner-city UK hospitals. Women were randomised to the intervention between
15+0 and 18+6 weeks’ gestation. The primary outcome of the RCT for the mother was GDM [as measured by
the International Association of the Diabetes and Pregnancy Study Groups (IADPSG)’s diagnostic criteria] and
for the infant, LGA delivery (i.e. customised birthweight ≥ 90th centile for gestational age).
In an economic evaluation, a within-trial cost–utility analysis was undertaken to estimate the cost-
effectiveness of the health training (intervention) over and above standard care (control). The items of
resource assessed were contacts to provide the health training intervention, antenatal admissions,
cessation of pregnancy and postnatal admissions.
Results
Phase 1: development phase
This phase of the study led to development of the intervention as described in the Background section
above. The questionnaire-based study of pregnant women’s (n = 103) intentions to adopt the dietary
recommendations identified by the intervention (reduced intake of high-sugar and high-fat foods and
increased fruit and vegetable consumption) found that perceived benefits for the health of the mother and
baby provided the strongest incentive for intentions of eating the target foods, whereas barriers to change
appeared to be discounted in pregnancy. This study informed the delivery of the intervention by the HTs,
as it suggested dietary interventions in pregnant women should emphasise health benefits for the mother
and child rather than focusing on barriers to change. A comparison in 58 overweight and obese women
between assessment of PA using a pedometer (CW701 Digi-Walker™ Pedometer; Yamax, Bridgnorth, UK)
step counts and an accelerometer (GT1M; ActiGraph, Pensacola, FL, USA) showed that there was poor
agreement between the two. It was concluded that accurate assessment of PA in the pilot study would be
best undertaken using an accelerometer as well as a validated questionnaire.
Phase 2: pilot trial
In total, 183 women [mean body mass index (BMI) of 36.3 kg/m2] consented to participate in a pilot RCT
of the UPBEAT intervention and 473 eligible women declined to participate. Dietary assessment by a
triple-pass 24-hour recall demonstrated that women in the intervention arm demonstrated a significant
reduction in dietary glycaemic load (GL) between recruitment and 28 weeks’ gestation [–33 points,
95% confidence interval (CI) –47 to –20 points] compared with women in the standard care arm. Objectively
measured PA (by accelerometry) was not different between control and intervention arms, whereas women
in the intervention arm self-reported an increase in walking for leisure (14 minutes, 95% CI 5 to 23 minutes).
This level of activity may not have been adequately captured by accelerometry, being a low-level activity,
but could have also reflected reporting bias. Process evaluation identified that the dietary advice was well
received by the participants and confirmed the results of the PA data which suggested that changes in PA
data were more difficult to achieve. Identification of barriers to recruitment, HT session attendance and
compliance led to modification of the intervention delivery but not to any change in the intervention per
se. The incidence of GDM (30% by IADPSG’s diagnostic criteria) in the pilot trial informed the sample size
for the RCT, powered for a 25% reduction in GDM (1546 women).
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An investigation of prediction of GDM in 106 of the pilot trial participants, of whom 27.4% developed
GDM, identified age, parity, diastolic blood pressure and black ethnicity to be associated with later
development of GDM. The area under the receiver operator characteristic curve for clinical risk factors
alone (0.760), increased significantly with the addition of adiponectin (0.834, χ2 = 4.00; p = 0.046)
measured at recruitment (early second trimester).
An investigation of the association between PA and pregnancy outcomes was undertaken among the
183 pilot trial participants. As no difference in objectively measured activity was observed between women
in standard care and intervention arms, light-intensity PA was lower in early pregnancy in women who
delivered macrosomic infants. Maternal sedentary time at 35–36 weeks’ gestation was positively associated
with neonatal abdominal circumference, and moderate-intensity PA was inversely related to neonatal
abdominal circumference. This suggested that PA is an appropriate target for interventions to improve
infant outcomes.
Phase 3: the UK Pregnancies Better Eating and Activity trial randomised
controlled trial
Following report of the pilot trial to the National Institute for Health Research (NIHR), agreement to continue
recruiting to the RCT was provided. In total, 1555 obese pregnant women (mean BMI of 36.3 kg/m2) were
recruited to the trial. Analysis was by intention to treat. The incidence of GDM was 26% in the standard care
group and 25% in the intervention group (risk ratio 0.96, 95% CI 0.79 to 1.16; p = 0.68). Eight per cent of
infants were LGA in the standard care group, compared with 9% in the intervention group (risk ratio 1.15,
95% CI 0.83 to 1.59; p = 0.40). Therefore, the intervention did not reduce GDM in pregnant obese mothers
or deliveries of LGA infants, despite a significant reduction in the dietary GL (p < 0.001), carbohydrate intake
(p < 0.001) and saturated fat intake (p < 0.001), and an increase in fibre uptake (p = 0.013) and PA (walking,
minutes/week, p = 0.0018), together with a 0.55-kg reduction in GWG (p = 0.041) and lower maternal sum
of skinfold thicknesses (p= 0.0081). There was no reduction in any other clinical pregnancy outcome of
relevance in either the mother or the infant (secondary outcomes). The number of LGA infants being born in
all trial participants was lower than expected; we suggested this could have arisen from universal screening
for GDM in mothers using IADPSG’s criteria and appropriate treatment following diagnosis.
Conclusions
A theoretically based intensive complex intervention combining dietary and PA advice to reduce GDM in
obese pregnant women and the number of LGA infant deliveries was developed, in accordance with
Medical Research Council guidelines, in three phases. The first, the development phase, provided useful
information on relationships between current dietary behaviours and intentions to change behaviours as
well as health incentives that could help delivery of the intervention. This phase also enabled assessment
of appropriate measures for objective assessment of PA, and the importance of determining whether or
not an intervention changes behaviours in the direction as expected. Structured interviews with obese
pregnant women identified issues likely to deter women from PA and the importance of how to address
the problems of obesity without causing offence, which informed delivery of the intervention. Phase 2,
the pilot study, demonstrated the practical feasibility and, importantly, the clinical effectiveness of the
intervention to reduce the self-reported dietary GL and saturated fat intake, with a modest increase in PA.
Finally, phase 3, the UPBEAT RCT, demonstrated that, despite evidence of improved dietary and PA
behaviours, this approach did not lead to a reduction in GDM in obese pregnant women or the number of
deliveries of LGA infants.
Although clinical outcomes were not improved by the UPBEAT intervention, ongoing follow-up of the
UPBEAT mothers and children will determine whether or not the improvements in maternal diet and PA
are maintained, and whether or not the risk of obesity in the children is affected by improved health
behaviours in the mother during and after pregnancy.
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Recommendations
Research recommendations
l Alternative strategies for reducing the risk of GDM in obese pregnant women and the number of LGA
infant deliveries, other than reducing the GL and saturated fat intake in unselected obese women,
as described in this programme, should be considered. These include:
¢ A major public health focus on development of clinically effective interventions to prevent obesity
in women of reproductive age.
¢ Development of clinically effective interventions to reduce weight retention following pregnancy,
thereby reducing the risk of adverse outcomes, including GDM, in the next pregnancy.
¢ Development of risk stratification tools in early pregnancy to enable targeted early pregnancy
interventions. These may include diet and PA and/or pharmacological interventions. Delivery of a
clinically effective intervention to all obese pregnant women irrespective of risk would incur major
health-care costs, as the prevalence of obesity is already high and increasing globally.
l Interventions that successfully change behaviour in obese pregnant women may have benefits through
improved dietary behaviours and reduced body fat mass during and beyond pregnancy. Follow-up
studies are warranted to determine the longer-term implications for the mother and child.
Clinical recommendations
l The UPBEAT intervention provides an evidence-based strategy to improve maternal diet, reduce
maternal body fat and reduce GWG in obese pregnant women.
l As the prevalence of LGA infant deliveries and other neonatal adverse outcomes was lower than
expected in obese pregnant women in the UPBEAT intervention, we recommend a RCT to investigate
the number of LGA infant deliveries and related maternal and neonatal outcomes following diagnosis
of GDM in obese pregnant women by IADPSG’s diagnostic criteria with previous World Health
Organization and/or current National Institute for Health and Care Excellence diagnostic criteria.
l Current guidelines for screening and treatment of obese pregnant women for GDM should be more
widely adopted to reduce associated adverse outcomes.
Trial registration
This trial is registered as ISRCTN89971375 and UK Clinical Research Network Portfolio 5035.
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Chapter 1 The UK Pregnancies Better Eating and
Activity Trial phase 1 – development phase:
involvement of patients and providers in development
of the UK Pregnancies Better Eating and Activity
Trial intervention
This programme of work was designed to develop a behavioural intervention combining dietary andphysical activity (PA) advice to improve insulin sensitivity, and thereby reduce gestational diabetes
mellitus (GDM) and large-for-gestational age (LGA) deliveries, in obese pregnant women. The programme
followed the UK’s Medical Research Council framework for the development and evaluation of complex
interventions, which is delineated by three phases.1
1. Development phase: to determine, following a review of the relevant literature, the best approach and
method of delivery of the proposed intervention, develop and standardise the content and delivery
method, and assess feasibility and acceptability to women and providers with a view to optimising the
intervention for use in a pilot trial.
2. Pilot: to undertake a pilot trial to establish the efficacy of the intervention in changing dietary and PA
behaviours, and to evaluate all practical aspects of delivering the intervention.
3. Randomised controlled trial (RCT): to undertake a RCT to determine whether or not the intervention
reduces GDM and LGA deliveries in obese pregnant women.
The aim of phase 1 was to determine the best approach and method of delivery for the proposed
intervention, develop and standardise content and delivery method, and assess feasibility and acceptability
to women and providers with a view to optimising the intervention for use in a pilot trial (phase 2).
Objectives and design
To assess appropriateness, acceptability and delivery of the intervention in
target groups
To understand likely motivations for, and barriers to, changes in diet and activity in pregnancy by
developing a quantitative measure of knowledge and attitudes about healthy eating and activity.
At the onset of this programme there were no pre-existing validated instruments to assess attitudes
towards diet and PA in obese pregnant women. Initial work was undertaken to explore the relative
clinical effectiveness of different behaviour change strategies used in previous studies of healthy lifestyle
interventions for pregnant women. All relevant studies had focused on the reduction of gestational weight
gain (GWG) as the primary end point. None was targeting insulin resistance, which was the focus of this
programme. Ten controlled trials of interventions that aimed to reduce GWG through changes in diet or
PA were reviewed. Meta-analysis showed that, overall, diet and PA change was effective in reducing GWG,
but there was considerable heterogeneity in outcomes.2 The analysis showed that sample characteristics
and aspects of intervention design, content, delivery and evaluation differed between studies, and that
these were likely to explain the variation between studies in effectiveness. A common issue was the failure
to evaluate changes in behaviour or its psychological determinants, as well as inadequate detail of the
intervention content. These were likely to have contributed to difficulty in identification of the processes by
which weight change was effected. Because of this, it was difficult to discern active intervention ingredients.
The study concluded that behaviour-based GWG reduction interventions should be more systematically
designed, evaluated and reported to build on insights from behavioural science. This important conclusion
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reinforced our intention to systematically develop an evidenced-based intervention based on known theory,
and our decision to pilot the intervention to evaluate all aspects of the intervention, particularly to evaluate
change in behaviour, acceptability and its psychological determinants.
A questionnaire to measure attitudes towards diet and PA in pregnancy was then developed, based on
psychological models of determinants of health behaviour, previous literature in pregnant women and
interviews conducted with pregnant women (see Appendix 1). The questionnaire comprised the following
constructs: attitudes to healthy behaviours, social norms, intention to change behaviour, knowledge
regarding nutritional and PA recommendations and motivations for food choices. The outcomes of a study
using this questionnaire were published as below by Gardner B, Croker H, Barr S, Briley A, Poston L,
Wardle J; UPBEAT Trial. Psychological predictors of dietary intentions in pregnancy. J Hum Nutr Diet
2012;4:345–53.3 Minor formatting edits have been made to the published text, which is reproduced
with permission.
Psychological predictors of dietary intentions in pregnancy
Abstract
Background: Consuming a healthy diet in pregnancy has the potential to improve obstetric outcome,
including minimising the risk of macrosomia. Effective promotion of dietary change depends on identifying
and targeting determinants of gestational diet. The present study aimed to model psychological predictors
of intentions to reduce the intake of high-fat and high-sugar foods, and increase fruit and vegetable (F&V)
consumption, among pregnant women.
Methods: One hundred and three pregnant women completed questionnaire measures of intentions to
modify the consumption of the target foods, current intake, perceived vulnerability to, and severity of,
adverse outcomes of non-healthful consumption of these foods (i.e. ‘threat’), benefits of dietary change to
mother and baby, barriers to dietary changes and social approval for dietary change (‘subjective norms’).
A cross-sectional design was used. Logistic regression analyses were undertaken to model dietary change
intentions.
Results: Participants who reported excessive current intake of high-fat and high-sugar foods were more
likely to commit to reducing the intake of these foods. The perceived benefits for mother and baby
enhanced the mothers’ intentions to eat more F&V and fewer high-fat foods and marginally significantly
increased their intentions to reduce the consumption of high-sugar foods. There were no effects of threat,
barriers or subjective norms.
Conclusions: Lack of effects for barriers, threat and subjective norms may indicate that pregnant women
discount barriers to health-promoting behaviour, understand the threat posed by unhealthy eating and
perceive social approval from others. Dietary change interventions for pregnant women should emphasise
likely positive outcomes for both mother and child.
Introduction
Research in gestational diet and nutrition has traditionally focused on preventing nutritional deficiencies
in the maternal diet and ensuring adequate neonatal growth.4 There is, however, growing interest in
the potential for dietary changes among pregnant women with GDM or obesity to minimise the risk of
macrosomia and associated adverse outcomes, including the risk of obesity in the child in later life.4–6
Maternal glucose is the main substrate for the growing fetus and, consequently, maternal hyperglycaemia
may result in fetal hyperinsulinaemia, thereby increasing growth rate and thus the risk of macrosomia.7
Maternal insulin sensitivity reduces with advancing pregnancy.8 Certain dietary interventions might,
theoretically, reduce insulin resistance among pregnant women.9 Reducing the consumption of foods rich
in carbohydrates that release glucose rapidly into the bloodstream [i.e. high-glycaemic index (GI) foods] can
promote glycaemic control and improve insulin sensitivity by manipulating the type of carbohydrate-rich
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foods and drinks consumed rather than necessarily restricting the quantity of carbohydrates per se.7,10
A recent review found some evidence to support the use of low-GI diets, defined by the consumption of
carbohydrates that release glucose gradually, in women with GDM, although it is less clear whether or not
they could also benefit non-diabetic women.7 Two intervention trials in non-diabetic women have yielded
promising results, with reduced delivery rates of babies who are LGA (i.e. > 90th birthweight percentile)
being observed among women who ate a low-GI diet relative to those consuming a usual diet.11,12
Notably, both studies included women with a range of body weights, suggesting that dietary glycaemic
control may benefit both normal and overweight women, although there are some concerns over ensuring
adequate fetal growth, particularly in normal-weight women.13 Another study investigating overweight and
obese pregnant women found that a low-glycaemic load (GL) diet (i.e. foods with low values on an index
that accounts for both GI value and carbohydrate content) improved cardiovascular risk factors, lengthened
pregnancy duration and increased infant head circumference.14 Further clinical trials are planned or are
under way that aim to explore the impact of such diets on pregnancy outcome in obese women, these
include the UK Pregnancies: Better Eating and Activity Trial [UPBEAT; International Standard Randomised
Controlled Trial Number (ISRCTN) 89971375], described in this programme, and another in women who
have had a previous macrosomic pregnancy.15
Reducing the GI relies on changing dietary behaviour in pregnant women. Changing pregnant women’s
food choices will be aided by identifying and targeting the determinants of diet in pregnancy. Behaviour
change is often portrayed as a consequence of changes in psychological variables: modifying knowledge,
attitudes and beliefs in turn influences intentions16 and ultimately alters behaviour.17 However,
interventions designed to improve diet in pregnancy, including those designed specifically to lower the GI
or GL,12,14 have neglected psychological changes.2,18 Identifying psychological determinants of dietary
decisions in pregnancy would assist intervention development in two respects. First, psychological variables
represent potential targets for intervention. Second, assessing changes on these variables can aid our
understanding of why diet has or has not changed in response to an intervention.17 However, little
empirical evidence is available regarding the psychological determinants of dietary behaviour in pregnancy.
Pregnancy has been portrayed as a transitional life event that is psychologically characterised by
heightened awareness of (and responsiveness to) threats to the health of either mother or child.19 Risk
perceptions may therefore underpin motivation to take health-protective action in pregnancy. The health
belief model (HBM)20 proposes that responses to risk are underpinned by two psychological dimensions:
threat perception and behavioural evaluation.21 Threat perceptions are a function of perceived susceptibility
to, and perceived severity of, a threat (e.g. GWG or its associated health complications), and behavioural
evaluations refer to the expected benefits of, and barriers to, taking action (e.g. consuming a nutritionally
balanced diet) to avert the threat. The HBM predicts that protective behaviour will be elicited where the
individual perceives themselves as vulnerable to a serious threat, the action is deemed beneficial and there
are few barriers to taking action. Although originally proposed as direct determinants of health behaviour,
subsequent research has indicated that the HBM constructs largely influence action indirectly via the
formation of intentions, which subsequently determine behavioural responses.16
As determinants of intention, the threat perceptions and cost–benefit analyses proposed by the HBM
compete with social influences in guiding health motivation in pregnancy.22 For example, intentions to
consume a healthy diet in pregnancy are likely to be a function not only of the subjective utility of a
nutritionally balanced diet for averting health threats, but also expected (dis)approval from relevant others
for consuming such a diet.22 Expectations of friends, family and health-care professionals may therefore
contribute to dietary decisions in pregnancy independently of a subjective threat and behaviour evaluations.
Dietary change focused on a reduced intake of saturated fat and high-sugar foods, as well as increased
F&V consumption, has been proposed as an approach for reducing insulin resistance in pregnancy,9 and is
consistent with the UK national guidance for healthy eating in pregnancy.23 The present study assessed
pregnant women’s attitudes and motivations concerning these food types, and examined which
psychological variables predicted intentions to consume healthier quantities of these foods over the
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remainder of the pregnancy term. Our analysis draws on variables from the HBM,20 augmented by a measure
of perceived social approval (i.e. ‘subjective norms’).22 To isolate the unique influence of psychological
variables on behaviour change intentions, we controlled for the current intake of each of the three foods,
as well as the pregnancy-related personal characteristics that may influence dietary intentions or behaviour
[pre-pregnancy body mass index (BMI), gestational age and parity].24,25
Materials and methods
Participants and procedures
Participants were approached, in person, by a researcher at antenatal clinics and given a paper questionnaire
(together with a prepaid envelope) for return (see Appendix 1). One hundred and three pregnant women
returned completed questionnaires. Data were collected from one hospital outpatient clinic and five
community clinics in south-east England (n = 92) and one hospital outpatient clinic in north-east England
(n = 11). Response rate data were not available. A cross-sectional design was used. Ethics approval for
the study was obtained from a NHS Research Ethics Committee (reference number 09/H0802/5).
Measures
Personal characteristics
Participants completed self-report measures of parity, gestational age (in weeks), height (m/cm or ft/in)
and pre-pregnancy weight (kg or st). Height and weight measures were used to compute pre-pregnancy
BMI values. For sample description purposes, participants also indicated their ethnicity and highest
educational qualification.
Psychological variables
Unless otherwise indicated, psychological variables were measured using single items in the form of
statements with which participants indicated (dis)agreement on a five-point scale (1 = strongly disagree to
5 = strongly agree). Scores on multi-item scales represented the mean of all component items. Measures
related to three dietary behaviours in pregnancy: eating (more) F&V, eating (less) high-fat food and eating
(less) high-sugar food.
Current behaviour was estimated based on the perceived adequacy of current dietary intake [‘Do you think
the amount of (F&V/high-fat food/high-sugar food) you eat is much too little/too little/about right/too
much/much too much?’]. Participants who reported eating ‘too much’ F&V or ‘too little’ high-fat or
high-sugar food were excluded from analyses; this removed nine participants (7%) from the high-fat and
high-sugar food analyses, respectively, and four participants (3%) from the F&V analyses. Remaining values
were dichotomised to denote deficient current health behaviour (‘much too little’ or ‘too little’ F&V, ‘too
much’ or ‘much too much’ high-fat or high-sugar foods, coded as 0), or adequate current behaviour
(‘about right’, coded 1).
Intention items followed a stem: ‘Over the rest of your pregnancy, do you intend to eat much less/eat a
little less/ not change/eat a little more/eat much more [F&V, high-sugar foods, high-fat foods]?’. Participants
intending to eat less healthily (i.e. less F&V, more high-sugar food or more high-fat food, one participant
per behaviour, 1%) were excluded from respective analyses. Intention scores were transformed into binary
values to represent no intended change (coded 0) or an intention to consume a healthier diet (coded 1,
i.e. more F&V, less high-fat food and less high-sugar food).
Perceived vulnerability and perceived severity were each measured using two items. Items related to
adverse health outcomes for mother and baby separately [e.g. vulnerability, ‘Eating too few F&V could
cause problems for (me/my baby)’; severity, ‘I would worry about (my health/my baby’s health) if I ate too
few F&V’]. For each behaviour, all four items were consistently highly intercorrelated (minimum a = 0.91)
and so were combined into a composite threat measure.
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Perceived benefits related to positive outcomes for mother [e.g. ‘Eating (more F&V/less high-fat foods/less
high-sugar foods) than I do now would . . . make me look better/make me feel better/prevent me putting
on too much extra weight’] and baby (‘. . . be good for my baby/reduce my chances of having a baby that
is too big’). Items were adapted from previous research.26,27 For each behaviour, the five items were
combined into a reliable composite index (minimum a = 0.82).
Perceived barriers items were combined into behaviour-specific indices. Barriers to consuming F&V related
to difficulty of access and preparation, and cost (e.g. ‘It costs too much to eat more F&V’). Barriers to
reducing fat consumption related to high-fat foods being easy to cook, satisfying cravings and helping deal
with stress. Barriers to reducing sugar consumption related to using high-sugar foods to satisfy cravings
and helping deal with stress.
For each behaviour, subjective norm items, which focused on expected approval from family and health-care
professionals, respectively (e.g. ‘My family would approve of me eating fewer high-fat foods during
pregnancy’), were combined because of strong inter-item correlations (minimum, r = 0.66; minimum, a= 0.80).
Statistical analysis
Data were analysed using predictive analytics software (PASW Statistics version 18.0; SPSS Inc., Chicago, IL,
USA). Multiple logistic regressions were run to explore psychological predictors of intentions to consume a
healthier diet, controlling for personal characteristics (pre-pregnancy BMI, gestational age, parity) and
current behaviour. For ease of interpretation, psychological variables (threat, benefits, barriers, subjective
norms) were dichotomised, using a median split to separate lower (below the median value) and higher
scores (at or above the median).
Cases with missing intention values were excluded from the analyses to ensure that dependent variable
scores were observed rather than estimated. This removed four cases relating to F&V consumption, 12 for
high-fat consumption and 11 for high-sugar consumption, thereby reducing the sample size to n = 99 for
analyses of F&V consumption intentions, n = 91 for high-fat foods and n = 92 for high-sugar foods.
Results
Sample characteristics
Participants were aged from 20 to 45 years (mean age 33 years), and between 8 and 40 weeks pregnant
(mean 27 weeks). The majority (n = 49; 48%) were in the second trimester (13–28 weeks) or third
trimester (29 weeks to birth; n = 47; 46%), with seven participants (7%) in the first trimester (up to
12 weeks) of pregnancy. Most participants (n = 68; 66%) were nulliparous. Pre-pregnancy BMI was in
the range 14.8–45.8 kg/m2 (mean 24.9 kg/m2). Twenty-two participants (21%) were overweight (BMI of
≥ 25.0 kg/m2 < 30.0 kg/m2) and a further 17 participants (17%) were obese (BMI of ≥ 30.0 kg/m2).
Participants were predominantly of white ethnic origin (n = 72; 70%). Eleven participants (11%) were of
black or black British ethnicity, eight were Asian or Asian British (8%), nine were of mixed (n = 6; 6%) or
other ethnicity (n = 3; 3%) and three participants did not indicate their ethnicity. Most had a university
education (n = 74; 72%). Ten participants (10%) had an A-level education, 15 participants (15%) had
National Vocational Qualifications or General Certificate of Secondary Education qualifications, and one
participant had no formal qualifications (1%). Three participants (3%) did not report qualifications.
Descriptive statistics
Most participants intended to increase their F&V consumption (n = 66, 67%) or decrease their high sugar
intake (n = 54, 57%) during their pregnancy, although fewer than half of the participants intended to
reduce their fat consumption (n = 41, 45%). Only a minority felt that they ate too few F&V (n = 21, 21%),
too much high-sugar food (n = 31, 34%) or too much high-fat food (n = 26%), with most participants
viewing their current intake of these foods as ‘about right’.
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Current behaviour and intentions were negatively correlated for each behaviour: participants who felt they
ate ‘too little’ F&V had stronger intentions to increase F&V consumption (r = –0.26; p = 0.009) and those
who felt they consumed ‘too much’ high-sugar or high-fat foods were more likely to want to decrease
their intake (r = –0.41 and –0.42; p < 0.001, respectively).
Correlations were observed between high-fat and high-sugar consumption intentions (r = 0.69; p < 0.001)
and between current intake of high-fat and high-sugar foods (r = 0.57; p < 0.001), indicating similar
beliefs and behaviour surrounding these two foods. Weaker correlations were observed between F&V
intentions and high-fat or high-sugar intentions (maximum r = 0.35; p < 0.001). Correlations between
perceived adequacy of F&V consumption and of high-fat or high-sugar foods (maximum r = 0.22; p = 0.03)
were moderate in size.
Participants tended to be aware of the potential health threat associated with unhealthy dietary consumption
in pregnancy (mean score 4.25), although the perceived benefits of healthy eating for mother and baby were
more modest (mean score 3.66; Table 1). Average barrier scores were consistently below the scale mid-point,
implying that participants felt relatively unhindered in changing their diet, although participants tended
to expect even fewer barriers to consuming more F&V (mean score 1.81) than to reducing high-fat (mean
score 2.78) or high-sugar foods (mean score 2.85). Social approval from family and health-care professionals
was seen as supportive for all three behaviours (mean score 3.91) and strong intergroup correlations for each
behaviour reflected perceived agreement between family and health-care professionals in this respect.
Predicting dietary consumption intentions
For each of the three food types, a model comprising demographic variables, current behaviour and
psychological variables was significantly predictive of intentions to eat more healthily (minimum model
χ2 = 25.37; p = 0.001).
TABLE 1 Descriptive statistics: psychological variables
Variables
Food type
F&V (n= 99)
High-fat food
(n= 91)
High-sugar food
(n= 92)
Perceived adequacy of current
behaviour, n (%)
About right: 78 (78%) About right: 67 (74%) About right: 61 (66%)
Too few F&V: 21 (21%) Too much high-fat
food: 24 (26%)
Too much high-sugar
food: 31 (34%)
Intention to engage in health
behaviour, n (%)
Do not intend to
change: 33 (33%)
Do not intend to
change: 50 (55%)
Do not intend to
change: 38 (41%)
Intend to increase:
66 (67%)
Intend to decrease:
41 (45%)
Intend to decrease:
54 (59%)
Threat (posed by inaction), mean (SD),
median
4.25 (0.78), 4.25 4.39 (0.53), 4.25 4.43 (0.55), 4.38
Benefits of healthy behaviour for
mother and baby, mean (SD), median
3.66 (0.67), 3.80 3.67 (0.81), 3.80 3.65 (0.84), 3.60
Barriers to healthy behaviour, mean
(SD), median
1.81 (0.82), 1.67 2.78 (0.72), 2.67 2.85 (1.02), 3.00
Subjective norms (family, health
professionals), mean (SD), median
4.07 (0.89), 4.00 3.91 (0.96), 4.00 3.89 (0.98), 4.00
SD, standard deviation.
Note
Values on psychological variables are in the range of 1 to 5, where 5 is a high threat, greater benefits, greater barriers and
more supportive social norms.
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As shown in Table 2, participants who perceived their current intake to be excessive were significantly
more likely to intend to eat less high-fat foods [odds ratio (OR) 5.28; p = 0.02] and high-sugar foods
(OR 5.65; p = 0.01) than those who believed their intake to be adequate. A tendency for participants who
perceived that they ate ‘too few’ F&V to intend to increase their F&V intake (OR 3.36) was not statistically
significant (p = 0.15).
There was no effect of threat on intentions for any of the three food types (maximum OR 2.05; p = 0.18).
However, strong effects were found for perceived benefits of action for mother and baby, with participants
who expected greater benefits being more likely to intend to eat more F&V (OR 3.59; p = 0.02) and fewer
high-fat foods (OR 5.70, p = 0.003). A similar tendency was found for intention to eat fewer high-sugar
foods (OR 2.66), although this was only marginally significant (p = 0.10). There were no effects of
perceived barriers (minimum p = 0.21) or of subjective norms (minimum p = 0.21) on dietary intentions.
TABLE 2 Logistic regression of dietary intentions on psychological variables, controlling for pre-pregnancy BMI,
gestational age and parity
Variables
Intention to eat
More F&V (n= 99) Less high-fat foods (n= 91)
Less high-sugar foods
(n= 92)
OR (95% CI)
p-value
for trend OR (95% CI)
p-value
for trend OR (95% CI)
p-value
for trend
Current
engagement
in health
behaviour
About right: 1.00
reference
0.15 About right: 1.00
reference
0.02 About right: 1.00
reference
0.01
Too few F&V: 3.36
(0.64 to 17.60)
Too much high-fat
food: 5.28 (1.38 to
20.19)
Too much high-
sugar food: 5.65
(1.50 to 21.22)
Threat Lower threat: 1.00
reference
0.83 Lower threat: 1.00
reference
0.68 Lower threat: 1.00
reference
0.18
Higher threat: 0.89
(0.31 to 2.55)
Higher threat: 1.27
(0.41 to 3.89)
Higher threat: 2.05
(0.72 to 5.89)
Benefits for
mother and
baby
Lower benefits:
1.00 reference
0.02 Lower benefits:
1.00 reference
0.003 Lower benefits:
1.00 reference
0.10
Higher benefits:
6.59 (1.28 to
10.11)
Higher benefits:
5.70 (1.78 to
18.21)
Higher benefits:
2.66 (0.82 to 8.66)
Barriers Higher barriers:
1.00 reference
0.27 Higher barriers:
1.00 reference
0.86 Higher barriers:
1.00 reference
0.21
Lower barriers:
0.56 (0.20 to 1.57)
Lower barriers:
1.12 (0.33 to 3.80)
Lower barriers:
0.50 (0.17 to 1.49)
Subjective
norms
Lower norms: 1.00
reference
0.22 Lower norms: 1.00
reference
0.29 Lower norms: 1.00
reference
0.21
Higher norms:
1.98 (0.66 to 5.91)
Higher norms:
1.93 (0.57 to 6.57)
Higher norms:
2.24 (0.64 to 7.85)
R2 (Cox and
Shell)
0.23 0.33 0.32
R2 (Nagelkerke) 0.31 0.45 0.43
Model χ2 25.38*** 36.84*** 34.93***
***p ≤ 0.001; CI, confidence interval.
Note
Predictor variables dichotomised using a median split.
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Discussion
A low-GI diet in pregnancy has the potential to improve obstetric outcome.12,14 The design of diet-based
interventions in pregnancy may be aided by identifying the psychological determinants of dietary choices
because modifying these variables should translate into dietary change.17 The present study examined
appraisals of benefits and barriers, threat perceptions, evaluations of current behaviour and perceived
social pressures (subjective norms) as potential influences on intentions to improve three aspects of diet
linked to insulin resistance (increased F&V consumption, decreased high fat and high sugar consumption19)
in a community sample of pregnant women. Perceived levels of current behaviour predicted intentions
to eat fewer high-fat and high-sugar foods, with participants who felt that they ate too many high-sugar
or high-fat foods being more likely to intend to reduce their consumption. Perceived benefits of action
for mother and baby were associated with the intention to eat more F&V and less high-fat food, with
participants who perceived greater benefits of adopting more healthy eating patterns being more likely
to intend to do so. A similar association, which was only marginally significant, was observed between
perceived benefits and intention to eat less high-sugar food. There were no associations between perceived
barriers, threat perceptions and subjective norms and intentions.
Our analysis drew on variables derived from the HBM,20 which proposes that health behaviour arises
from deliberation over the threat posed by health risks, as well as the benefits of, and barriers to, taking
action recommended to minimise these threats. We observed consistently high levels of perceived threat
among our sample and, perhaps as a result of minimal variation in threat levels, there was no association
between threat and dietary intentions. As predicted by the HBM, perceived benefits for mother and baby
were associated with healthy eating intentions, although, in contrast to theoretical predictions,16 perceived
barriers had no impact. Although further evidence from larger samples is needed, these results suggest
that, when making the cost–benefit analyses that underpin evaluations of health-related behaviours,28
pregnant women may weigh barriers to behaviour less heavily than do the general population. Perhaps
this may be understood in the light of the immediacy with which health threats faced by pregnant women
can be realised. Perceived health benefits of diet outside pregnancy may be typically distal and orientated
towards the prevention of later morbidity or mortality, whereas barriers relate to immediate short-term
obstacles (e.g. missing out on tasty foods, choosing less favoured options). By contrast, the benefits
of healthy eating in pregnancy, such as the prevention of macrosomia and the reduced likelihood of
delivery complications, are typically more proximal, becoming apparent at or shortly after birth.
Consequently, these benefits may be easier to foresee or are perceived to be more real than the distal
benefits associated with health behaviours outside pregnancy. To support this hypothesis, further
exploration is needed of the health decision processes in pregnancy and other conditions when the health
effects are more immediate than the decision processes in non-pregnant community samples. However,
the stronger effects of perceived benefits than perceived barriers in our sample, coupled with raised threat
perceptions, support the conceptualisation of pregnancy as a period of heightened responsiveness to
potential health risks and a greater appreciation of the value of health-protective action. Pregnancy may
therefore represent ‘an opportune time to initiate (behavior) change’.
Several behaviourally based pregnancy interventions have been described based on the provision of dietary
‘counselling’.29–33 However, the term ‘counselling’ can refer to a variety of behaviour change techniques.34
Although some interventions have focused primarily on identification of barriers to healthy eating,30,32 the
results of the present study indicate that bolstering expectations of positive outcomes for both mother and
child associated with adopting a healthier diet may have more impact. The under emphasis of the benefits
of healthy diet in interventions tested to date may reflect an assumption that pregnant women are aware
of the implications of gestational diet.2 Changing dietary choices in pregnancy may require efforts to
ensure that pregnant women consistently prioritise the benefits of healthy eating over beliefs that support
consumption of unhealthy foods. No relationship was observed between perceived social approval from
family or health-care professionals and healthy eating intentions. However, the high mean scores, coupled
with the strong positive correlation between family and health-care professional expectations, suggest that
our sample perceived strong and consistent approval for healthier dietary choices. The absence of an
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association between norms and intentions may therefore be the result of a lack of variation, although
more work is needed to establish the generalisability of the normative beliefs of our sample.
The findings of the present study are limited in several respects. The survey was cross-sectional, and so
we could not observe ‘prediction’ of intentions in a temporal sense or assess the effects of intentions on
subsequent consumption of each of the three foods types. Although further longitudinal research is needed,
there is considerable theoretical and empirical evidence to support the temporal relationships that we have
inferred, as well as the assumption that modifying dietary intentions will change dietary behaviour.35 The
data were also based on self-report, which is susceptible to responses biased by participants’ motivations to
portray themselves positively.36 Retrospective self-reports may underestimate true pre-pregnancy weight
especially in obese women,37 although objective weight data were not available to validate our BMI measure.
Participants were not informed by us of weight gain or gestational diet recommendations or of the potential
consequences of healthy and unhealthy eating in pregnancy, and the accuracy of their perceptions was not
tested and cannot be estimated. Nonetheless, our findings suggest that modifying such perceptions may
boost healthy eating intentions over the remainder of pregnancy. The representativeness of our sample is
questionable; for example, participants were mostly white and well educated, and more than two-thirds
were educated to university level. This may reflect a systematic participation bias within our pool of
potential participants, although we cannot test this because no data were available from those who
declined participation. However, our sample encompassed a wide distribution of participant BMI scores
and gestational age. Most participants were in the second or third trimester of pregnancy, and more work
is needed to explore beliefs and behaviour earlier in pregnancy because dietary changes achieved in early
pregnancy and maintained over the remaining gestational period may be most beneficial. Our sample
was also modest in size and, therefore, unable to identify small effects, neither could we reliably explore
differences in the beliefs, intentions and behaviour of demographic subgroups of pregnant women. Further
research, using larger samples, is needed into whether or not nutrition beliefs, intentions and behaviour
differ systematically by, for example, parity, age, socioeconomic status or ethnicity. Such differences may
have implications for the design and delivery of effective dietary interventions in pregnancy.
Notwithstanding these limitations, our results offer some insight into the health beliefs and dietary choices
of pregnant women. Best practice for diet modification in pregnancy is likely to require the adoption of
health promotion strategies to target the underlying psychological determinants of gestational diet.
Implications for intervention development
This study provided important insights into optimising delivery of the intervention, the results indicating
that pregnant women are likely to respond to bolstering their expectations of positive outcomes for both
mother and child through focus on a healthier diet, rather than an emphasis on overcoming perceived
barriers to behavioural change.
To assess delivery style, mode andmethod of delivery and acceptability
to recipients
Exploratory study: interviews with obese pregnant women to inform the
development of a pilot randomised controlled trial intervention and protocol
This pre-trial exploratory interview study aimed to examine the sociocultural context within which women
made decisions about pregnancy, diet and lifestyle, body image, health beliefs and their readiness to
engage with the type of health interventions that the trial team was in the process of developing.
A total of 30 women were approached, and semistructured qualitative interviews were undertaken with
13 pregnant women with a BMI of ≥ 30 kg/m2. Maximum variation sampling was used, selecting by
maternal age, family composition (e.g. lone parent, first baby) and sociodemographic characteristics
(employment, education level, ethnicity). The interviews aimed to explore pregnant women’s existing
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beliefs about diet and activity in pregnancy, their receptiveness to dietary change, perceived economic and
time implications, increased activity levels and other views on acceptability. We explored obese women’s
preferred approaches to intervention delivery (e.g. individual or group contacts, inclusion of family
members, frequency of contacts, setting for intervention delivery, etc.) and barriers and constraints to
change, including the impact of family circumstances and need for childcare. We investigated what types
of activity obese pregnant women perceive to be feasible and what they believe to be the key features
of a healthy diet in pregnancy. The interview schedule is provided in Appendix 2. Interviews were taped,
transcribed and analysed using a framework approach geared to producing policy- and practice-relevant
findings. The interviews were undertaken at either Guy’s and St Thomas’ Hospital, London, or the Royal
Victoria Infirmary, Newcastle. The qualitative studies were given ethics approval [Integrated Research
Application System (IRAS) reference number 09/H0802/05].
Sample characteristics
The mean age of the women was 35 years (range 25–41 years). The mean gestational age at the time of
the interview was 30 weeks (range 15–39 weeks). The mean BMI was 38 kg/m2 (range 32–58 kg/m2).
Eight of the women were self-defined as white and five were black. Five women were multiparous and
the others were primiparous. Eight women were employed at the time of the interview. Four women were
managing pre-existing chronic health conditions.
Findings
Comparative thematic analysis of the interview data led to the identification of themes and subthemes that
contributed to an overall category, ‘willingness to engage with diet and lifestyle changes during pregnancy’.
This category included two first-order themes (meaning that they are drawn directly from interview text):
‘feeling ill, pregnancy symptoms, and complex obstetric histories’ and ‘experience of stigma’. Each had
the potential to impact upon women’s engagement with the proposed RCT and willingness to engage
in lifestyle change was also mediated (either facilitated or reduced) by the relative complexity of the
women’s lives.
Theme 1: feeling ill, pregnancy symptoms and complex obstetric histories
Interviewees reported feeling ill during pregnancy or described experiencing pregnancy in the context
of past pregnancy loss, including miscarriage and stillbirth. Four out of 10 of the interviewees were
affected by GDM in their current pregnancies (note that women with known GDM were excluded from
recruitment in phase 3, UPBEAT, but approximately one in four developed GDM, see Chapter 5). Common
pregnancy-related symptoms, particularly nausea, tiredness and pelvic or back pain, also interfered
substantially with women’s eating patterns and ability to undertake PA.
Some women interviewed had worked hard to address their weight and activity before pregnancy or as
part of treatment for infertility. These activities involved notable cost and effort: some interviewees had
attended diet groups such as Weight Watchers® (New York City, NY, USA) or Slimming World (Alfreton,
UK) or bought diet plan foods; others paid to attend gyms or fitness classes or took up exercise activities
with their partners. However, once pregnant, they were advised to stop dieting by commercial weight loss
group leaders. Others were advised against exercise by clinicians, particularly after they had experienced
past miscarriages:
I know that I was overweight before I was pregnant, but I was quite conscious of the fact and I was
doing something about it, I was exercising loads, but then as soon as I fell pregnant I was like, I’m not
doing any exercise, because I was scared in case anything happened.
White English ethnicity, aged 27 years, married, a BMI of 36 kg/m2 and interviewed at 29 weeks’ gestation
The tiredness and nausea of early pregnancy, combined with busy lives looking after other children, doing
household chores and working, all decreased likelihood of additional physical exercise. Pelvic pain was a
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significant problem for 6 out of 10 interviewees, and others reported back pain. The combination of pain
and illness symptoms as pregnancy progressed meant that many led increasingly sedentary lives:
I mean I was quite keen to like stay quite fit, and I go for long walks and stuff, just because I thought
it’s better for me long term, but with this [pelvic] pain I’ve had I’ve been literally like, the physio who I
see at the hospital, she’s just literally said, ‘You’ve got to treat it like a sprained ankle and rest it.’ And
I’m saying, ‘Yeah but then you just sit, it’s not good for us just sitting all the time either.’ So that was
kind of a goal, I think I wanted to like do more exercise but I haven’t been able to.
White English ethnicity, aged 27 years, married, a BMI of 36 kg/m2 and interviewed at 29 weeks’ gestation
At thirty-five I first got pregnant and I had . . . a miscarriage at 13 weeks. It was quite traumatic . . . And
then I had three more [miscarriages], in the December I got pregnant again . . . I had a 7-week scan and
there was no heart beat . . . then I lost it. So I thought to myself, well, it could be stress, maybe I should
change my lifestyle . . . I didn’t feel that fit, I felt overweight . . . I actually stopped exercising because with
my other pregnancies the doctor had said, ‘Don’t exercise, we don’t really know why you’re miscarrying’.
And I really missed the exercise. I missed that feel-good factor. I’ve managed my expectations, I’m hoping
to breastfeed successfully and the doctors have said that can help shift the weight. I’m definitely going to
be eating an extremely healthy diet, in fact my mother would be proud of me.
White English ethnicity, aged 41 years, married, a BMI of 32 kg/m2 and interviewed at 39 weeks’ gestation
Researcher: Do you have any specific goals for yourself during this pregnancy?
Interviewee: No. Just to get to the end of it.
White English ethnicity, aged 35 years, single, a BMI of 34 kg/m2 and interviewed at 38 weeks’ gestation
Interviewees rarely envisaged their pregnancies as ‘normal’ or healthy, and some had been informed by
health professionals that the induction of labour at, or before, term was a possibility, either because a
diagnosis of GDM meant they were being screened for elective induction to reduce complications of birth
with a LGA baby or for other reasons, such as pre-eclampsia. However, this perspective was not universal:
at least one interviewee who had GDM felt more positive about her physical health during pregnancy. She
reported substantial weight loss prior to pregnancy, and felt confident that she was managing her diet and
blood sugars well and could lose weight again following birth.
Theme 2: experience of stigma
Linked to the notion that their pregnancies were not experienced as healthy or ‘normal’, some
interviewees recounted occasions when they felt stigmatised, singled out or labelled, with assumptions
made about their intelligence and life skills on the basis of their body size. They felt that they did not
receive the positive public reinforcement that other pregnant women experience as their ‘bumps’ were
often assumed to be body fat. However, some interviewees challenged the stereotype of overweight
women as lazy, uneducated consumers of fast food. Others felt happy with their size because, having
struggled with being larger all their lives, they had come to terms with this, or because they had already
lost substantial weight. Given the difficulties that openly discussing weight during pregnancy posed for
women, the medical language used to discuss weight generated controversy. The term ‘obese’ was often
problematic because it did not equate to women’s own views of their bodies. Some felt that even the term
‘BMI’, while perhaps more neutral than ‘overweight’ or ‘obese’, was still not useful, because failed to
reflect their overall weight trajectories, especially if they had achieved pre-pregnancy weight loss:
I think the term ‘obese’ or ‘morbidly obese’ is absolutely horrendous. I think it’s really awful, even if
you were a hundred stone or 12 stone, it’s a really, really awful word. Um . . . it’s just an awful kind of
terminology. I just think if you’re overweight just say they’re overweight, you know, there’s no need to
kind of say ‘morbidly’, it sounds like you’re some sort monstrous disgusting person type thing.
White English ethnicity, aged 27 years, married, a BMI of 36 kg/m2 and interviewed at 29 weeks’ gestation
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Several interviewees recalled being told their BMI was raised or high, and that they found it painful and
offensive to be described in this way (they described being ‘singled out’ or ‘pounced on’) and felt that
health professionals addressed the subject in ways which were rude and insensitive. Other interviewees
had not heard the term ‘BMI’, and said that their doctors or midwives had not mentioned their weight but
focused instead on other issues, such as smoking or pregnancy complications.
Theme 3: willingness to engage with diet or lifestyle changes during pregnancy
Although interviews were undertaken with pregnant women who were known to have a BMI of 30 kg/m2 or
above, and whose routine care during pregnancy included information about weight gain, diet and lifestyle
from health professionals, most mentioned broad public health messages about diet (such as the need to
eat ‘five-a-day’), rather than identifying implications of raised BMI for their individual pregnancy outcomes.
In the interviews, women volunteered information about their age, blood sugar control and smoking, but
did not talk about whether or not altering their own behaviour might change pregnancy outcomes for
themselves or their babies. Despite their awareness of broad public health dietary advice, women did not
volunteer more specific information about fat or carbohydrate intake during pregnancy. Interviewees also
questioned dietary advice during pregnancy, reasoning that health advice varies over time and should
be taken with ‘a pinch of salt’, citing too much focus on food ‘scares’ and too little effort towards
individualised education.
Many women felt they needed to suspend their attempts to manage their diet or exercise while they were
pregnant; pregnancy was seen as time when weight gain was inevitable, dieting contraindicated and when
metabolic demands and nausea altered food preference and appetite. Instead, their efforts were focused
upon ‘getting through’ this pregnancy, with a view to addressing diet and exercise goals during the
postnatal period:
I don’t have any problems with [pregnancy body changes] because when I had [my daughter] I lost all
the weight I gained quite quickly, . . . so it’s not been a problem for me to worry about. And I’ve
actually gained less weight now than I did when I was having her, so I haven’t really had any negative
thoughts or worries about that. So that’s been good. [Laughs] That’s been good.
Black African ethnicity, aged 32 years, married, a BMI of 35 kg/m2 and interviewed at 36 weeks’ gestation
When the proposed pilot RCT diet and PA intervention was described to interviewees, responses were
mixed. Most supported the idea of an educational approach to diet and cooking, but fewer thought that
advice about PA would be valuable. The suggestion of a group-based intervention engendered a polarised
response; about half welcomed this idea and thought they would benefit from sharing their experiences
and social support. The remainder said they would not participate in a group intervention, either because
this would pose difficulties in the contexts of their work commitments and family lives or because the
intention to single women out on this basis was patronising and grew from a perceived assumption that
they needed to be educated about issues that they understood only too well:
Interviewer: If [the health trainer (HT) group] was happening now, would that be something you’d be
interested in?
Participant: Yes, I would. Because sometimes, especially about food, I don’t know what to eat and
maybe they can give me ideas what I can do. Or maybe they can encourage me to go to the classes.
Black African ethnicity, aged 38 years, has partner, a BMI of 34 kg/m2 and interviewed at
15 weeks’ gestation
I would feel very belittled. [Laughs] I wouldn’t . . . no, I wouldn’t like that at all. Yes, fair enough, they
could offer it. I know what’s healthy . . . well yes, I do know, even though I can understand some
people say it and they don’t, but I do know! And, yes, I wouldn’t like someone telling me.
White English ethnicity, married, a BMI of 36 kg/m2 and interviewed at 27 weeks’ gestation
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Me personally, no. Because of the fact of the family I’ve got. A new time mum it would be good for,
somebody that can devote more time to it.
White English ethnicity, aged 41 years, lives with partner, a BMI of 37 kg/m2 and interviewed at
37 weeks’ gestation
Conclusions
The phase 1 exploratory study, undertaken with pregnant women with a BMI of ≥ 30 kg/m2 who matched
criteria for inclusion in the proposed UPBEAT pilot RCT other than gestational age at recruitment and
concurrent underlying health problems (see Implications for intervention development and limitations)
but were not involved in the subsequent pilot RCT, suggested that willingness to change lifestyle was
diminished by pregnancy illness and symptoms and by the demands placed upon women’s time by their
family and work responsibilities. A lack of concrete knowledge about the effect of changing diet or
increasing PA on pregnancy or birth complications also appeared to reduce the perceived value of the
intervention. Previous experience of being stigmatised by peers or health professionals affected some
women’s willingness to participate. Although most of these findings were also identified during the pilot
trial process evaluation, the influence of stigma was less apparent. It is unclear whether or not this is
because women who felt stigmatised were less likely to participate in the pilot RCT or whether
modifications to the recruitment approach reduced the experience of stigma.
Implications for intervention development and limitations
Important information was provided by these interviews that contributed to the delivery of the intervention,
notably the need to avoid stigmatisation of women with a higher than normal BMI and the care required
to approach the subject. This became a topic of continued discussion and learning throughout the trial
development and the trial itself. In addition, these interviews led us to appreciate that some pregnant
women who are obese may suffer considerable physical discomfort, which is likely to impact upon their
motivation to undertake PA.
There were several important limitations to this study. These included many of the interviews being carried
out towards term rather than at the proposed time of recruitment, and that several of the women were
already affected by health complications, including existing diagnosis of GDM. Relevance to women
approached to join the trial at 15–18 weeks of pregnancy was therefore limited.
To produce a combined diet and activity intervention for use in
obese pregnant women
An intervention was developed based on goal-setting and review, to be delivered over a period of 8 weeks
from recruitment by study-specific health trainers (HTs). Full details are provided in Chapters 2 and 4.
1. Dietary intervention: a dietary intervention was developed by a postdoctoral nutritionist (Dr S Barr) and,
principal investigator (PI), Professor T Sanders based on the intention of reducing insulin resistance and
improving maternal glucose homeostasis; the dietary component of the intervention included a low
dietary GI, reduced consumption of sugar-sweetened beverages and reduced saturated fat intake.
2. PA intervention: PA advice was developed by a postdoctoral researcher (Dr Kinnunen) and PI (Dr Ruth Bell)
based on the available literature and the intention of improving maternal glucose homeostasis and on
Royal College of Obstetricians and Gynaecologists guidelines. This component of the intervention was
designed to encourage obese pregnant women to increase their daily activity incrementally over the
period of delivery of the intervention and to maintain the achieved activity level as long as possible as their
pregnancy progressed. Pedometers would be provided as a self-motivational tool and women would set
individual step targets weekly.
3. Behavioural intervention: the behavioural theory on which to base the intervention was developed from
control theory with elements from social cognitive theory. Strategies used included graded goals,
behavioural goal-setting, monitoring behaviours, providing feedback regarding goal attainment,
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identification and problem-solving of barriers, enlisting social support and providing opportunities for social
comparison. This approach also supported the building of self-efficacy. HTs delivered the intervention,
following training that included the information gained during the development phase. Training of the HTs
and midwifery staff who recruited the women continued during the 5-year programme.
To develop patient information leaflets, a provisional treatment
manual and a training package to support intervention
The following were developed: patient information leaflets and consent forms, goal-setting and monitoring
logbook, a PA ‘work-out’ digital versatile disc (DVD), a HT manual (standard operating procedures) (see
Appendix 3) and a handbook for women in the intervention arm of the trial (see Appendix 4). All the trial
literature was read, approved and amended with the help of obese women attending antenatal clinics at
Guys and St Thomas’ NHS Foundation Trust, and approved by the King’s College London division of
women’s health patient and public involvement group.
To assess feasibility, acceptability, validity and reliability of
outcome measures
Physical Activity Measurement Study
The measurement of PA in a large number of subjects within a trial setting presents practical and financial
issues. Accurate objective assessment would be the ideal, and at the time of study validation studies had
shown that certain accelerometers could provide reasonably accurate objective measures. However,
expense and collection and download of the accelerometer data were preclusive for the purposes of the
main trial. A study was therefore designed to determine whether or not pedometers could be used instead
of accelerometers in the pilot trial and the main RCT. This has been published as Kinnunen TI, Tennant PW,
McParlin C, Poston L, Robson SC, Bell R. Agreement between pedometer and accelerometer in measuring
physical activity in overweight and obese pregnant women. BMC Public Health 2011;11:501.38 © Kinnunen
et al.; licensee BioMed Central Ltd 2011. This article is published under license to BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. For the purposes of this report minor
formatting edits have been made to the original text.
Agreement between pedometers and accelerometers in measuring
physical activity in overweight and obese pregnant women
Abstract
Background: Inexpensive, reliable objective methods are needed to measure PA in large-scale trials.
This study compared the number of pedometer step counts with accelerometer data in pregnant women
in free-living conditions to assess agreement between these measures.
Methods: Pregnant women (n = 58) with a BMI of ≥ 25 kg/m2 at a median of 13 weeks’ gestation wore a
GT1M (ActiGraph, Pensacola, FL, USA) accelerometer and a CW701 Digi-Walker™ Pedometer (Yamax,
Bridgnorth, UK) for four consecutive days. The Spearman rank correlation coefficients were determined
between pedometer step counts and various accelerometer measures of PA. Total agreement between
accelerometer and pedometer step counts was evaluated by determining the 95% limits of agreement
estimated using a regression-based method. Agreement between the monitors in categorising participants
as active or inactive was assessed by determining kappa.
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Results: Pedometer step counts correlated moderately (r = 0.36–0.54) with most of the accelerometer
measures of PA. Overall step counts recorded by the pedometer and the accelerometer were not significantly
different (medians 5961 vs. 5687 steps/day; p = 0.37). However, the 95% limits of agreement ranged from
–2690 to 2656 steps/day for the mean step count value (6026 steps/day) and changed substantially over the
range of values. Agreement between the monitors in categorising participants to active and inactive varied
from moderate to good depending on the criteria adopted.
Conclusions: Despite statistically significant correlations and similar median step counts, the overall
agreement between the pedometer and accelerometer step counts was poor and varied with activity
level. Pedometer and accelerometer steps cannot be used interchangeably in overweight and obese
pregnant women.
Background
Current recommendations emphasise that regular moderate-intensity leisure-time PA during an
uncomplicated pregnancy may have benefits such as reducing fatigue, back pain, stress and depression and
improving glycaemic control but has no known harmful effects on the health of the mother or the fetus.39,40
However, the available evidence is limited, and larger and better-quality trials are needed to define the
potential role for PA promotion in preventing pregnancy complications such as GDM and pre-eclampsia.41
Most previous studies assessing PA in relation to pregnancy outcome have used questionnaires or other
self-reported measurements of PA, as these are cheap to administer in large-scale studies.42 Although some
of the questionnaires have been validated in pregnant women either against accelerometer,43–45 a portable
activity monitor46 or pedometer and a PA logbook,47 their validity has usually been low or moderate,
especially with regard to the low-intensity activity that is common among pregnant women.48 These
limitations are also observed for PA questionnaires in other populations.49,50 Therefore, inexpensive,
objective PA measurement methods are needed for large-scale studies to obtain more accurate information
on PA levels during pregnancy. Accelerometers and pedometers are the most commonly used objective
methods of assessing PA in epidemiological studies, and have been used in a number of previous studies
of pregnant women.43,44,48,51–54 Although accelerometers provide more detailed information on PA than
pedometers, pedometers are much less expensive and, therefore, more economically feasible for larger
studies.55 It is unclear whether or not pedometers and accelerometers provide comparable estimates of PA
in pregnant women. This issue was recently explored in two small studies (n = 30 in both cases) examining
pregnant women in free-living conditions56 and on a treadmill.57 Similar comparisons have also been
reported in healthy adults58,59 infected with human immunodeficiency virus60 and older people61 in
free-living conditions. These studies suggest that pedometer and accelerometer step counts are highly
correlated, but large individual differences in step counts exist. Nevertheless, pedometer step counts for
assessing overall PA were advocated in most of these studies.56,59–61
This study was designed as a preliminary investigation to determine appropriate PA measurement methods
for a large RCT (UPBEAT) of a lifestyle intervention in obese pregnant women. Overweight and obese
women have a higher risk of several pregnancy complications and may benefit from increasing their PA
levels during pregnancy.62,63 The aim of this study was to compare pedometer step counts with several
accelerometer-derived measures of PA in overweight and obese pregnant women in free-living conditions.
Methods
Study participants
Participants were overweight and obese pregnant women with a BMI of at least 25 kg/m2 based on
self-reported height and measured weight at the first visit to antenatal care, usually before 12 weeks’
gestation. The exclusion criteria were a BMI of < 25 kg/m2, age < 16 years, multiple pregnancy, abnormal
ultrasound scan result, complicated medical problems, inadequate language skills in English or inability to
give written informed consent. A research midwife recruited the participants when they attended for their
routine ultrasound scan at either 11–14 or ≥ 20 weeks’ gestation at the Royal Victoria Infirmary, Newcastle
upon Tyne, UK, between July and December 2009. The participants were recruited in early pregnancy
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because information on the appropriate PA measurement methods for the intervention study starting in
early pregnancy was needed.
A total of 286 women were eligible for the study and 93 (33%) agreed to participate. All participants
signed a written informed consent for participation. Ethics approval for the study was obtained from
St Thomas’s Hospital Research Ethics Committee, London, UK (National Research Ethics Service, Research
Ethics Committee reference number 09/H0802/5).
Data collection
This study was a cross-sectional comparison of two objective PA measurement methods. The research
midwife asked participants to wear an accelerometer and a pedometer for four consecutive days, including
one weekend day. In adults, 3–5 days of monitoring by accelerometer usually provides a reliable estimate
of PA.64 The participants kept a diary to record when the monitors were put on and when they were taken
off. Data on participants’ demographic details were collected using a short structured questionnaire.
An appointment for returning the monitors was arranged after the 4-day period.
Accelerometer
The GT1M accelerometer used in this study was a small uniaxial monitor, which detects vertical accelerations
over a user-specific time interval (epochs).65 The former version of the ActiGraph accelerometer [Computer
Science and Applications (CSA) 7164 model; ActiGraph, Pensacola, FL, USA] is one of the most extensively
validated accelerometers and its activity counts correlate reasonably with double-labelled water-derived
energy expenditure in non-pregnant populations.66
Participants were asked to wear the accelerometer on the right hip during waking hours except while
swimming or having a shower or bath. They were given the choice of belt or waistband attachment and
information was recorded on which they found to be the most comfortable. Most participants (n = 40,
69%) wore the accelerometer using a belt, whereas 14 (24%) clipped it on to the waistband of their
clothing; in four participants (7%) the status was unknown. A 60-second epoch length was used in this
study. The raw data were processed using the MAHUffe program [Medical Research Council (MRC)
Epidemiology Unit, University of Cambridge, Cambridge, UK] (www.mrc-epid.cam.ac.uk/physical-activity-
downloads). Periods of at least 60 minutes with no counts and days with < 500 minutes of total valid
recording time were excluded.
The following cut-off points were used to assess time spent at different intensity levels: sedentary
< 100 counts per minute (cpm),67 light activity 100–1951 cpm, moderate activity 1952–5724 cpm and
vigorous activity > 5724 cpm.68 These cut-off points were originally developed for CSA Model 7164
accelerometer. Currently, there is no consensus on the best cut-off points to be used and these may vary
in different populations. The Freedson cut-off points, derived from treadmill conditions, were selected
because leisure time PA in our population mainly consisted of walking and because these cut-off points
have been used in previous studies comparing pedometers to accelerometers.56,58–60
Pedometer
The CW701 Digi-Walker™ pedometer was used to measure daily step counts. Yamax Digi-Walker models
have been shown to be among the most accurate models in measuring step counts.69,70 The participants
were asked to wear this device during the same time period as the accelerometer. The participants clipped
the pedometer either to the accelerometer belt or to the waistband of their clothing depending on how
the accelerometer was attached.
Categorising participants as active or inactive
Three different criteria were used to categorise participants as active: (1) ≥ 30 minutes moderate to
vigorous PA (MVPA)/day (for accelerometer data only, as this information could not be derived from the
pedometer data), (2) ≥ 10,000 steps/day and (3) ≥ 8000 steps/day. The first criterion was based on current
PA recommendations. The second criterion is a commonly used step target in health promotion and has
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been shown to be associated with health benefits.71,72 The third criterion was chosen as there is some
evidence to suggest that 8000 steps/day corresponds to 30 minutes of MVPA/day measured by
accelerometer when using similar intensity cut-off points as in the present study.58,59,72
Statistical analyses
All activity data were averaged over the valid days of recording. The majority of variables were not normally
distributed and, therefore, non-parametric methods were employed for all analyses. Continuous variables
were described using the median and interquartile range. Differences in background characteristics of
included (n = 58) and excluded (n = 35) participants were tested using Mann–Whitney U-test for continuous
variables and chi-squared test for categorised variables.
Agreement between the accelerometer and the pedometer was assessed in several ways. Absolute step
count measurements were compared using the Wilcoxon signed-rank test. The relative agreement
between pedometer-derived step counts and various accelerometer measures of PA was examined by
determination of the Spearman rank correlation coefficient (r).
Total agreement between accelerometer-derived and pedometer-derived step counts was evaluated by
determination of the 95% limits of agreement. The difference between both measures of step counts was
plotted against the mean of both measures. As there was a statistically significant negative correlation
between these variables, which was not resolved by transformation, the limits of agreement were estimated
by a regression-based method. To test whether or not the limits of agreement varied by baseline BMI
(25.0–29.9 kg/m2 vs. ≥ 30.0 kg/m2) or gestational age (11–14 vs. ≥ 20 weeks’ gestation), interactions terms
were added to regression models, and absolute residuals were compared by Student’s t-tests.
The classification of participants according to whether or not they recorded a daily mean of at least 8000 or
10,000 steps/day was compared between pedometer and accelerometer by calculating Cohen’s kappa over
2 × 2 contingency tables. Kappa was also determined to assess the agreement between those reaching
8000 pedometer steps/day and those achieving 30 minutes MVPA, as measured by accelerometer. Kappa
values of 0.81–1.00 were regarded as indicating almost perfect agreement, while values of 0.61–0.80
indicated good agreement, 0.41–0.60 moderate agreement, 0.21–0.40 fair agreement and 0.0–0.20
slight agreement.73
Confidence intervals (CIs) and p-values for r were estimated by bootstrapping over 5000 iterations. A
p-value of < 0.05 was considered statistically significant. The majority of statistical analyses were performed
using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA); however, bootstrapping methods used
Stata® version 10.2 (StataCorp LP, College Station, TX, USA).
Results
Of the 93 women recruited, 32 (34%) had valid accelerometer data for fewer than three days, 17 (18%)
had valid data for 3 days and 44 (47%) had valid data for 4 days. All valid days from women with valid
data for at least 3 days (n = 61) were included in further analyses, excluding three women who did not
have pedometer data. The final study sample consisted of 58 women (62% of those recruited). The
excluded women (n = 35) were younger (median age 28 vs. 32 years; p = 0.018) and more often smokers
during the previous year (46% vs. 13%; p = 0.002) than the included women, and fewer of them were
highly educated (5% vs. 59%; p < 0.001), but gestational age, BMI, parity, ethnicity, marital status and
employment status were similar to those of the included women. The background characteristics of the
included women are described in Table 3. The median age was 32 years and the median BMI was
29.3 kg/m2 (range 25.3–46.2 kg/m2).
Descriptive activity data
The median wear time of the accelerometer was 13 hours 40 minutes/day (Table 4). The women were
sedentary for most of that time and total active time (median 4 hours 50 minutes/day) mainly comprised
light-intensity activity. The median time spent in MVPA was 18 minutes/day.
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TABLE 3 Background characteristics of the participants
Background characteristics Participants
Continuous variables, median (interquartile range)a
Age (years) 32 (27–36)
Weeks’ gestation 13 (12–20)
BMI (kg/m2) 29.3 (27.5–33.8)
Categorised variables, number (%)
Weeks’ gestation category
11–14 32 (55.2)
≥ 20 26 (44.8)
BMI category
25.0–29.9 kg/m2 35 (60.3)
≥ 30.0 kg/m2 22 (39.7)
Parity
0 27 (46.6)
1 21 (36.2)
≥ 2 10 (17.2)
Education (highest qualification)b
GCSE or equivalent (at age ≥ 16 years) 9 (17.0)
A-level or equivalent (at age ≥ 18 years) 13 (24.5)
Degree or higher postgraduate qualification 31 (58.5)
Ethnicity
White 48 (88.9)
Other 6 (11.1)
Smoked during the last year
Yes 7 (12.7)
No 48 (87.3)
Employed at the beginning of pregnancy
Yes 48 (84.2)
No 9 (15.8)
Hours of employmentc
Full time (≥ 37 hour/week) 30 (63.8)
Part time (< 37 hour/week) 17 (36.2)
Living with a partner/husband
Yes 55 (96.5)
No 2 (3.5)
GCSE, General Certificate of Secondary Education.
a n= 58 for continuous variables.
b Higher postgraduate qualification includes Professional Graduate Certificate in Education (or Postgraduate Certificate in
Education), Master of Science, Doctor of Philosophy, etc.
c Including 48 women who were employed.
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Agreement between continuous pedometer and accelerometer measures of PA
There was no significant difference between the overall step counts recorded by the pedometer and the
accelerometer (median 5961 vs. 5687 steps/day, respectively; p = 0.37; see Table 4). Pedometer step counts
were significantly correlated with all accelerometer measures of PA except for sedentary time (Table 5). The
correlation was good for accelerometer step counts (r = 0.78) and moderate (r = 0.36 to 0.54) for all other
measures of PA. Pedometer step counts are plotted against accelerometer step counts in Figure 1. Despite
these statistically significant correlations, the 95% limits of agreement were very broad, ranging between
–2690 and 2656 steps/day for the mean value (mean of accelerometer and pedometer steps/day = 6026)
(Figure 2). The limits of agreement also varied substantially over the range of values, indicating a differential
bias. At the lowest recorded step count (mean of accelerometer and pedometer steps/day = 906), the limits
were –927 to 4897 steps/day (a range of 5824), indicating that the accelerometer was on average recording
more steps/day than the pedometer. In contrast, at the highest step count value (mean of accelerometer
and pedometer steps/day = 12,018) the limits were –4753 to 33 steps/day (a range of 4786) indicating that,
TABLE 4 Descriptive data on PA measures among participants with valid data for at least 3 days (n= 58)a
PA measure Median (interquartile range) Range
Accelerometer
Total included wear timeb 821.8 (754.0–869.3) 608.0–1111.0
Sedentary timeb 514.0 (464.3–583.1) 255.7–849.8
Total activity timeb 290.9 (245.8–340.1) 127.7–473.5
Light activityb 271.3 (218.8–315.4) 99.3–429.3
Moderate activity 18.0 (11.4–29.1) 5.3–70.0
Vigorous activity 0.0 (0.0–0.0) 0.0–4.3
Moderate or vigorous activity 18.0 (11.7–30.1) 5.3–70.0
Total counts/day 202,680 (166,951–248,348) 92,131–429,497
Average cpm 256.3 (209.5–323.7) 131.0–615.5
Steps, counts/day 5687 (4452–7086) 1545–11,453
Pedometer
Steps, counts/dayb 5961 (3727–8510) 267–12,833
a Minutes/day unless otherwise specified. The values represent the average of all valid days.
b A normally distributed variable.
TABLE 5 Spearman correlation coefficients between pedometer step counts and accelerometer measures of
PA (n= 58)
Variable measured Correlation coefficient 95% CI p-value
Sedentary time (minutes/day) –0.30 0.51 to 0.05 0.023
Total activity time (minutes/day) 0.40 0.13 to 0.63 0.002
Light activity (minutes/day) 0.36 0.10 to 0.58 0.006
Moderate or vigorous (minutes/day) 0.47 0.18 to 0.69 < 0.001
Activity (minutes/day) 0.51 0.24 to 0.72 < 0.001
Total counts/day 0.54 0.28 to 0.74 < 0.001
Average 0.78 0.59 to 0.90 < 0.001
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(n= 58). The limits of agreement were calculated using a regression method previously described by Bland and Altman.74
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while the level of random disagreement had decreased, the direction of bias had reversed, with the
accelerometer recording less steps/day than the pedometer on average. BMI and gestational age did not
modify the limits of agreement as there were no statistically significant differences in the slope of the
regression line (p = 0.28 for BMI; p = 0.68 for gestational age) or in the absolute spread from the regression
line (p = 0.64 for BMI; p = 0.35 for gestational age).
Agreement between categorised pedometer and accelerometer measures of
physical activity
Based on the accelerometer data, 15 (26%) of these women recorded ≥ 30 minutes MVPA/day, 12 (19%)
recorded ≥ 8000 steps/day and three (5%) recorded ≥ 10,000 steps/day. The pedometer data showed that
18 (29%) of the women recorded ≥ 8000 pedometer steps/day and four (7%) recorded ≥ 10,000 steps/day.
There was moderate agreement between those achieving ≥ 8000 pedometer steps/day and those
achieving ≥ 30 minutes MVPA/day (kappa 0.45, 95% CI 0.24 to 0.67) (Table 6). Agreement between the
pedometer and the accelerometer in categorising women to < 8000 or ≥ 8000 steps/day was good (kappa
0.63, 95% CI 0.43 to 0.83). Very few women achieved ≥ 10,000 steps/day with either of the monitors
(n = 3 for accelerometers and n = 4 for pedometers), thus the agreement between these was artificially
high (results not shown).
Discussion
Large-scale trials are needed to assess the potential impact of increased PA on reducing pregnancy
complications and these trials should ideally use objective measurement methods to measure changes in
PA.40,41,75 Pedometers would be a cost-effective measurement tool for large studies, provided that the
simple step count measure is broadly comparable to the more specific accelerometer data. Our results
show that, although there was a significant correlation between pedometer step counts and most
accelerometer measures of PA and no difference in median step counts between the two devices, the
95% limits of agreement were very broad, especially among those participants who were less active. In
addition, the direction of difference between the monitors appeared to reverse across the range of activity
levels, suggesting a complicated pattern of disagreement. Agreement between the monitors in categorising
participants as active and inactive varied from fair to good depending on the criteria adopted, being good
when achievement of ≥ 8000 steps/day was used as the criterion. Pedometer step counts have been compared
with accelerometer data in a number of previous reports,56,58–61 all of which used one of the ActiGraph/CSA/
Manufacturing Technology Inc. accelerometer models and one of the Yamax pedometer models, as in the
present study. These accelerometer models are not entirely comparable to each other in measuring steps
and activity counts.76,77 The study by Harrison et al.56 included 30 overweight or obese pregnant women at
26–28 weeks’ gestation in Australia. The participants wore an accelerometer (GT1M) and a pedometer for
5–7 days and the accelerometer data processing rules were very similar to those used in our study. Despite a
statistically significant correlation (r = 0.69, p < 0.01) between the step counts of each monitor, the mean
difference was 505 steps/day and the limits of agreement were large (from –2491 to 3501 steps/day).
The other studies were not conducted in pregnant women and, generally, included subjects who were
more active than our participants. However, the findings were essentially similar to those in the present
study. Tudor-Locke et al.,58 in a study of 60 adult volunteers in South Carolina, USA, observed a high
TABLE 6 Agreement between categorised pedometer and accelerometer measures of PA: kappa and 95% CI
Accelerometer dataa Kappa (accelerometer data vs. ≥ 8000 pedometer steps counts/day)b 95% CI
≥ 30 minutes MVPA/day 0.45 0.24 to 0.67
≥ 8000 steps/day 0.63 0.43 to 0.83
a 15 (26%) of the participants recorded ≥ 30 minutes MVPA/day and 12 (19%) recorded ≥ 8000 steps/day.
b 18 (29%) of the participants recorded ≥ 8000 pedometer steps/day.
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correlation between accelerometer (CSA model 7164) and pedometer step counts (r = 0.86), but the
accelerometer detected 1845 ± 2116 more steps/day, on average, than the pedometer and the limits of
agreement were even broader (–2387 to 6077 steps/day) than reported in the present study. In a larger
study of older adults in the UK (n = 121),61 Harris et al. reported that pedometer step counts were highly
correlated to the accelerometer (GT1M) step counts (r = 0.86) and the mean step counts were similar.
However, the limits of agreement were again large, around –3500 to 35,0081 steps/day. Ramirez-Marrero
et al.60 reported similar findings among 58 adults infected with human immunodeficiency virus in Puerto
Rico. Although the limits of agreement were not calculated in that study, individual variation in differences
in step counts seemed to be large. When comparing pedometer step counts with other accelerometer
(ActiGraph model 7164) measures of PA, the correlations observed in the present study are generally
similar, although weaker than in the previous studies.58,60,61 Macfarlane et al.59 observed, among 57 adult
volunteers in Hong Kong, that the means for accelerometer (Manufacturing Technology Inc. model 7164)
measures of PA increased with increasing pedometer step counts, but the CIs were broad.
Among the previous studies, Tudor-Locke et al.58 were the only authors to conclude that agreement
between pedometer step counts and accelerometer measures of PA was unacceptably low, despite others
also reporting broad limits of agreement56,61 or CIs.59 Future studies should pay more attention to correct
interpretation of Bland–Altman plots and limits of agreement.
The present study confirms the findings of these studies in a sample of 58 overweight and obese pregnant
women. Although there are currently no methods available to calculate 95% CI for the limits of
agreement determined by a regression-based method, it is important to note that a larger sample size
would not have affected the size of the limits of agreement. There are also no guidelines for acceptable
95% limits of agreement for step counts.
We propose that they should be no larger than ± 500 steps/day (i.e. a range of 1000 steps/day), which is
likely to correspond to a maximum of a 10-minute difference in the duration of MVPA, such as brisk
walking,71 and may therefore be of clinical and public health importance.
The difference between the accelerometer and the pedometer step counts was correlated to the mean
of both measures in the present study, but not in the other studies.56,58,61 In this study, the difference
between the step counts was in the opposite direction for less active and more active women, that is the
accelerometer detecting more steps among less active women and the pedometer detecting more steps
among more active women. This discrepancy may be related to the general limitations of the monitors
or differences in their sensitivity to detect PA. Pedometer accuracy is reported to be diminished at slow
walking speeds, especially below 3 miles/hour,69,78 and both active and inactive participants undertook many
episodes of low-intensity activity in the present study. This may also be the case with some accelerometers,
although the GT1M model used in our study has been shown to have lower inter-monitor variability and
lower sensitivity for low-intensity activity than the previous 7164 model.76,77 On the other hand, the previous
CSA model has also been reported to erroneously detect slightly more non-steps, for example when
travelling by a motor vehicle.79
The accuracy of the latest ActiGraph accelerometer model (GT3X, ActiGraph, Pensacola, FL, USA) and the
Yamax Digi-Walker SW200 (Yamax, Bridgnorth, UK) was recently investigated in 30 pregnant women.57
Both monitors underestimated the number of steps, especially at slow walking speeds, and even when the
monitors were repositioned at a tilt angle, there was no correlation with the percentage of actual steps
detected by either monitor. In contrast, Crouter et al.69 suggested that the tilt angle reduced the accuracy
of spring-levered pedometers in overweight or obese adults. The tilt angle may also reduce the accuracy of
accelerometers in assessing vertical movement, which may happen more often among overweight and
obese than normal weight people.55 The tilt angle was not directly measured in the present study.
However, BMI and gestational age did not significantly modify the results of the Bland–Altman plot,
suggesting that the potential effect of the tilt angle on the results may have been the same regardless of
BMI or gestational age.
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We also assessed agreement between the monitors in categorising participants as active or inactive.
Although agreement was relatively good (kappa 0.63) when using 8000 steps/day as the criterion for both
monitors, agreement was lower (kappa 0.45) when comparing participants achieving 8000 pedometer
steps/day with those achieving 30 minutes of MVPA/day measured by a accelerometer. Of the previous
studies, Ramirez-Marrero et al.60 reported fair agreement between 10,000 pedometer steps/day and
150 minutes of MVPA/week (kappa 0.25, p = 0.01). These discrepancies between pedometers and
accelerometers in categorising participants into active and inactive may partly be because of the data
processing rules, such as selection of the epoch length and intensity cut-off points to define MVPA for the
accelerometer data.
Accelerometry should not be regarded as a gold standard to measure free-living PA nor necessarily as a
more accurate method of measuring daily steps than with a pedometer. Although the previous version of
the ActiGraph accelerometer was the only commercially available accelerometer66 that correlated reasonably
with double-labelled water, most validation studies have been conducted in controlled environments.
Validity is lower when applied to free-living settings.55 Two armband accelerometers have also recently been
shown to be highly correlated with double-labelled water in free-living conditions.42 Both the accelerometer
and the pedometer measure biomechanical body movement. Hence, validity of the monitors against energy
expenditure should not be a major concern when assessing agreement between these devices.
This study had some limitations. First, although the participants were asked to record the times when they
wore the monitors, we cannot be sure that both monitors were worn exactly for the same time. Some
women had very low pedometer step counts but moderate accelerometer step counts, suggesting that the
wearing time may have been different for each monitor or the pedometer may have been in a tilt angle.
Therefore, studies in controlled conditions, such as that by Connolly et al.,78 would be necessary to be
certain that monitors were worn for exactly the same time. Second, almost all of our participants were in
the first or second trimester of pregnancy and, therefore, we do not know whether or not the results can
be generalised to the third trimester, when activity decreases and the abdominal circumference is much
larger. On the other hand, these results may be generalised to non-pregnant overweight and obese
women of similar age.
Third, participation was low (33%) and 34% of the participants were excluded because valid accelerometer
data were available for fewer than 3 days. The activity levels of the participants were similar or slightly lower
than those reported in pregnant women in other comparable studies.42,44,54,80 The purpose of this study,
however, was to compare methods of measurement, rather than to obtain representative estimates of PA
levels in pregnancy.
Conclusions
Comparing median step counts or assessing correlation coefficient overestimates agreement between
pedometer and accelerometer data. Examination of the 95% limits of agreement revealed a substantial
lack of agreement between step counts measured by the two types of monitor. Pedometer step counts
were not comparable to accelerometer data at an individual level in overweight and obese pregnant
women. The choice of measurement method may depend on the target of the intervention. For example,
accelerometers may be better at assessing changes in PA in trials that promote increases in moderate or
vigorous PA or reduction in sedentary time, whereas spring-levered pedometers may be more appropriate
for studies evaluating walking interventions in more active populations.
Implications for intervention development
As a result of this report, the decision was taken to use validated accelerometers for the pilot study to
provide the most accurate, although not perfect, objective assessment of PA and that the pedometer would
be supplied to all women in the intervention arm of both the pilot study and the main trial as a motivational
aid only. Assessment in the pilot study would also include a self-reported validated questionnaire, and it was
decided that self-reported questionnaire would provide the only practical measurement of PA for the main
trial (phase 3).
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Dietary assessment and analysis
A decision was made to calculate the dietary GI in obese pregnant women using the commercially
available WISP version 3 (Tinuviel software, Llanfechell, Anglesey, UK) dietary analysis software. In order
to assess diet most accurately, it was decided that dietary data in the pilot study would be obtained from
a triple-pass 24-hour dietary recall at three time points in duplicate, performed at baseline and post
randomisation [28/29(+1) weeks’ gestation and 36/37(+1) weeks’ gestation] (for details see Chapter 4). This
dietary assessment methodology was undertaken in preference to a 4-day food diary, owing to recall bias
and data quality issues reported with this method in similar population groups. A shortened food frequency
questionnaire (FFQ) was also employed for assessment of long-term dietary habits, with particular reference
to the dietary GI and for validation in the pilot study (for details see Chapter 4).
Method development for health-care cost assessment
This was undertaken by the Department of Health Economics, York University, York, UK. A within-trial
cost–utility analysis was planned to estimate the cost-effectiveness of the health training (intervention) over
and above routine care (control). Quality-adjusted life-years (QALYs) would be used to measure health
outcomes and were derived from participant-completed EuroQol-5 Dimensions (EQ-5D) questionnaires.81
Development of trial database
A secure, password-protected internet-based database was developed (MedSciNet Ltd, Stockholm,
Sweden). This facilitated contemporaneous data collection and cleaning and enables 24-hour
randomisation. The information collected includes maternal and paternal demographics; assessment of
eligibility; consent; previous maternal, medical, family, social and obstetric history; maternal anthropometric
measurements, maternal food questionnaires; maternal PA data (uploaded from accelerometer; pilot study
only); lifestyle questionnaire; depression questionnaire; quality-of-life questionnaire; EQ-5D questionnaire;
and, maternal pregnancy outcome and neonatal outcome data. The database also included sample data
storage and management fields.
Ethics approval
Ethics approval was granted for the entire programme (IRAS 09/H0802/5) and research and development
approvals obtained from the trial centres. When necessary substantial amendments were requested and
granted. The UPBEAT was accepted on the UK Clinical Research Network portfolio number 5305.
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Chapter 2 The UK Pregnancies Better Eating and
Activity trial: phase 2 – pilot trial
Following development of the intervention, detailed in this chapter and the protocol (see Chapter 4), theprogramme progressed to phase 2, a pilot trial designed to establish the efficacy of the intervention in
changing dietary and PA behaviours and to evaluate all practical aspects of delivering the intervention.
This chapter has been published as Poston L, Briley AL, Barr S, Bell R, et al. Developing a complex
intervention for diet and activity behaviour change in obese pregnant women (the UPBEAT trial);
assessment of behavioural change and process evaluation in a pilot randomised controlled trial. BMC
Pregnancy Childbirth 2013;13:148.150 © Poston et al.; licensee BioMed Central Ltd. 2013. This article is
published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited. The text below includes minor additions and formatting changes to the original text.
Abstract
Background: Complex interventions in obese pregnant women should be theoretically based, feasible
and shown to demonstrate expected behavioural change prior to inception of large RCTs. The aim was to
determine if (1) a complex intervention in obese pregnant women leads to expected changes in diet and PA
behaviours, and (2) to refine the intervention protocol through process evaluation of intervention fidelity.
Methods: We undertook a pilot RCT of a complex intervention in obese pregnant women, comparing
routine antenatal care with an intervention to reduce dietary GL and saturated fat intake and increase PA.
Subjects included 183 obese pregnant women (mean BMI 36.3 kg/m2). Diet was assessed by repeated
triple-pass 24-hour dietary recall and PA by accelerometry and questionnaire at 16+0–18+6 and at 27+0–28+6
weeks’ gestation in women in control and intervention arms. Attitudes to behaviour change and quality
of life were assessed and a process evaluation undertaken. The full RCT protocol was undertaken to
assess feasibility.
Results: Compared with women in the control arm, women in the intervention arm had a significant
reduction in dietary GL (33 points, 95% CI −47 to −20 points), (p < 0.001) and saturated fat intake
(−1.6% energy, 95% CI −2.8% to −0.3%) at 28 weeks’ gestation. Objectively measured PA did not
change. Physical discomfort and sustained barriers to PA were common at 28 weeks’ gestation. Process
evaluation identified barriers to recruitment, group attendance and compliance, leading to modification of
intervention delivery.
Conclusions: This pilot trial of a complex intervention in obese pregnant women suggests greater
potential for change in dietary intake than for change in PA, and through process evaluation illustrates the
considerable advantage of performing an exploratory trial of a complex intervention in obese pregnant
women before undertaking a large RCT.
Trial registration: Trial registration number ISRCTN89971375.
Background
Obesity is prevalent in women of reproductive age in both high- and low- to middle-income countries.82
Obese pregnant women have a heightened risk of adverse pregnancy outcomes,82 but at present there is
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no evidence-based intervention that can be introduced into clinical practice to improve pregnancy outcome
in obese women. The majority of attempts to develop interventions have hitherto focused on limiting GWG
in accordance with the US Institute of Medicine’s recommendations.83 Recent meta-analyses of relevant
studies in obese women show modest restriction of GWG without robust evidence for improved clinical
outcome.84,85 Limitations of the existing evidence include poor study design, small sample size, absence of
a theoretical basis and, importantly, no a priori demonstration of the feasibility of the intervention in regard
to changing the specific behaviours targeted. We have developed a theoretically based behavioural group
intervention (diet and PA) for obese pregnant women with the primary aim of improving maternal glucose
homeostasis. As maternal insulin resistance is integral to many complications of obese pregnancy, the dietary
intervention focuses on lowering the dietary GI, previously shown to improve pregnancy outcome in women
with GDM.9,86 Recommendations were also made to lower saturated fat intake, as a diet high in saturated
fats has been implicated in insulin resistance and GDM.87 Increased PA can also improve metabolic control
and reduce GDM risk in pregnant women.88
Prior to embarking on a large RCT, and in accordance with UK Medical Research Council Guidance for
development of a complex intervention,89 we first explored the theoretical basis for an intervention in
obese pregnant women,2,3,85,90 leading to development of a novel intervention (phase 1). We now report
on phase 2, an exploratory trial to determine whether or not this intervention achieved the changes in
dietary and PA behaviours expected, and to undertake a process evaluation of every aspect of fidelity of
the intervention and the protocol.
Participants
Potentially eligible participants attending clinics for general antenatal care were approached by research
midwives in four UK study centres in urban settings providing a range of models of care. The contributing
hospitals were (1) The Southern General Hospital and Princess Royal Maternity Hospital (Glasgow),
(2) The Royal Victoria Infirmary (Newcastle), (3) Guy’s and St Thomas’ NHS Foundation Trust (London) and
(4) King’s College Hospital Foundation Trust (London).
Methods
The protocol for the exploratory trial is shown in Figure 3. Verbal and printed information was provided to
potential participants at a routine antenatal appointment in the first trimester of pregnancy and women
were contacted > 24 hours later to ascertain willingness to participate. For those declining participation,
consent to record basic demographic data and BMI was obtained. Those willing to participate were invited
to return for their first study appointment in the early second trimester (> 15+0 to < 17+6 weeks’ gestation).
This window of recruitment allowed adequate time for arrangement of the one-to-one session with the HT
followed by the 8-week intervention programme prior to the oral glucose tolerance test (OGTT), carried
out between 27+0 and 28+6 weeks’ gestation. Research midwives received a study-specific manual,
attended at least one training session with the trial manager and continued feedback and training sessions
for the study duration.
Inclusion criteria: a BMI of ≥ 30 kg/m2, singleton pregnancy and a gestational age of > 15+ and < 17+6 weeks.
Exclusion criteria: unable or unwilling to give written informed consent; gestation age of < 15+0 and
> 17+6 weeks; pre-existing diabetes mellitus; pre-existing essential hypertension (treated); pre-existing renal
disease; multiple pregnancy; systemic lupus erythematosus; antiphospholipid syndrome; sickle cell disease;
thalassaemia; coeliac disease; currently prescribed metformin; thyroid disease; or current psychosis.
All data were entered onto a password-protected secure database (MedSciNet Ltd). Randomisation was
performed online. The randomised treatment was allocated automatically, balanced by minimisation for
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Potentially eligible women
contacted by research midwife
Declines participation
• Confirm permission to collect 
   outcome data
Agrees to take part
First appointment 
(15+0–17+6 weeks’ gestation)
• Consent; BMI; eligibility check; demography
   and socioeconomic status; dietary assessment;
   attitudinal assessment questionnaire; and
   accelerometer provided
Second appointment 
(1 week later)
• Randomisation; dietary assessment; 
   accelerometer data downloaded; EPDS, 
   EQ-5D, RPAQ questionnaires; anthropometry; 
   weight; and blood sample
Fourth appointment 
(1 week later)
• Dietary assessment; accelerometer data 
   downloaded; RPAQ questionnaire; and weight
Fifth appointment 
(34+0–35+6)
• As third appointment (no OGTT)
Sixth appointment 
(1 week later)
• As fourth appointment
Maternal and neonatal outcome data
Third appointment 
(27+0–28+6 weeks’ gestation)
• OGTT; dietary assessment; attitudinal 
   assessment, EPDS, EQ-5D questionnaires; 
   weight; anthropometry; blood sample; and 
   accelerometer provided
Intervention arm
• Eight weekly sessions with
   health trainer
Control arm
• Standard antenatal care
FIGURE 3 Pilot study protocol. EPDS, Edinburgh Postnatal Depression Scale; OGTT, oral glucose tolerance test;
RPAQ, Recent Physical Activity Questionnaire.
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maternal age, centre, ethnicity, parity and BMI. Data were analysed using Stata (version 11.2; StataCorp,
College Station, TX, USA). All women randomised between 29 March 2010 and 13 May 2011 were
included. Postcodes were matched to two national indices of deprivation: the Index of Multiple
Deprivation91 for English addresses or the Scottish Index of Multiple Deprivation92 for addresses in Scotland.
Control arm
Following randomisation, women in the control arm (standard care) returned for data collection
appointments with the study midwife at 27+0–28+6 and 34+0–36+6 weeks’ gestation, when possible
coinciding with routine antenatal visits.
Intervention arm
Following randomisation, participants attended a one-to-one appointment with the HT and were invited
to weekly group sessions for 8 consecutive weeks from approximately 19 weeks’ gestation. All women
attended routine antenatal care appointments and received advice regarding diet and PA in accordance
with local policies, which draw on the UK’s National Institute for Health and Care Excellence (NICE)’s
guidelines.93
Sample size
The primary outcome was change in dietary and PA behaviours at 28 weeks’ gestation (coinciding with
the primary maternal outcome for the main RCT, GDM at 28 weeks’ gestation). No prior investigation in
obese pregnant women was available to inform power at the planning stage. The sample size of 183 was
determined by the predefined duration of phase 2, the exploratory phase. This number was adequate to
enable power calculations for primary end points of the subsequent RCT, by providing estimates of the
variance to within approximately 7% of the true value.
Ethics
Research Ethics Committee approval was obtained in all participating centres, UK IRAS reference number
09/H0802/5 (South East London Research Ethics Committee).
The intervention
The intervention was informed by psychological models of health behaviour including control theory94 and
social cognitive theory.95 Although no clear patterns between intervention characteristics and outcomes
have been seen to date in lifestyle interventions in pregnancy, and few studies have described their
theoretical basis,2,85 self-regulation techniques, drawn from control theory, suggest that behaviour change
is facilitated by feedback about performance compared with prespecified goals.94,96 This approach was
utilised in this study by setting specific, measurable, achievable, relevant and time-specific (SMART) diet
and activity goals, with behaviours recorded in a logbook. Identification of benefits of, and overcoming
barriers to, behaviour change, and increasing self-efficacy were also included, and social support was
facilitated through the group format.95 As identified in social cognitive theory, the intervention aimed to
build self-efficacy through mastery experiences (e.g. maximising the chance of success with SMART goals),
vicarious experiences (encouraged through modelling in the group setting), and social persuasion (e.g.
through enlisting social support). Following initial feedback from HTs regarding difficulties encountered by
some women in attending sessions, for those women unable to attend, the session content was delivered
by telephone or e-mail.
Dietary advice
Prespecified dietary outcomes were a change in the GI, GL [an indicator of carbohydrate quality (GI) and
quantity consumed] and energy intake from saturated fatty acids (SFAs). The focus of the dietary advice to
the intervention group was therefore on increased consumption of foods with a low dietary GI, including
replacement of sugar-sweetened beverages with low-GI alternatives. Reduction in saturated fats and
replacement with monounsaturated and polyunsaturated fat was also recommended. Exchange of foods
was emphasised, for example a high-GI food for a low-GI food, rather than limiting energy intake.
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Physical activity advice
Women in the intervention arm were encouraged to increase daily PA incrementally, setting goals of
incremental step counts (monitored by pedometer) and maintaining the achieved PA level after the
intervention period. Recommendations included an emphasis on walking at a moderate-intensity level.39
Intervention delivery
The intervention was delivered by HTs. In the UK, HTs do not have prespecified health professional
qualifications, but relevant experience [http://informationstrategy.dh.gov.uk/health-trainer-workforce
(last accessed 10 March 2013), information now available at www.healthcareers.nhs.uk/explore-roles/
public-health/health-trainer (last accessed 20 March 2017)]. All HTs received a comprehensive treatment
manual, pre-study training (and within-study supervision) in behaviour modification and conducting group
sessions (organised by Weight Concern; registered charity number 1059686). The sessions were held in a
hospital setting in all but one centre, in which women attended a community children’s centre. At the initial
one-to-one appointment women were provided with a participant handbook, reflecting the rationale and
content of the HT sessions, a pedometer (Yamax SW200 Digi-Walker), a logbook for weekly SMART goals
and related behaviours (steps, PA and diet) and a DVD of a specially devised pregnancy exercise regime.
Potential benefits of attending group sessions were discussed. Each group session delivered a different
element of the dietary and PA intervention. (Table 7). Goals from the previous week were reviewed and
goals set for the following week. Discussion included barriers to behavioural change and ways these might
be overcome.
The following information was obtained from all participants (at visits indicated in Figure 3).
Attitudinal assessment questionnaire
The attitudinal assessment included questions relating to perceived benefits and barriers and confidence
to carry out the dietary and PA behaviours.27,97 The target behaviours were to consume lower-GI
carbohydrates, to reduce saturated fat intake and to increase PA.
Health status and mental health
The EQ-5D98 was used to assess health status and the Edinburgh Postnatal Depression Scale (EPDS) to
assess mental health.99
TABLE 7 Summary of session content
Session and main topics Content
Introductory one-to-one session
Introduction to the programme Overview of programme structure, content and participant materials
Participant expectations of taking part and what they hope to gain
Information regarding safe exercise in pregnancy
Participants given pedometer and information on how to use it
UPBEAT DVD and logbook given
Session 1
Swapping soft drinks
First steps to PA
Introductions and group rules
Review of pedometer use
Information on soft drinks
Introduction to goal-setting
continued
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TABLE 7 Summary of session content (continued )
Session and main topics Content
Session 2
Reducing added sugar
Increasing everyday activity
Information on reducing added sugar
Information on SMART goal-setting
Information on increasing everyday PA
Session 3
Swapping bread
Overcoming barriers to PA
Problem-solving of barriers to being physically active
Information on choosing lower-GI bread
Session 4
Swapping other starchy foods
Benefits of PA
Half-way review
Information on choosing lower-GI rice, potatoes and other starchy foods
Information on benefits of PA
Review of own PA level
Discussion about the UPBEAT DVD
Session 5
Swapping snacks
Active leisure time
Information on choosing healthier snacks
Cravings vs. hunger
Discussion on leisure time PA and how to access services
Session 6
Swapping breakfast cereals
Local leisure services
Discussion on experiences of accessing local leisure services
Information on choosing lower-GI breakfast cereals
Discussion on maintaining changes made to behaviour
Session 7
Choosing lower-fat dairy products
Keeping active throughout the day
Review of dietary and activity topics covered so far, any benefits participants have
experienced and accessing support after the sessions
Discussion on keeping active throughout the day
Information on choosing lower-fat dairy products
Session 8
Choosing lower-fat meat and meat
products
PA in late pregnancy
Information on choosing lower-fat meat and meat products, and non-meat
alternatives
Information on PA in late pregnancy
Maintaining behaviour changes
Every session
Review of goal attainment from previous week
Review of self-monitoring (logbook) from previous week, including pedometer
Setting of dietary and activity SMART goals for coming week
After the sessions (until 36 weeks)
Biweekly telephone support to discuss maintenance of behaviour changes and any
further changes participants want to make
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Dietary assessment
Repeated, triple-pass 24-hour recall data obtained at baseline (randomisation) and at 28 weeks’ gestation
were evaluated twice, 1 week apart, in both the intervention and control groups. The 24-hour dietary recall
is a standard retrospective, interviewer-led dietary assessment methodology used to capture information on
all food and drinks consumed in the preceding 24 hours. This is carried out in three stages (the triple pass):
(1) recording a ‘quick’ list of foods eaten or drunk, (2) collecting more detailed information of these foods
and (3) reviewing all items once more in order to clarify any ambiguities or omissions. A short FFQ, for later
validation, was also completed.
Physical activity assessment
At the first and third appointments participants were asked to wear an ActiGraph accelerometer (either
GT1M or GT3X set to uniaxial mode) for 7 consecutive days, removing it for washing, bathing, swimming
and at night. PA was also assessed by questionnaire [via the Recent Physical Activity Questionnaire (RPAQ)].
Process evaluation
A process evaluation, following the framework of Steckler and Linnan,100 was undertaken. This explored
(1) context (environmental, socioeconomic or political factors), (2) reach (the proportion of the intended
target audience that participates and which subgroups, if any, do not participate), (3) dose delivered and
dose received (the proportion of intended intervention received), (4) fidelity (if each component of the
complex intervention was provided as intended) and (5) acceptability (if the intervention materials and
advice were well-received by providers and participants).
Qualitative semistructured interviews were conducted to capture women’s experiences and perceptions
of the trial and intervention. Women were recruited from each of the participating study sites using a
maximum diversity sampling approach, following an informed consent procedure. Interviews took place
between November 2010 and February 2011, and were either face to face (n = 17), mostly in hospital
settings, or by telephone (n = 4). Control (n = 12) and intervention (n = 9) interviewees were asked about
their involvement in the research and their experiences of the trial appointments, measurements, blood
tests and accelerometry recordings. Women in the intervention arm were additionally asked about their
perceptions of the different components of the intervention, and how these impacted upon their lives. The
interviews were conducted by one researcher and took place during pregnancy after the intervention had
been provided. In addition, HTs completed audio diaries (130 recordings) in which they reflected on the
fidelity and feasibility of the intervention delivery. Attendance at sessions was recorded on the study database.
Clinical outcome data
Maternal primary outcome for the subsequent randomised controlled trial
(diagnosis of gestational diabetes mellitus)
A blood sample for fasting glucose and insulin was taken after an overnight fast. For the OGTT, following
a glucose load [410 ml of Lucozade (Suntory Holdings Ltd, Osaka, Japan) or 75 g of glucose in water],
1-hour and 2-hour samples were taken for glucose measurement. Diagnosis of GDM was confirmed by a
fasting glucose level of ≥ 5.1 mmol/l and/or 1-hour glucose level of ≥ 10 mmol/l or 2-hour glucose level of
≥ 8.5 mmol/l, in accordance with the International Association of the Diabetes and Pregnancy Study Groups
(IADPSG)’s guidelines.6 Following GDM diagnosis, women were referred for routine GDM care in
accordance with local criteria.
Neonatal primary outcome for the subsequent randomised controlled trial
(large-for-gestational age delivery defined as ≥ 90th customised
birthweight centile)
Customised birthweight centiles were calculated correcting for gestational age, maternal ethnicity, weight
and height in early pregnancy, parity and infant sex. Weight adjustment for women with a BMI of ≥ 30 kg/m2
is based on a notional weight corresponding to a BMI of 29.9 kg/m2.
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Outcome data also recorded (not reported)
These included maternal outcomes: diagnosis of GDM and pre-eclampsia, mode of delivery, blood loss at
delivery, inpatient nights, detailed clinical and family history, health in current pregnancy, early pregnancy
data (ultrasound scan, nuchal screening), blood pressure, routine blood results; neonatal outcomes:
gestational age at delivery, birthweight, anthropometry and inpatient nights. Maternal urine and cord
blood samples were also provided.
Data handling and statistical analysis
Health quality and attitudinal assessment questionnaires
The generic EQ-5D health-related quality-of-life instrument98 is reported as the proportion of women
with problems on individual dimensions (mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression). It is given as a summary index score calculated from preference values of different
combinations of the dimensions elicited using the time trade-off method in a sample representative of
non-institutionalised adults in England, Scotland and Wales (range −0.59 to 100, where −0.59 is severe
problems on all dimensions);101,102 and also the visual analogue scale of health-related quality of life
(range 0 to 100, where 0 is worst imaginable health state). The change between baseline and 28 weeks’
gestation in the percentage of women with any problem was assessed using McNemar’s test of changes.
Attitudes to target behaviours (attitudinal assessment questionnaire) are based on the average of multiple
responses on five-point scales (three responses for diet, 13 for PA) with five indicating the greatest
perceived barrier, perceived benefit or level of confidence.
Assessment of deprivation
These scales for estimation of deprivation in England and Scotland91,92 use different reference populations
to determine the actual indices of deprivation, and are therefore not directly comparable. For the purposes
of this study, the most deprived quintile is presented separately for women in each population and
compared with the remainder of the population (quintiles 1–4).
Dietary analysis
The quality of dietary data was checked within 1 week of entry. Dietary coding utilised McCance and
Widdowson’s Composition of Foods (6th edition)103 food codes and nutrient composition was evaluated
using WISP version 3 for GI and GL values.104 Estimates using previously published methodology were made
when GI values were not available.105 Twenty-four-hour recall data obtained at baseline (randomisation)
and at 28 weeks’ gestation were evaluated twice, 1 week apart, and then averaged. The validity of the short
FFQ was assessed against the dietary recall data. Prespecified dietary outcomes were a change in GI, GL
and energy intake from SFA. Total energy intake and the proportion of energy derived from macronutrients
were assessed. GWG at 28 and 36 weeks’ gestation, a relevant secondary outcome of interest, is also
reported.
ActiGraph analysis
An epoch length (time sampling interval) of 15 seconds was specified. Data were processed using the
MAHuffe software package. Sedentary behaviour was defined as < 100 cpm, light activity as 100–1951 cpm,
moderate-intensity activity as 1952–5725 cpm and vigorous activity as > 5725 cpm.68 As time spent in
vigorous activity was very low, minutes of moderate and vigorous physical activity (MVPA) were combined.
Runs of zero counts lasting > 60 minutes were excluded, as these indicated monitor removal. A valid
recording was defined as a day in which > 500 minutes of monitored on-time was recorded in 24 hours.106
Data from participants recording ≥ 3 days of valid accelerometry data on 3 or more days were included
in the analysis. The specified PA outcome was an increase in minutes per day of MVPA recorded by
accelerometry.
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Recent Physical Activity Questionnaire
The RPAQ was modified for the assessment of PA in the preceding 7 days. Estimates of minutes per day
spent in light, moderate and vigorous activity in each of the domains were calculated. Sedentary activities
were defined as those with a metabolic equivalent (MET) of < 1.5. Light activities were those of 1.5–3
METs. Moderate activities were those of 3–6 METs. Vigorous activities were those of 6 METs or greater.107
MVPAs were combined to give one summary variable.
Process evaluation
Interviews were recorded and transcribed verbatim. Transcripts were anonymised and a unique identifier
(ID) number was used to maintain confidentiality. Data were imported into a qualitative software analysis
package (NVivo version 8, QSR International, Warrington, UK) and subject to comparative thematic
analysis.108 To enhance study validity and reliability, themes arising from the research were discussed, the
data supporting these were reviewed by co-researchers, and data were compared between sites and with
existing literature. By these methods, assumptions were tested and observations of differences and their
relationship to the theoretical models underpinning the study were explored.
Statistical analysis
Analyses followed the intention-to-treat principle. Following Consolidated Standards of Reporting Trials
(CONSORT) guidelines, risk ratios and risk differences were estimated by binary regression for yes/no
outcomes. When measures were repeated at baseline and 28 weeks’ gestation, results of mean [standard
deviation (SD)] or n (%) are presented separately at each time point. Randomised comparisons at 28 weeks
were made using linear regression with robust standard errors, adjusting for the baseline value. For PA
data, dummy variables were used when the baseline values were missing. Correlations between PA as
assessed objectively (accelerometry) and when self-reported (RPAQ) were explored.
Results
Figure 4 provides a flow chart of participants through the study.
Participants
The mean first visit BMI was 36.3 kg/m2. More than half the women were white and the remainder were
from black (38%) and minority ethnic communities. More than half (56%) already had at least one child.
More than half of those from centres in England and over 40% in Scotland came from regions in the
highest quintile of social deprivation (Table 8).
Diet and gestational weight gain
Table 9 shows the dietary intakes at baseline and at 28 weeks’ gestation. There were no differences
between groups in energy intakes, GI, GL or other macronutrient at baseline. However, following the
intervention, at 28 weeks’ gestation, total energy intake, dietary GL, GL (% energy), saturated fat
(% energy) and total fat (% energy) were significantly lower, and fibre intake measured as non-starch
polysaccharides was greater, in the intervention group than in the control arm. The proportion of energy
derived from protein was higher in the intervention group, but absolute protein intake did not differ. There
was a difference of 7 GI points between the intervention and control group, which achieved borderline
statistical significance (p = 0.054).
There was a marginal difference in GWG of –0.9 kg between the intervention and control group at
28 weeks’ gestation (p = 0.065).
Physical activity
There were no differences between the intervention and the control arms in objectively measured PA
variables at baseline or at 28 weeks’ gestation, after adjustment for baseline activity. Self-reported
moderate to vigorous PA at 28 weeks’ gestation was increased in the intervention group (mean difference
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Assessed for eligibility
(n = 909)
Randomised
(n = 183)
• Singleton pregnancy 15+0–17+6 weeks’ gestation and BMI > 30 kg/m2
• Women with certain pre-existing conditions excluded
Excluded
(n = 726)
• Did not meet inclusion criteria, n = 243
• Declined to participate, n = 473
• Miscarriage/TOP after consent, n = 10
Allocated to intervention arm
(n = 94)
Lost to follow-up
• Women, n = 15
• Neonates, n = 9
• Discontinued intervention, n = 4
• Preterm delivery, n = 0
• Withdrew, n = 4
Analysed
• Women, n = 79
• Neonates, n = 85
• Excluded from analysis, n = 0
Allocated to control arm
(n = 89)
Lost to follow-up
• Women, n = 14
• Neonates, n = 5
Analysed (primary end point)
• Women, n = 75
• Neonates, n = 84
• Excluded from analysis, n = 0
FIGURE 4 The UPBEAT pilot study CONSORT diagram.
TABLE 8 Description of subjects at baseline (16+0–18+6 weeks’ gestation) by randomised treatment
Demographic variable
Trial arm
Control (n= 89) Intervention (n= 94)
Age (years),a mean (SD) 30.7 (4.9) 30.4 (5.7)
Age categories (years), n (%)
18–25 16 (18) 22 (23)
26–30 25 (28) 27 (29)
31–40 46 (52) 42 (45)
≥ 41 2 (2) 3 (3)
Anthropometry, mean (SD)
Height (m) 1.64 (0.07) 1.64 (0.07)
Weight (kg) 96.8 (16.2) 97.8 (12.7)
BMI (kg/m2) 36.1 (4.8) 36.5 (4.7)
Ethnicity,a n (%)
White 51 (57) 52 (55)
Black 32 (36) 38 (40)
Asian 1 (1) 2 (2)
Other 5 (6) 2 (2)
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TABLE 8 Description of subjects at baseline (16+0–18+6 weeks’ gestation) by randomised treatment (continued )
Demographic variable
Trial arm
Control (n= 89) Intervention (n= 94)
Parity,a n (%)
0 38 (43) 63 (67)
1 36 (40) 25 (27)
≥ 2 15 (17) 6 (6)
Cigarette smoking, n (%)
Never 61 (68) 63 (67)
Ex-smoker 22 (25) 25 (27)
Current 6 (7) 6 (6)
Number of cigarettes, n (%)
0 83 (93) 83 (88)
1–5 per day 3 (3) 3 (3)
6–10 per day 1 (1) 6 (6)
11–20 per day 2 (2) 2 (2)
Index of multiple deprivationb
England
n 76 79
Mean (SD) 34 (12) 36 (14)
Quintiles, n (%)
1–4 (less deprived) 35 (46) 29 (37)
5 (most deprived) 41 (54) 50 (63)
Scotland
n 12 14
Mean (SD) 28 (11) 30 (20)
Quintiles, n (%)
1–4 (less deprived) 7 (58) 8 (57)
5 (most deprived) 5 (42) 6 (43)
Living arrangements, n (%)
Single 35 (39) 50 (53)
With partner 66 (74) 69 (73)
With parent(s) 7 (8) 13 (14)
Without partner or parents 17 (19) 17 (18)
Accommodation, n (%)
Owned 27 (30) 21 (22)
Rented (private) 26 (29) 27 (29)
Rented (council owned) 36 (40) 46 (49)
a The randomised treatment allocation is balanced by minimisation on maternal age, centre, ethnicity and parity.
b The index of multiple deprivation is calculated for the region of residence (lower-layer super output area in England and
data region in Scotland).14,15 Different methods and reference populations are used in England and Scotland, and the
indices are not directly comparable.
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TABLE 9 Dietary outcomes and GWG
Dietary measure
Time point of
measurement
Trial arm, mean (SD)
Difference (95% CI) p-value
Control
(n= 89, 69)
Intervention
(n= 94, 71)
Total energy
(MJ/day)
Baseline 7.53 (2.21) 7.26 (2.29) −0.94 (−1.72 to −0.18) 0.016
28 weeks’ gestation 7.71 (2.30) 6.75 (2.57)
Dietary GI (%) Baseline 58 (6) 58 (5) −7 (−15 to 0) 0.054
28 weeks’ gestation 60 (26) 53 (13)
Dietary GL (g/day) Baseline 133 (48) 129 (41) −33 (−47 to −20) < 0.001
28 weeks’ gestation 146 (55) 111 (39)
GL (% energy) Baseline 27.7 (5.3) 28.5 (5.9) −4.8 (−8.5 to −1.0) 0.013
28 weeks’ gestation 31.3 (13.3) 26.6 (8.0)
Carbohydrate
(% energy)
Baseline 48.0 (8.4) 48.9 (9.6) 1.7 (−1.0 to 4.4) 0.207
28 weeks’ gestation 48.2 (8.0) 50.0 (8.2)
Protein (% energy) Baseline 15.5 (3.6) 16.0 (4.2) 1.5 (0.1 to 2.8) 0.034
28 weeks’ gestation 15.5 (3.2) 17.1 (4.9)
Protein (g) Baseline 69.3(25.3) 68.5 (26.1) −4.8 (−12.3 to 2.6) 0.204
28 weeks’ gestation 70.6 (24.0) 66.5 (23.5)
Total fat (% energy) Baseline 36.0 (8.2) 34.9 (9.3) −3.2 (−5.6 to −0.8) 0.010
28 weeks’ gestation 35.9 (7.7) 32.5 (7.4)
SFA (% energy) Baseline 12.7 (3.9) 12.0 (4.3) −1.6 (−2.8 to −0.3) 0.015
28 weeks’ gestation 12.9 (3.9) 11.1 (3.8)
MUFA (% energy) Baseline 12.1 (4.1) 11.4 (4.0) −1.0 (−2.2 to 0.2) 0.088
28 weeks’ gestation 11.6 (4.0) 10.4 (3.2)
PUFA (% energy) Baseline 6.4 (3.0) 6.0 (3.1) 0.13 (−0.8 to 1.1) 0.774
28 weeks’ gestation 5.9 (2.8) 6.0 (2.7)
P to S ratio Baseline 0.56 (0.31) 0.56 (0.40) 0.13 (−0.01 to 0.28) 0.075
28 weeks’ gestation 0.51 (0.35) 0.64 (0.52)
NSP (g) Baseline 11.2 (4.6) 10.4 (4.6) 1.77 (0.08 to 3.47) 0.040
28 weeks’ gestation 10.5 (4.2) 12.0 (6.0)
(n = 88, 88;
75, 61)
(n = 94, 94;
80, 69)
Maternal weight
(kg)
Pre-pregnancy
(estimated)
95.75 (16.21) 97.06 (12.62)
Baseline 97.00 (16.21) 98.31 (12.62)
28 weeks’ gestation 102.10 (16.71) 101.44 (12.22) –0.87 (–1.80 to 0.05) 0.065
34–36 weeks’ gestation 105.06 (16.70) 104.13 (12.82) –0.54 (–2.09 to 1.01) 0.494
MUFA, monounsaturated fatty acid; NSP, non-starch polysaccharide; P to S ratio, polyunsaturated fatty acid to saturated
fatty acid ratio; PUFA, polyunsaturated fatty acid.
Notes
For each dietary variable, results are presented in two lines: at trial entry (baseline and at 16+0–18+6 weeks’ gestation) and
after randomised treatment, with comparisons and p-values only for the randomised comparison. Comparisons are adjusted
for baseline levels throughout.
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34 minutes/day; 95% CI 9 to 59 minutes/day), but this was not supported by the objective data. Women
in the intervention group self-reported walking for leisure for 14 minutes/day more than those in the
control group at 28 weeks’ gestation (95% CI 5 to 23 minutes; p = 0.003). Agreement between the RPAQ
questionnaire and accelerometry was very poor; for example, correlation between MVPA in the two
formats at baseline was r = 0.275 (95% CI 0.107 to 0.428) and at 28 weeks’ gestation was r = −0.069
(95% CI –0.296 to 0.165) (Table 10).
Attitudinal assessment of target behaviours
Benefits, barriers and confidence in making the target PA and dietary changes were unchanged in either
the control and intervention groups from baseline to 28 weeks’ gestation (Table 11).
Health Status, Mental Health Edinburgh Postnatal Depression Scale and
EuroQol-5 Dimensions
There was no influence of the intervention on the numbers of women reporting problems in each of
the EQ-5D domains, but, as a group, obese women experienced a significant increase in problems with
mobility, self-care, usual activities and pain and discomfort from baseline to 28 weeks’ gestation. There
was a 10% prevalence of probable depression at baseline and a 13% prevalence at 28 weeks (i.e. EPDS
score of > 12), with no significant effect of the intervention on anxiety and depression at 28 weeks’
gestation (see Table 11).
TABLE 10 Physical activity as measured by accelerometer and RPAQ questionnaire
PA measure Time point of measurement
Trial arm, mean (SD)
Treatment effectControl Intervention
By accelerometer (n = 72, 39) (n = 68, 36)
Sedentary Baseline 1172 (95) 1165 (91) 21 (−13 to 55)
28 weeks’ gestation 1175 (86) 1197 (77)
Active Baseline 217 (65) 225 (58) −11 (−42 to 19)
28 weeks’ gestation 209 (82) 194 (68)
Light Baseline 178 (54) 184 (50) −9 (−38 to 19)
28 weeks’ gestation 175 (81) 161 (61)
MVPA Baseline 40 (20) 42 (20) −2 (−9 to 5)
28 weeks’ gestation 34 (18) 33 (15)
By RPAQ questionnaire (n = 80, 54) (n = 79, 56)
Sedentary Baseline 1007 (207) 1009 (187) −50 (−115 to 16)
28 weeks’ gestation 1068 (177) 1020 (226)
Active Baseline 408 (189) 415 (180) 45 (−16 to 106)
28 weeks’ gestation 367 (175) 410 (219)
Light Baseline 354 (180) 356 (164) 11 (−46 to 68)
28 weeks’ gestation 333 (165) 340 (204)
MVPA Baseline 54 (87) 60 (99) 34 (9 to 59)
28 weeks’ gestation 34 (52) 70 (78)
Notes
Results are measured in minutes/day presented as mean (SD).
Treatment effects are mean differences (95% CI), adjusted for baseline activity with dummy variables when baseline levels
are missing (two accelerometer, three RPAQ).
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TABLE 11 Attitudes to target behaviours, quality of life and mental health assessment
Attitudes to target behaviours
Time point of
measurement
Trial arm
Treatment effectControl Intervention
Barriers, mean (SD)
Diet Baseline 2.49 (0.58) 2.37 (0.61) −0.18 (−0.35 to 0.00)
28 weeks’ gestation 2.45 (0.58) 2.14 (0.68)
PA Baseline 2.64 (0.55) 2.48 (0.63) −0.20 (−0.37 to −0.03)
28 weeks’ gestation 2.47 (0.50) 2.20 (0.61)
Perceived benefits, mean (SD)
Diet Baseline 3.75 (0.72) 3.80 (0.64) 0.13 (−0.10 to 0.36)
28 weeks’ gestation 3.79 (0.67) 3.97 (0.80)
PA Baseline 3.94 (0.70) 4.04 (0.54) 0.17 (−0.04 to 0.38)
28 weeks’ gestation 3.84 (0.60) 4.06 (0.69)
Confidence, mean (SD)
Diet Baseline 3.78 (0.75) 3.84 (0.64) 0.11 (−0.15 to 0.37)
28 weeks’ gestation 3.71 (0.72) 3.85 (0.81)
PA Baseline 3.76 (0.88) 3.92 (0.81) −0.05 (−0.40 to 0.30)
28 weeks’ gestation 3.77 (0.88) 3.81 (1.06)
Quality of life (EQ-5D) (n = 87; n = 75) (n = 94; n = 80)
Numbers reporting problems
Mobility, n (%) Baseline 10 (11%) 11 (12%) 4% (−10 to 18)
28 weeks’ gestation 21 (28%) 25 (31%)
Change (all women) 19% (11 to 27)
Self-care, n (%) Baseline 1 (1%) 0 (0%) −0.3% (−6 to 6)
28 weeks’ gestation 3 (4%) 3 (4%)
Change (all women) 4% (0 to 8)
Usual activities, n (%) Baseline 16 (18%) 13 (14%) −1% (−15 to 12)
28 weeks’ gestation 26 (34%) 26 (33%)
Change (all women) 16% (8 to 24)
Pain and discomfort, n (%) Baseline 38 (43%) 34 (36%) 10% (−1 to 22)
28 weeks’ gestation 45 (60%) 54 (67%)
Change (all women) 25% (17 to 34)
Anxiety and depression, n (%) Baseline 22 (25%) 20 (21%) 5% (−4 to 15)
28 weeks’ gestation 11 (15%) 17 (21%)
Change (all women) −6% (−14 to 1)
TTO score, mean (SD) Baseline 0.85 (0.18) 0.88 (0.14) −0.03 (−0.07 to 0.02)
28 weeks’ gestation 0.79 (0.24) 0.79 (0.16)
Change (all women) −0.08 (−0.10 to −0.06)
VAS score (0 to 100), mean (SD) Baseline 76 (20) 76 (21) 4 (−3 to 10)
28 weeks’ gestation 75 (21) 78 (21)
Change (all women) −2 (−6 to 2)
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Process evaluation
Context
This study coincided with the publication of new reports and guidance for obesity in pregnancy, with
associated media coverage.93,109 Most control group interviewees demonstrated awareness and reported
taking steps to improve their diet or fitness (Box 1).
Reach
The mean age of those approached who were eligible for recruitment but declined to participate (n = 473)
was 29.9 years and their mean BMI was 35.39 kg/m2; 59.7% were white, and 32.8% were black and
43.0% were in the lowest quintile for the Index of Deprivation, indicating the most severe deprivation.
The characteristics of participants providing semistructured interviews (n = 21) are shown in Table 12. Their
demographic profile was similar to that of study participants (see Table 7). Overall, 29 out of 183 (15.8%)
women were lost to follow-up (see Figure 4).
Dose
Of the 94 women randomised to the intervention, 82 (88%) attended at least one group session, and 60
(64%) attended four or more. A total of 42 women (45%) received material from all eight sessions, six by
full attendance (6%) and the remainder when partly/wholly covered by subsequent telephone contact.
The mean number of sessions attended or partly/wholly covered was 6.1 (SD 2.6).
Fidelity
The intervention package (eight HT group sessions) was provided with good consistency at each study site.
Goals were set at all group sessions, of which 88% were considered SMART by HTs according to their
diaries. The maximum group size was 5 (mean 2).
Acceptability
Women in both arms of the trial found the research processes acceptable and felt supported by the study
midwives. Women in the intervention group were generally willing, in principle, to attend the eight HT
sessions, and most women who attended valued the group approach, citing opportunities to raise questions
TABLE 11 Attitudes to target behaviours, quality of life and mental health assessment (continued )
Attitudes to target behaviours
Time point of
measurement
Trial arm
Treatment effectControl Intervention
EPDS
Total, mean score (SD) Baseline 7.1 (4.6) 7.4 (4.5) 0.1 (−1.1 to 1.3)
28 weeks’ gestation 6.9 (4.2) 7.1 (5.2)
Total score of > 9, n (%) Baseline 25 (29) 28 (30) 1% (−9 to 11)
28 weeks’ gestation 17 (23) 21 (26)
Total score of > 12, n (%) Baseline 9 (10) 10 (11) 7% (−1% to 16)
28 weeks’ gestation 6 (8) 14 (18)
TTO, time trade-off health state ratings calculated from standard values elicited using the time trade-off method; VAS, visual
analogue scale.
Notes
Attitude to target behaviours are based on the average of multiple responses on five-point scales, with 5 indicating the
greatest barrier, perceived benefit, or level of confidence, and 1 the least.
For the EQ-5D subscales, the overall change over time is estimated as a risk difference, by McNemar’s test of changes.
Elsewhere, differences are calculated by linear or binomial regression as appropriate, adjusting for baseline values.
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BOX 1 Process intervention findings (context: interventions and controls)
Context: intervention and control participants
It [being part of the research] just makes you a bit more conscious of what you eat; even though you’re
pregnant and you might crave for all these different things, you think what impact it will have on you
afterwards when, obviously when your baby’s born and you’re trying to get off the weight and it just
makes you think of what you put in your mouth really.
ID 3, control, aged 33 years, multiparous, a BMI of 44 kg/m2 and black African
[Being part of the research has] reminded me a lot more, because I’m overweight, it could be that it was
on the radio yesterday as well, I’m thinking about it a lot more . . . Obviously as part of the control group
I’m not supposed to necessarily do anything specific and change anything but obviously I’m trying anyway.
I don’t think I’d take part [in the research] if I regarded being overweight as perfectly alright and perfectly
fine and I wasn’t interested in fixing the situation.
ID 12, control, aged 35 years, multiparous, a BMI of 35 kg/m2 and white British
The midwife I’ve got through my GP [general practitioner] isn’t very friendly so I think it’s beneficial for me
to come in and speak to [the research midwives] about the issues I have with the pregnancy and other
stuff, because the one I have at my GP seems to be too busy to care, to listen to any of these things so it’s
nice to come in and speak to them, it’s a bit reassuring I guess.
ID 1, control, aged 26 years, nulliparous, a BMI of 37 kg/m2 and black British
I’ve really enjoyed it (blood tests, measurements, questionnaires) because it’s really reassuring, because you
do a lot of the stuff with the midwives and you feel like if there was something wrong I’d be told about it.
ID 4, intervention, aged 25 years, nulliparous, a BMI of 35 kg/m2 and white British
You feel more looked after. You feel like it’s more private care, more special than just the normal midwife
care or the GP. Because they just want to get you in and out really quickly. Cos they have loads more
people to see. But here you feel like you have the time to talk or say what you have to say. And ask any
fears about anything, really, I think.
ID 17, intervention, aged 22 years, multiparous, a BMI of 37 kg/m2 and mixed ethnicity
TABLE 12 Structured interview sample characteristics compared with trial population
Demographic variable n Interview sample Pilot trial population (n= 183)
Control 12
Intervention 9
Ethnicity (%)
White 8 38 56
Black 12 57 38
Asian 0 0 2
Other 1 5 4
Age (years), mean (SD) 29.6 (4.9) 30.5 (5.4)
Parity, %
Nulliparous 9 43 44
Multiparous 12 57 56
Gestational age at interview (weeks) 29 Not interviewed
BMI (kg/m2) at recruitment, mean (SD) 37.6 (4.6) 35.6 (5.1)
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and discuss each other’s experiences. Some were surprised at the extent of the intervention, having expected
a less intensive, more advice-based approach. Consistency of attendance at the sessions varied for different
reasons including work commitments, school pick-up times or feeling too unwell or tired. Occasionally initial
involvement waned when groups proved smaller than expected, although the HT input by telephone or
e-mail was considered valuable. Some women found the information contained in the handbook new,
whereas for others it was too basic. The pedometers and step goals were generally well received. Setting
and reflecting on weekly goals was motivational for most but could also invoke feelings of guilt, or a sense
of being observed and judged. Women reported having watched the DVD, but few used it regularly.
When interviewees were asked whether or not they had made any changes as a result of the intervention,
most reported some degree of change, especially in relation to dietary intake. Reported changes in PA
were more limited, particularly because of pelvic pain or tiredness as pregnancy progressed. Women often
reported aspirations to increase exercise postnatally (Box 2 and Table 13).
BOX 2 Evaluation of intervention
Dose received and acceptability of study components: intervention group
Expectations of the intervention
I thought it was going to be healthy eating and exercising. I thought it was going to be like how they tell
you in the news, that we have to eat better. Or what you hear media-wise. But it’s more in-depth and
more suitable to how you are, basically. It’s more fitted to how you are. Instead of every thousand people.
It’s just for you. It’s more suitable that way, I feel.
ID 17, intervention, aged 22 years, multiparous, a BMI of 37 kg/m2 and mixed ethnicity
The groups that I went to, there was only . . . two of us at maximum. I think there were supposed to be four.
ID 4, intervention, aged 25 years, nulliparous, a BMI of 35 kg/m2 and white British
Access to intervention
I couldn’t come to all the sessions, I think it started at 3 and school finishes at 3:15 so it’s a bit difficult to
try and get [to the hospital] for that time.
ID 2, intervention, aged 27 years, multiparous, a BMI of 34 kg/m2 and black African
The only thing I was worrying about was being able to commit every week. But I think there was once
that I couldn’t do it and [HT] e-mailed and she phoned so I didn’t miss out on anything.
ID 8, intervention, aged 29 years, a BMI of 43 kg/m2 and white British
I also found it quite hard saying ‘Oh, I need eight Thursday afternoons off work’, and I just felt like I was
taking advantage of them by taking extra time off work.
ID 4, intervention, aged 25 years, nulliparous, a BMI of 35 kg/m2 and white British
Affect on mood
. . . I just felt quite . . . quite bad, and I felt that . . . that I wasn’t doing good . . . I wasn’t doing what was
good for my baby . . . by not being healthy and fit and . . . and all of that, I felt like I was doing something
wrong, so . . . I don’t know . . . you’re on a diet of guilt, you know, you should be eating this because
otherwise you’re doing badly.
ID 4, intervention, aged 25 years, nulliparous, a BMI of 35 kg/m2 and white British
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. . . because you’re on the [research] project, you feel good when you do something good. And when you
do something bad, you feel bad. Because you feel like you’re letting yourself down.
ID 17, Intervention, aged 22 years, multiparous, a BMI of 37 kg/m2 and mixed ethnicity
Handbook and dietary change
Instead of the basmati rice, I’d had the normal long grain rice, and instead of mashed potato, you can
have sweet potatoes, it’s just really silly things you didn’t know, you thought you were eating healthily and
you weren’t, so changing that, swapping . . . The benefits are you’re definitely not gaining that much
weight, which is a plus. All the women will like that bit of it, so it kept you going.
ID 13, intervention, aged 36 years, multiparous, a BMI of 32 kg/m2 and black African
I’ve always bought wholemeal bread but because we were encouraged to buy seedy bread, I am still
buying it and I think I’ll continue to buy it.
ID 11, intervention, aged 35 years, multiparous, a BMI of 41 kg/m2 and black African
I don’t know how to say it, [the handbook] was more for people who didn’t really have . . . good
knowledge with food, or cooking or eating well, do you know what I mean? It’s just like . . . I eat healthy
. . . maybe too many desserts or cakes or sweets or whatever, but I do know how to eat healthy, but [the
handbook] was more aimed at people who don’t know, who are just eating for the sake of eating.
ID 4, intervention, aged 25 years, nulliparous, a BMI of 35 kg/m2 and white British
Physical activity
The logbook was fantastic with the pedometer. It was so motivating. We were aiming for 10,000 steps a
day so every day I was doing extra trying to get to that and that really motivated me and the family, all the
kids were behind me.
ID 13, intervention, aged 36 years, multiparous, a BMI of 32 kg/m2 and black African
If I didn’t leave home at all [1 day], I would have like 1000 steps and I’m like ‘Oh my God, that’s really
[low] . . .’ it sort of motivated me to try and do something about it the next day . . . if I hadn’t done this
[research], I suppose I’d still be in that mindset, that, ‘Oh, I am pregnant, I’m not allowed to do anything’
whereas now, because of having looked at my step count, I am very aware that I have to stay active and
when I don’t, it does bug me.
ID 11, intervention, aged 35 years, multiparous, a BMI of 41 kg/m2 and black African
I developed a condition called SPD [Symphysis Pubis Dysfunction], it was my pelvis which becomes really
unbearable and very painful to walk . . . but obviously after this baby comes I am going to make a
conscious effort to do a lot more. And obviously I’ll not have the problems with my pelvis as well which
will be a great help.
ID 8, intervention, aged 29 years, nulliparous, a BMI of 43 kg/m2 and white English
I want to start on my diet after my baby’s born. More healthy cooking and stuff. And once or twice a
week, swimming and stuff like that. It makes you feel positive about yourself to do more. So afterwards
you feel, okay, if I can do this while I’m pregnant, I can do 100 times more when I’m not. So I think it’s a
motivation thing. It makes you think about, basically, it makes you think about your health during your
pregnancy. But it makes you think afterwards, as well, so if I can take this much care when I’m pregnant,
I can do a lot more afterwards.
ID 17, intervention, aged 22 years, multiparous, a BMI of 37 kg/m2 and mixed ethnicity
BOX 2 Evaluation of intervention (continued)
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Maternal and neonatal outcomes
The primary maternal and neonatal outcomes for the subsequent RCT are shown in Table 13. There were
no significant differences in GDM or LGA (≥ 90th customised centile) between control and intervention
arms. There was also no significant difference in GWG between control and intervention arms (secondary
outcome). The overall incidence of GDM, the primary outcome of the subsequent RCT (not powered for),
in accordance with recent IADPSG criteria,6 was 30%, enabling calculation of the subsequent RCT sample
size (1546 women) for the RCT, powered for a 25% reduction. As 38% of potentially eligible women took
part in the pilot study, to achieve this sample size in the main RCT, approximately 4100 would need to
be approached.
Discussion
This study describes a pragmatic and rigorously evaluated pilot study of a complex intervention for diet and
activity behaviour change in obese pregnant women. The intervention was associated with a significant
change in dietary behaviour. Process evaluation showed overall acceptability of the protocol, but led to
several refinements to improve acceptability and fidelity.
In any lifestyle intervention of diet and PA, it is important that the pilot study design includes methods to
assess the potential of the intervention to change these behaviours in the expected direction of effect.
Few assessments of dietary intake in similar investigations of overweight or obese women have been
attempted.110–112 We used a 24-hour recall method to assess dietary intake and, while this may lead to
under-reporting of energy intakes, the reported values are not dissimilar to those of non-pregnant women
in the general UK population.113 Both objectives of the dietary intervention, to bring about reductions in
GL and the proportion of energy derived from SFAs, were achieved. This suggests that obese pregnant
women are amenable to changing their diet in response to an intervention based on established theory,
and that dietary advice, frequently delivered by health professionals, is likely to be successful in achieving
dietary change in obese pregnant women, as previously implied.111 The reduction in dietary GL achieved
was similar (33% vs. 45%) to that reported in obese type 2 diabetic non-pregnant subjects, in whom
improved glycaemic control was achieved.114 Recently, a similar intervention in 759 pregnant women
showed a lower change in GL (13%), which was associated with a reduction in GWG in women who had
previously delivered a LGA infant.115
TABLE 13 Maternal and neonatal primary outcomes
Outcome
Trial arm
Comparison Treatment effect (95% CI) p-valueControl Intervention
Maternal (n = 75) (n = 79)
GDM 24 (32%) 22 (28%) Risk difference –4% (–19% to 13%) 0.574
Risk ratio 0.87 (0.54 to 1.41)
Neonatal (n = 84) (n = 86)
LGA 7 (8%) 7 (8%) Risk difference 0% (–8% to 8%) 0.982
Risk ratio 0.99 (0.36 to 2.7)
> 4 kg 16 (19%) 13 (15%) Risk difference –4% (–15% to 8%)
Notes
GDM defined by IADPSG’s criteria; LGA delivery defined as ≥ 90th customised birthweight centile. Customised centiles are
adjusted for maternal age, height, ethnic group, gestational age and gender.
Weight adjustment for women with a BMI of ≥ 30 kg/m2 (all women in the study) is based on a notional weight
corresponding to a BMI of 29.9 kg/m2. Continuous variables are given as mean (SD) with mean difference and 95% CI.
Binary outcomes are n (%), with risk difference and risk ratio.
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The reduction in energy intake observed is consistent with other studies that have restricted the intake of
fat from meat and dairy products and which has not been replaced by other sources of food energy.116
The reduced GL may also have contributed through effects on satiety.117 To our knowledge this is the first
study demonstrating that expected changes in diet occur following delivery of an intervention to lower GL
and saturated fat in obese pregnant women without GDM. Importantly, this occurred despite the focus
being on reducing GL by lowering the intake of added sugars as well as advocating foods with a lower GI.
Focusing on GI tends to modify the GL from starch, whereas the GI from sugar-sweetened beverages is
less amenable to change. Consequently, dietary advice to decrease the intake of added sugar, particularly
as sugar-sweetened beverages, is likely to have had an important impact on GL.
This study adds to the scant literature on the habitual diet of obese pregnant women. The macronutrient
profile at randomisation was similar to that of women in the general population, with fibre (non-starch
polysaccharides) intake below, and total sugars and saturated fat above, recommended UK guidelines.118
The overall energy intake and macronutrient profile accords with one previous report in obese pregnant
women.111 Because of the time required to rigorously assess diet using the 24-hour recall method, which,
according to the process evaluation, is likely to have influenced recruitment and compliance, a short FFQ
(5–10 minutes) was evaluated for use in the subsequent RCT.
The few studies that have attempted to measure changes in PA in intervention trials in pregnancy have
generally relied on self-report, and results have been equivocal.111,119–122 Accelerometry, the standard
method of objective assessment used previously in observational studies in pregnancy,121 has, to our
knowledge, been employed in only one relevant RCT, the FitFor2 study,123 a supervised exercise
intervention in 121 overweight and obese women. Consistent with the Fitfor2 study, we found no effect
of the intervention on PA using the ActiGraph accelerometer, concurring with the reported absence of
change in barriers to PA. The failure of accelerometry to mirror the increase in self-reported walking in the
intervention group could reflect insufficient intensity of this activity, but also reporting bias49 that is
common in the reporting of low-intensity activities, such as those frequently undertaken by pregnant
women.44 As reported elsewhere, compliance with accelerometry in pregnancy was an issue.52,124
Nonetheless, 60% of obese pregnant women providing baseline accelerometry data met the current
guidelines for PA in pregnancy (i.e. > 30 minutes of MVPA per day). A similar level of activity has been
observed in pregnant women (all BMIs)52 and overweight and obese non-pregnant adults,125 but not
previously among obese pregnant women. Levels of PA were similar to those we found previously among
overweight and obese women,49 but substantially higher than those reported for non-pregnant women in
the UK.126 There is no consensus on change of MVPA over pregnancy.51,124,127,128 In this study of obese
women, both groups reduced the level of objectively measured MVPA as pregnancy progressed.
This assessment has highlighted a critical need to evaluate PA behaviour objectively. We may otherwise have
erroneously concluded in the following RCT that increased PA does not affect clinically relevant outcomes.
Despite showing no increase in PA, we have not recommended that the RCT focuses on diet only,84 but
rather that women continue to be encouraged to adhere to PA recommended in clinical guidelines.
Although there were no changes in attitudinal outcomes, women were generally positive about the
recommended dietary and PA behaviours despite perceived barriers to change. Attitudinal data relating to
diet were comparable to those obtained in a population sample of pregnant women.3 The intervention did
not achieve any reduction in perceived barriers but, despite this, important dietary changes were achieved,
which may imply low levels of self-efficacy. However, barriers to increasing PA appeared too great to
overcome, possibly reflecting increased physical discomfort with gestation, as indicated by the
EQ-5D questionnaire.
The relationship between mental health, diet and PA in obese pregnancies warrants further investigation in
the RCT in view of the high prevalence of depressive symptoms (EPDS score of > 12). Another report129 has
also found no effect on these symptoms of a complex behavioural intervention in obese women.
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In terms of context, the process evaluation recruited women in urban hospitals serving regions with areas
of high socioeconomic deprivation. Obesity rates are higher among women with lower socioeconomic
status and fewer qualifications130 and among particular ethnic groups, particularly black African and black
Caribbean.131 It was important therefore to explore not only if recruitment was feasible, but also whether
or not the intervention was acceptable to the women recruited. Prominent media coverage about obesity
raised the possibility that women in the control group might proactively address diet and PA, and some
interview data supported this, but the evaluation suggested that awareness through the media alone was
not adequate to achieve sufficient behavioural change.
In relation to reach, just over one-third of eligible women agreed to participate. Similarly low recruitment
rates are consistent with other intervention studies, particularly in populations with lower uptake of health
care. In one previous relevant study of lifestyle advice in non-obese pregnant women, recruitment was
slower than expected and low attendance at group exercise sessions and participant concern about
burdensome data collection contributed to dropout.132 However, perceived advantages to participation
such as extra clinical tests and continuity of care from research midwives supported study uptake and
continuation. Given the continued rise in obesity in the adult population in England,130 approximately one
in five pregnant women would be eligible for inclusion. Recruitment of the numbers needed to be
approached (4100) for the full trial is therefore unlikely to be affected by a shortage of eligible women.
Overall, the wide social and ethnic diversity among participants was similar in participants and those who
declined, indicating that the intervention would be unlikely to increase health inequalities by attracting
more educated and higher-income participants.133 Importantly, although obese pregnant women, once
recruited, were generally willing to attend group sessions, practicalities often interfered with regular
attendance, thereby influencing dose.
However, the sessions did not appeal to all women. Some appreciated finding common issues with
other group members, whereas others preferred one-to-one contact. Evidence for health improvement
interventions in group settings is varied93 and this study adds to the recognition that a ‘one size fits all’
approach may not be effective,133 and that flexibility is key to retention. Fidelity was good with consistently
high-level provision of SMART goals by HTs, which were viewed as a positive achievement, particularly since
poor adherence to goal-setting has been associated with moderate attendance among pregnant women.134
The high acceptability of the participant handbook and pedometer reinforced the theoretical approach,94
and women also responded well to motivational techniques, but physical issues presented barriers to PA.
The information provided was valued, including increasing awareness of safe PA in pregnancy, and seen to
have important educational benefit. Several components of the intervention therefore appeared beneficial
and were well received by women. The intervention is relatively intensive and presents costs for providers,
and while a full assessment of cost and benefit was not conducted in this pilot, steps taken during the
preclinical development phase (using HTs rather than clinicians to deliver the intervention, adopting local
group-based approach) helped keep the overall costs of the intervention low, recognising that, if beneficial,
it should also be affordable to health providers and to women. The rationale for this choice of HTs to
deliver the intervention lay principally in the lower cost of employment compared with trained health
professionals, and from our experience in working with Weight Concern, a charity which has pioneered
self-help programmes and self-support groups for the treatment of obesity, and which was employed in
this programme to train the HTs. All HTs were employed on the basis of having received some training in
behaviour change techniques relevant to the delivery of the UPBEAT intervention. Another major advantage
is that the expertise required is attainable within the participant materials and HT manuals. This was
deliberate, so that it could be delivered by anyone who has received the appropriate training (as delivered
as part of the RCT and pilot). Indeed, Weight Concern has previously used a peer-learning approach to
good effect; importantly, this enables service providers to adapt the delivery (regarding who is delivering)
according to their local population and skill set.
There was also suggestion from the process evaluation that the intervention may extend to peers and
family, and some women aspired towards better fitness following birth. This study has reinforced earlier
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reports suggesting that rapport between study staff and participants, interviews requiring short time
commitment and participants’ perception of the study as informative are all important recruitment and
retention factors.135 Formal evaluation of the reasons for the high refusal rate was not permissible because
of ethical constraints, but the time commitment was frequently commented upon by the recruitment staff,
as well as lack of appreciation of the health consequences of obesity in pregnancy.
In summary, this study has emphasised the value of a pilot trial to assess expected behaviour change.
Although seldom attempted by others, we have also highlighted the importance of process evaluation in
a complex intervention of diet and PA for pregnant women. The pilot trial demonstrated reductions in
GL and in the proportion of energy derived from saturated fat are achievable in obese pregnant women
without GDM. The process evaluation identified that dietary advice and education were well-received, and
confirmed that PA change is more problematic to achieve, although it remains important to consistently
measure and support PA using technologies acceptable to women. The process evaluation also helped
explain issues arising in relation to uptake, dose, fidelity and retention which informed the feasibility of the
full trial.
As a consequence of this study, several modifications to improve compliance and fidelity have now been
implemented in the protocol for the main trial. As well as process evaluation, HT feedback highlighted
potential barriers to fidelity of the intervention and informed protocol modifications for the RCT. Flexibility
has been increased regarding the timing and delivery of the sessions, and goal-setting can be undertaken
by telephone or e-mail. It is recommended that women should receive at least five out of eight sessions.
The two extra visits required for objective assessment of PA and accurate evaluation of diet have been
omitted in all but two sites (as planned) and dietary assessment reduced to a validated FFQ. The RPAQ
includes domestic and childcare activities considered appropriate for pregnant women,136 but following
feedback has been replaced by the shorter and more relevant International Physical Activity Questionnaire
(IPAQ).137 Maintenance of dietary and PA behaviour change in the participant and her family is being
formally evaluated at 6 months and at 3 years post partum. Although there was no significant influence of
the intervention on objectively measured PA, and only a modest increase in self-reported MVPA, it was
decided to continue to recommend PA, as this aligns with best practice as set out in clinical guidelines. To
minimise loss to follow-up and attendance at these appointments, strategies that have been put in place
include regular newsletters and sending greetings cards on special occasions such as the child’s birthday.
Conclusions
Assumptions should not be made that interventions in obese pregnant women necessarily change
behaviour. We recommend that a pilot trial such as that described here, which has demonstrated evidence
for expected change in behaviour, is a necessary prelude to any RCT of a complex intervention of diet and
PA designed to improve pregnancy outcome in obese women. Without prior evidence for change in
behaviour in the expected direction, pursuit of a large and costly trial would be futile. Similarly, we have
demonstrated the value of early process evaluation, which can lead to important refinements in protocol to
improve feasibility and compliance in the definitive trial.
Implications for proceeding to phase 3, the randomised controlled trial
As detailed in the discussion and conclusion section of the above report, there were many benefits gained
from undertaking the pilot trial which led to us to change the delivery of the intervention, but not any of
the principal elements of the intervention. Feasibility and general acceptability were established and, most
importantly, the intervention led to changed dietary behaviours. PA behaviours that, as we found in the
process evaluation, were less amenable to the women proved difficult to change, but the intervention was
continued as PA is recommended nationally for all pregnant women. The study also enabled us to better
define the power calculations for the main trial, based on the incidence of GDM in the women in the pilot
study (see Chapter 4). The process evaluation provided some similar outcomes as structured interviews
in phase 1, but several different outcomes, probably because the women in the pilot were more
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representative of the population to be recruited for the intervention. Importantly, it was recognised that
recruitment rates would be lower than expected when the original application for funding was submitted,
and that full recruitment to the main UPBEAT intervention would not be feasible within the time frame
allotted. Following the pilot trial, an application for an extension to the trial funding was therefore
submitted to the National Institute for Health Research (NIHR), and additional funding was provided to
allow completion of recruitment.
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Chapter 3 Pilot trial: additional analyses
The pilot trial provided the opportunity for additional analyses. In this chapter, two studies are reportedwhich addressed hypotheses related to pregnancy outcomes in women with obesity. The first addressed
the question of whether or not early second-trimester pregnancy measurements of clinical and biochemical
markers could contribute to the development of a tool for early pregnancy risk assessment of GDM later
in pregnancy, with the potential for targeted intervention. The second was a review of the relationships
between PA and insulin sensitivity that also explored relationships between maternal PA and maternal and
neonatal outcomes. Both studies used samples and data provided by the pilot trial.
Prediction of gestational diabetes mellitus in obese pregnant
women from the UK Pregnancies Better Eating and Activity
trial pilot trial
This study has been published in a shorter version as Maitland RA, Seed PT, Briley AL, Homsy M, Thomas S,
Pasupathy D, Robson SC, Nelson SM, Sattar N, Poston L on behalf of the UPBEAT trial consortium. Prediction
of gestational diabetes in obese pregnant women from the UK Pregnancies Better Eating and Activity
(UPBEAT) pilot trial. Diabet Med 2014;31:963–70. © 2014 The Authors. Diabetic Medicine © 2014 Diabetes
UK. Reproduced with permission.138
Abstract
Aim: The aim was to examine the prediction of GDM in obese women using routine clinical measures and
measurement of biomarkers related to insulin resistance in the early second trimester.
Methods: A total of 117 obese pregnant women participating in a pilot trial of a complex intervention
of dietary advice and PA were studied. Blood samples were obtained at recruitment (15+0–17+6 weeks’
gestation) and demographic data, clinical history and anthropometric measures recorded. The biomarkers
analysed were plasma lipids [high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides], high-sensitivity C-reactive protein, alanine transaminase, aspartate transaminase,
ferritin, fructosamine, insulin, adiponectin, tissue plasminogen activator, interleukin 6, visfatin and leptin.
Univariate and logistic regression analyses were performed to determine independent predictors and the
area under the receiver operating curve was calculated for the model.
Results: Of the 106 participants included in the analysis, 29 (27.4%) developed GDM. Participants with
GDM were older (p = 0.002), more often of a parity ≥ 2, had higher systolic (p = 0.02) and diastolic blood
pressure (p = 0.02), and were more likely to be black (p = 0.009). Among the blood biomarkers measured,
plasma adiponectin alone remained independently associated with GDM in adjusted models (p = 0.002).
The area under the receiver operating curve for clinical factors alone (0.760) increased significantly [area
under the curve = 0.834, χ2(1) = 4.00; p = 0.046] with the addition of adiponectin.
Conclusions: A combination of routinely measured clinical factors and adiponectin measured in the early
second trimester in obese pregnant women may provide a useful approach to the prediction of GDM.
Validation in a large prospective study is required to determine the usefulness of this algorithm in clinical
practice (clinical trial registry number ISRCTN89971375).
Introduction
The prevalence of obesity in adults and children continues to rise. Obesity remains the sixth most
important determinant of adverse health and reduced adult life expectancy globally.139 In the UK, the
incidence of obesity in women of reproductive age has almost doubled in the past 20 years;140 the most
recent World Health Organization (WHO) Global InfoBase of obesity (BMI of ≥ 30 kg/m2) in UK women
aged > 15 years (2010) reports an age-adjusted prevalence of obesity of 26.3% across all ethnic groups.38
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Maternal obesity carries a significant risk of adverse pregnancy outcomes, particularly GDM. Short- and
long-term metabolic complications follow a continuous linear relationship with BMI,141 with the risk of
developing GDM rising from two- to eightfold with increasing BMI category.142 Not all obese women
develop GDM, but this heterogeneity poses a burden on limited resources, with all women with a BMI of
≥ 30 kg/m2 currently managed as if at risk, often resulting in suboptimal management. Accurate and early
identification of obese pregnant women who will subsequently develop GDM would enable early risk
stratification, more appropriate use of health-care resources and the targeting of intervention strategies.
Currently, NICE, in the UK, recommends selected rather than universal GDM screening, according to risk
factors that include obesity. Women who have previously delivered a macrosomic infant, who have had
previous GDM or who have a first-degree relative with diabetes mellitus and high-risk ethnicity are also
screened. A systematic review of screening for GDM undertaken for a health technology assessment
reported low sensitivities (50–69%) and specificities (58–68%; eight studies) when traditional methods of
risk factor screening were used.143 Although there is at present no accepted early pregnancy intervention
to improve clinical outcome in obese pregnant women,84 increased recognition of the problem has led to
an international research effort to develop effective interventions. Several large-scale RCTs, including
UPBEAT (registered as ISRCTN89971375), are investigating targeted dietary and PA interventions or
metformin to improve glucose homeostasis and pregnancy outcome in overweight and obese women.15,144
Research into the prediction of adverse outcomes in other pregnancy-related conditions, such as pre-eclampsia,
has shown that a combination of clinical history and early pregnancy clinical measures, together with the
addition of biomarkers measured in biological samples, may provide an effective strategy in early pregnancy
risk assessment.145 Several studies have adopted this approach to the prediction of GDM,146,147 but, to our
knowledge, not previously in a population of obese women.
The aim of the present study was to undertake a preliminary investigation in obese pregnant women to
determine whether or not the addition of biomarkers to routine clinical measurements further improves
the prediction of GDM. For this purpose, we studied 117 women participating in a pilot trial for UPBEAT,
and measured 16 biomarkers frequently implicated in the pathogenesis and prediction of GDM and/or
type 2 diabetes mellitus and reflecting inflammatory pathways, markers of adipose tissue function, hepatic
fat accumulation and vascular dysfunction.146,148,149 As abnormal fatty acids (FAs) are associated with insulin
resistance and fetal macrosomia and because significant differences were found in the dietary intake of
SFAs and the ratio of polyunsaturated fatty acid to SFA, a detailed analysis of FAs was also undertaken.150
Prediction models were then developed incorporating clinical and biomarker data.
Methods
UPBEAT is a multicentre RCT of a complex dietary and PA intervention aimed at improving glucose
homeostasis in obese pregnant women. A pilot trial was undertaken in 183 women in four UK hospitals to
evaluate changes in dietary and PA behaviours, trial all aspects of the protocol and undertake process
evaluation.150 Details of the intervention and protocol are available on the trial website (www.medscinet.net/
upbeat/about.aspx).
NHS Research Ethics Committee approval was obtained by all contributing centres (UK IRAS reference
number 09/H0802/5).
At recruitment (15+0–17+6 weeks’ gestation) and after informed consent had been obtained, information
was collected on demographics, maternal history, maternal family and current pregnancy health.
Randomisation to the intervention arm or the control arm (which consisted of standard antenatal care) was
carried out at the second appointment, approximately 1 week later (7–10 days), between 16+0 and 18+6
weeks’ gestation, by a secure internet-based data management system (MedSciNet Ltd, www.medscinet.
net/upbeat). The randomisation schedule was minimised according to ethnicity, parity (0 vs. ≥ 1), age and
BMI (30–34.9 kg/m2 vs. 35–39.9 kg/m2 and > 40 kg/m2). Blood pressure was recorded using the Micro-life®
BP3BT0-A automated blood pressure monitor (Micro-life, Widnau, Switzerland), which is validated for use
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in pregnancy. Maternal skinfold thickness (triceps, biceps, subscapular and suprailiac) was measured in
triplicate with Harpenden skinfold callipers (validated for values ≤ 80 mm; Holtain Ltd, Felin-y-Gigfran,
Crosswell, UK), in addition to the following circumferences: waist, mid-arm, thigh and hip. Skinfold
thicknesses at four sites (triceps, biceps, suprailiac and subscapular) were summed. Blood samples were
obtained from 117 participants in the three centres that had facilities for sample handling and storage.
Serum and plasma was stored at –80 °C for future analysis.
At 28 weeks’ gestation, an OGTT was performed on all participants. Diagnosis of GDM following a 75-g
2-hour OGTT at 27+0–28+6 weeks was defined in accordance with the IADPSG’s criteria (fasting blood
glucose concentration of ≥ 5.1 mmol/l or 1-hour glucose of ≥ 10.0 mmol/l or 2-hour glucose of
≥ 8.5 mmol/l).6 If a diagnosis of GDM was made, women were referred for routine GDM care in
accordance with local criteria.
Biochemical analyses
Plasma total cholesterol, HDL cholesterol triglycerides, alanine transaminase, aspartate transaminase,
high-sensitivity C-reactive protein, fructosamine (c311, Roche Diagnostics, Burgess Hill, UK) and ferritin
(Elecsys 2010, Roche Diagnostics, Burgess Hill, UK) were measured on clinically validated automated
platforms using the manufacturers’ quality controls (QCs) and calibration materials. The coefficient of
variation (CV) was < 6%. Plasma insulin was measured with an enzyme-linked immunosorbent assay
(Mercodia, Uppsala, Sweden) that does not cross-react with proinsulin and the interassay’s CV was < 7%.
Baseline plasma adiponectin, interleukin 6, leptin (R&D Systems, Abingdon, UK), tissue plasminogen
activator (Stago, Theale, UK) and visfatin (Phoenix Peptide, Karlsruhe, Germany) were measured by
enzyme-linked immunosorbent assay. These methods had an interassay CV of < 10%.
Plasma non-esterified fatty acids (NEFAs) and FAs were measured on samples obtained after fasting for
12 hours at 27+0–28+6 weeks’ gestation in the Division of Nutritional Sciences, King’s College London,
London, UK.
Non-esterified fatty acids were measured on a clinically validated automated platform (Clinical Analyser
ILab 650, Instrumentation Laboratories, Warrington, UK) using the Randox (FA115, Randox Laboratories,
Montpellier, France) kit. QC was performed after each 60-sample batch at the upper and lower range of
the assay, with the following CVs: QC1 target of 1.24 mmol/l (%CV = 0.95) and QC2 target of 0.58 mmol/l
(%CV = 0.97). Plasma FAs were measured by gas–liquid chromatography.151 Esterified and non-esterified
fatty acid methyl esters were analysed using the one-step transesterification direct method.152 Main FA
peaks [C16:0, C18:0, C18:1(n-9), C18:2(n-6), C18:3(n-3), and C20:4(n-6)] were recognised by referring
to standard retention times (Sigma-Aldrich Co. Ltd, Gillingham, UK). C20:5(n-3) and C22:6(n-3) were
determined by cod liver oil fatty acid methyl esters standards (Sigma-Aldrich Co. Ltd, Gillingham, UK).
The remaining FAs were measured by gas–liquid chromatography mass spectrophotometry. Each plasma
FA concentration was determined as the area under the peak matched with the known standard.153
All analyses were performed on previously unthawed ethylenediaminetetraacetic acid and serum samples.
Samples were processed by technicians blinded to the identity of the samples.
Statistical methods
The analysis was exploratory with the aim of identifying potentially useful combinations of clinical and
biochemical predictors154 of maternal GDM; therefore, potentially useful biomarkers were not excluded
and no adjustment was made for multiple testing. Standard distributional checks (Box–Cox regression
and normal distribution plots) were carried out, and separate decisions made on the appropriate
transformation. Based on these findings, log-transformation was carried out for all biochemical variables.
Differences between patient groups are reported as geometric means and ratios of geometric means, with
95% CIs.
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The association of clinical indicators with GDM was established using linear or logistic regression as
appropriate, with robust standard errors. Biochemical indicators were assessed as predictors of GDM,
adjusting for significant clinical indicators. After univariate analysis, those variables which were identified as
independent predictors of GDM were included in the model. The overall performance of the markers as
predictors of GDM was assessed by comparison of receiver operating curve areas. Areas under receiver
operator characteristic curves are compared using a non-parametric approach suggested by DeLong
et al.154 and implemented in Stata as the commands roccomp and rocgold. When necessary, composite
predictors were derived using multiple logistic regression.
All data analysis was carried out using the statistical package Stata version 11.2.
Results
A total of 11 women were omitted from the analysis because of inadequate OGTT data. Of the remaining
106 women (53 in the control group and 53 in the intervention group), 29 were diagnosed with GDM
(27.4%). The demographic and clinical characteristics of women who developed GDM compared with
those who did not are summarised in Table 14. In general, women with GDM were older, more often of
higher parity (≥ 2), had higher systolic and diastolic blood pressure and were more likely to be black than
those without. BMI was not significantly different between the two groups, although skinfold thicknesses
were greater in women who developed GDM; women who developed GDM had greater triceps thickness
(37 vs. 31 mm; p = 0.004) and total sum of skinfold thicknesses (93 vs. 86 mm; p = 0.03). There was no
evidence of interaction in terms of prediction of GDM by treatment group (p = 0.85).
Table 15 shows the first trimester biomarkers for women who subsequently developed GDM and those
who did not. Women with GDM had 34% lower plasma concentrations of adiponectin (95% CI –47% to
–19%), adjusting for clinical predictors of age, parity ≥ 2, diastolic blood pressure and systolic blood
pressure. There was a trend towards significance for fructosamine in the GDM group (p = 0.05), which
attenuated to the null after adjustment (p = 0.82) (see Table 15).
In a combined logistic regression model, including the biomarkers and clinical risk factors, the only consistent
predictive variables were adiponectin (OR for a halving in adiponectin concentration 4.04, 95% CI 1.69 to
9.64; p = 0.002) and maternal age (OR per additional year 1.18, 95% CI 1.04 to 1.34; p = 0.01; Table 16).
An area under the receiver operating curve of 0.760 (95% CI 0.645 to 0.875) for prediction of GDM was
achieved with clinical predictors (age, parity, ethnicity and blood pressure) alone. The area under the receiver
operating curve increased significantly to 0.834 [95% CI 0.742 to 0.927, χ2(1) = 4.00; p = 0.046] with the
addition of adiponectin (Figure 5).
TABLE 14 Simple unadjusted comparisons of clinical predictors by OGTT test result
Maternal characteristic
GDM status
Comparison (95% CI) p-value
GDM (as measured
via IADPSG’s
guidelines) (n= 29)
No GDM
(n= 77)
Age categories (years), median
(interquartile range)
34 (31–36) 31 (26–34) –3 (–5 to –1)
18–25, n (%) 2 (6.9) 17 (22.1) – 0.004
26–30, n (%) 4 (13.8) 20 (26.0) 1.7 (0.3 to 10.5) –
31–40, n (%) 10 (34.5) 26 (33.8) 3.3 (0.6 to 16.8) –
35+, n (%) 13 (44.8) 14 (18.2) 7.9 (1.5 to 41.0) –
Height (m), mean (SD) 1.65 (0.08) 1.65 (0.07) 0.00 (–0.03 to 0.03) 0.94
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TABLE 14 Simple unadjusted comparisons of clinical predictors by OGTT test result (continued )
Maternal characteristic
GDM status
Comparison (95% CI) p-value
GDM (as measured
via IADPSG’s
guidelines) (n= 29)
No GDM
(n= 77)
Weight (kg), mean (SD) 95.79 (12.38) 97.98 (15.56) –2.19 (–7.93 to 3.54) 0.45
BMI (kg/m2), mean (SD) 35.27 (3.60) 36.11 (4.95) –0.84 (–2.57 to 0.89) 0.34
Circumferences (cm), mean (SD)
Waist 107.8 (7.4) 107.6 (10.8) 0.3 (–3.4 to 3.9) 0.88
Mid-arm 37.8 (4.1) 37.2 (4.0) 0.6 (–1.1 to 2.4) 0.48
Hip 120.5 (9.2) 122.9 (11.8) –2.4 (–6.7 to 1.9) 0.27
Thigh 66.4 (9.0) 69.4 (7.7) –3.0 (–6.7 to 0.8) 0.12
Skinfolds (mm), mean (SD)
Triceps 37.4 (10.2) 31.4 (7.4) 6.0 (2.0 to 10.1) 0.004
Biceps 28.0 (9.5) 24.4 (7.5) 3.6 (–0.3 to 7.5) 0.07
Subscapular 36.0 (8.2) 32.2 (9.2) 3.7 (0.1 to 7.4) 0.04
Suprailiac 29.9 (8.3) 29.7 (8.3) 0.2 (–3.4 to 3.7) 0.92
Total 93.9 (16.5) 86.1 (16.7) 7.8 (0.7 to 14.9) 0.03
SBP (mmHg), mean (SD) 123.3 (7.9) 119.0 (8.7) 4.3 (0.8 to 7.8) 0.02
DBP (mmHg), mean (SD) 76.4 (7.5) 72.5 (6.7) 3.9 (0.8 to 7.0) 0.02
Ethnicity, n (%)
White 11 (37.9) 53 (68.8) – –
Black 16 (55.2) 21 (27.3) 3.3 (1.4 to 8.0) 0.009
Asian 0 (0.0) 1 (1.3) – 0.99
Other 2 (6.9) 2 (2.6) 2.8 (0.4 to 20.7) 0.32
Parity, n (%) 0.03
0 9 (31) 37 (48.1) – –
1 10 (34.5) 31 (40.3) 1.33 (0.48 to 3.67) –
≥ 2 10 (34.5) 9 (11.7) 4.57 (1.43 to 14.55) –
Previous GDM, n/N (%) 1/29 (3.4) 1/77 (1.3) 2.71 (0.16 to 44.88) 0.49
Smoking, n (%)
Never 8/29 (27.6) 33/77 (42.9) 0.51 (0.20 to 1.29) 0.15
Current 2/29 (6.9) 5/77 (6.5) 1.07 (0.20 to 5.83) 0.94
Number of cigarettes (< 8 weeks), n (%)
0 27 (93.1) 66 (85.7) – –
1–5 per day 2 (6.9) 2 (2.6) – –
6–10 per day 0 (0.0) 5 (6.5) – –
11–20 per day 0 (0.0) 4 (5.2) – –
DBP, diastolic blood pressure; SBP, systolic blood pressure.
Note
Values are left blank when there are insufficient data.
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TABLE 15 Comparisons of biomarkers by OGTT test result [adjusted for routinely used clinical predictors: age,
parity (≥ 2), black ethnicity, systolic blood pressure and diastolic blood pressure]
Biomarker
GDM status
Comparison (95% CI) p-valueGDMa (n= 29) No GDMa (n= 77)
Fructosamine (µmol/l) 200.87b (1.10) 192.90 (1.09) 1.00 (0.97 to 1.04) 0.82
ALT (U/l) 21.41b (1.79) 19.00 (1.57) 1.12 (0.84 to 1.50) 0.42
AST (U/l) 30.63b (1.53) 25.07 (1.41) 1.17 (0.96 to 1.43) 0.11
Ferritin (ng/ml) 42.06b (2.27) 39.48 (2.29) 0.95 (0.64 to 1.41) 0.79
Adiponectin (µg/ml) 4.97b (1.72) 7.34 (1.76) 0.66 (0.53 to 0.81) < 0.001
tPA (ng/ml) 10.35b (1.49) 9.00 (1.47) 1.05 (0.86 to 1.28) 0.64
Interleukin 6 (pg/ml) 1.01c (2.08) 0.95d (2.54) 0.91 (0.66 to 1.24) 0.55
Leptin (pg/ml) 53.82b (1.49) 59.36e (1.52) 0.92 (0.76 to 1.13) 0.44
Visfatin (ng/ml) 4.94b (1.40) 5.28e (1.42) 0.93 (0.77 to 1.12) 0.42
Insulin (mU/l) 26.00 (2.99) 20.20 (2.78) 1.33 (0.80 to 2.21) 0.27
Cholesterol (mmol/l) 5.31 (1.18) 5.42 (1.21) 1.01 (0.93 to 1.10) 0.80
Triglycerides (mmol/l) 1.67 (1.42) 1.53 (1.38) 1.13 (0.96 to 1.32) 0.13
HDL (mmol/l) 1.64 (1.32) 1.71 (1.26) 0.94 (0.82 to 1.08) 0.39
CRP (mg/l) 9.18 (1.93) 7.77 (2.30) 1.28 (0.89 to 1.83) 0.18
VLDL (mmol/l) 0.76 (1.42) 0.71 (1.38) 1.13 (0.97 to 1.32) 0.12
LDL (mmol/l) 2.74 (1.39) 2.93 (1.34) 0.99 (0.86 to 1.14) 0.86
Cholesterol : HDL 3.23 (1.31) 3.17 (1.27) 1.07 (0.95 to 1.21) 0.27
LDL : HDL 1.67 (1.56) 1.71 (1.45) 1.05 (0.87 to 1.27) 0.63
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; tPA, tissue plasminogen activator;
VLDL, very low-density lipoprotein.
a Indicates geometric means and ratios of geometric means.
b n= 28.
c n= 27.
d n= 75.
e n= 74.
Note
Only adiponectin predictive after allowing for major clinical variables.
TABLE 16 Combined logistic regression using previous significant biomarkers and routine clinical risk factors that
were significant in Tables 16 and 17 [age, parity (≥ 2), black ethnicity, systolic blood pressure, diastolic blood
pressure and adiponectin]
Variable OR 95% CI p-value
Log-adiponectin 0.13 0.04 to 0.47 0.002
Age (for each additional year) 1.18 1.04 to 1.34 0.01
Parity ≥ 2 2.09 0.50 to 8.73 0.31
Black ethnicity 1.35 0.42 to 4.33 0.62
SBP 1.04 0.95 to 1.13 0.41
DBP 1.08 0.98 to 1.19 0.15
DBP, diastolic blood pressure; SBP, systolic blood pressure.
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Comparison of non-esterified fatty acids and fatty acid composition by gestational
diabetes mellitus status
The plasma concentration of NEFAs was significantly higher in women with GDM (p = 0.037) and,
although not significant, concentrations of the polyunsaturated fatty acid eicosapentaenoic acid (plasma
20:5n-3), an omega-3 fatty acid, were 25% higher in women with GDM (p = 0.28). Women without
GDM had greater concentrations of the naturally occurring trans-vaccenic acid from the omega 7 group
(C18:1n-7) (p = 0.01) and dihomo-γ-linolenic acid (C20:3n-6) (p = 0.016) (Table 17). Although these two
FAs showed significant differences, they were not considered in the logistic regression mode for the
development of a predictive algorithm, as it was considered that it would be impracticable to measure
these FAs in a routine clinical setting.
Further sensitivity analysis was conducted with the addition of maternal anthropometry increasing the area
under the receiver operating curve for clinical predictors alone to 0.796 [95% CI 0.692 to 0.898 (Table 18)];
however, in the fully adjusted model, only a low concentration of adiponectin remained independently
predictive of GDM.
Discussion
The present study highlights novel biochemical and clinical factors for the prediction of GDM in obese
pregnant women and suggests that an algorithm based on simple clinical variables plus adiponectin
concentration may provide a clinically useful method for the prediction of GDM in this population.
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FIGURE 5 Receiver operating curve and summaries using the basic model (including age, parity, ethnicity, blood
pressure), with the addition of adiponectin. AUC, area under the receiver operating curve.
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Four previous studies have identified a number of patient characteristics and biomarkers associated with
the prediction of GDM.146,149,155,156 These have been undertaken in populations of mixed risk, including
non-white ethnicity,146,155,156 family history of diabetes mellitus,146,149,155,156 previous history of GDM,146,155,156
high pre-pregnancy BMI,146,149,156 older maternal age146,155,156 and differing parity.149 Savvidou et al.149
measured nine biomarkers in the first trimester and found that high concentrations of tissue plasminogen
TABLE 17 Summary of NEFA concentration and composition of FAs by GDM status at 27+0–28+6 weeks’ gestation
NEFA and FA
composition (mmol/l)
GDM status
Comparison: difference in
arithmetic means (95% CI) p-valueNo GDMa (n= 75) GDMa (n= 29)
NEFA 0.30 (0.16) 0.38 (0.19) 0.08 (0.01 to 0.16) 0.037
Plasma 14:0 0.85 (0.26) 0.87 (0.41) 0.02 (–0.14 to 0.19) 0.77
Plasma 16:0 22.81 (1.69) 23.66 (2.34) 0.85 (–0.09 to 1.79) 0.08
Plasma 16:1 1.82 (0.66) 1.72 (0.92) –0.10 (–0.47 to 0.27) 0.593
Plasma 18:0 5.40 (0.46) 5.50 (0.62) 0.09 (–0.16 to 0.34) 0.46
Plasma 18:1n-9 22.59 (2.75) 22.49 (2.79) –0.10 (–1.30 to 1.10) 0.87
Plasma 18:1n-7 1.65 (0.25) 1.52 (0.21) –0.13 (–0.23 to –0.03) 0.01
Plasma 18:2n-6 26.22 (3.23) 25.89 (4.62) –0.33 (–2.18 to 1.51) 0.72
Plasma 18:3n-3 0.73 (0.20) 0.65 (0.23) –0.09 (–0.18 to 0.01) 0.07
Plasma 18:3n-6 0.23 (0.08) 0.23 (0.07) –0.01 (–0.04 to 0.02) 0.64
Plasma 20:3n-6 1.80 (0.41) 1.61 (0.33) –0.19 (–0.34 to –0.04) 0.016
Plasma 20:4n-6 6.66 (1.33) 6.56 (1.11) –0.10 (–0.61 to 0.41) 0.69
Plasma 20:5n-3 0.62 (0.73) 0.77 (0.61) 0.15 (–0.13 to 0.43) 0.28
Plasma 22:4n-6 0.24 (0.07) 0.23 (0.06) –0.00 (–0.03 to 0.02) 0.94
Plasma 22:5n-6 0.63 (0.19) 0.63 (0.17) –0.00 (–0.08 to 0.07) 0.95
Plasma 22:5n-3 0.36 (0.11) 0.37 (0.08) 0.01 (–0.03 to 0.04) 0.77
Plasma 22:6n-3 2.84 (0.77) 3.00 (0.81) 0.16 (–0.18 to 0.51) 0.36
Other plasma FAs 4.54 (0.56) 4.30 (0.71) –0.24 (–0.53 to 0.05) 0.10
a Indicates geometric means and ratios of geometric means.
TABLE 18 Combined logistic regression using biomarkers and clinical risk factors that were significant in Tables 16
and 17 including maternal anthropometry [age, parity (≥ 2), black ethnicity, systolic blood pressure, diastolic blood
pressure, triceps skinfold, total sum of skinfold and adiponectin concentration]
Variable OR 95% CI p-value
Log-adiponectin 0.18 0.05 to 0.67 0.01
Age (for each additional year) 1.15 1.01 to 1.31 0.04
Parity ≥ 2 3.38 0.75 to 15.24 0.11
Black ethnicity 0.80 0.21 to 3.05 0.74
SBP 1.0 0.91 to 1.11 0.93
DBP 1.09 0.98 to 1.21 0.10
Triceps skinfold 1.07 0.98 to 1.17 0.12
Total skinfold 1.01 0.96 to 1.05 0.82
DBP, diastolic blood pressure; SBP, systolic blood pressure.
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activator and low concentrations of HDLs increased the area under the receiver operating curve from 0.824
with clinical risk factors alone to 0.861 in a group of all comers, regardless of baseline BMI. The addition of
adiponectin to prediction models for GDM has consistently increased the area under the receiver operating
curve to values above those achieved with clinical measures alone. Further inclusion of adipokines and
biomarkers has frequently demonstrated a modest, non-significant, increase in the area under the receiver
operating curve. For example, in a case–control study of 400 women, those with GDM were reported to
have higher levels of maternal serum visfatin and lower serum adiponectin concentrations at 11–13 weeks
of gestation. The addition of adiponectin to the prediction model using clinical measures alone resulted in
a significant change in the area under the receiver operating curve, whereas there was a non-significant
increase after addition of visfatin [an area under the receiver operating curve of 0.828 (maternal
characteristics alone), 0.854 (adiponectin) and 0.855 (adiponectin and visfatin)].146 Nanda et al.156 measured
three biomarkers and found that in the GDM group, compared with controls, adiponectin and sex hormone-
binding globulin levels were lower. When screening for GDM by maternal characteristics alone, the
detection rate was 61.6% (false-positive rate 20%), increasing to 74.1% with the addition of adiponectin
and sex hormone-binding globulin. Alternative approaches to GDM risk assessment have included the
measurement of biomarkers in the preconception period, with a recent report finding that maternal
characteristics, fasting plasma glucose, glycosuria and preconception dyslipidaemia yielded an area under
the receiver operating curve of 0.90 for the prediction of GDM;155 however, the varied diagnostic criteria for
GDM used in previous studies limit comparisons with previous attempts to predict GDM. Importantly, no
study has specifically addressed risk assessment in obese pregnant women, which has important
implications for clinical practice given the recognition of obesity as the major risk factor for GDM, and the
likelihood that the biomarker profile may be dissimilar to other risk groups in women with a high BMI.
The present results suggest that clinically useful prediction of GDM in obese pregnant women is achievable
using a combination of clinical characteristics (older age, higher systolic and diastolic blood pressure, parity
≥ 2 and black ethnicity) combined with the plasma concentration of adiponectin. To reflect current clinical
practice, routine clinical measurements recorded at antenatal visits were included. The inclusion of detailed
maternal anthropometry (including skinfold thicknesses), which is undertaken in all women participating
in UPBEAT, suggested a limited potential role for taking such measurements routinely as an aid to GDM
prediction (see Table 18).
Adiponectin, an adipocyte-derived adipokine, is now recognised as being strongly associated with
improved glucose metabolism and increasing insulin sensitivity, although the causality of this relationship
remains debated. Irrespective of causal direction, adiponectin appears to provide a good ‘read-out’ of
whole-body insulin sensitivity. In a recent meta-analysis of non-pregnant individuals, adiponectin was
shown to be strongly predictive of type 2 diabetes mellitus, and inversely related to measures of insulin
resistance and BMI.157
The role of adiponectin in obese pregnant women may extend beyond usefulness as a biomarker. In the
Hyperglycemia and Adverse Pregnancy Outcome study,158 serum concentrations of adiponectin decreased
as glucose and maternal BMI increased and adiponectin was inversely associated with birthweight,
neonatal skinfold thickness and total body fat (estimated using anthropometry), giving rise to the
hypothesis that this cytokine may play a role in fetal growth regulation by modulation of placental nutrient
transport in addition to maternal glucose homeostasis. Data in support of a placental origin of adiponectin
remain equivocal, with evidence favouring maternal origin of adiponectin measured in the blood of
pregnant women.159 Maternal adiponectin has, therefore, the potential to be a ‘functional’ target for
interventions in obese pregnant women whereby achievement of increased plasma concentrations could
parallel a reduced risk of macrosomia. This may be a realistic target, as adiponectin has been shown to be
modifiable by dietary intervention in non-pregnant populations.160 Lifestyle interventions in pregnant
women of differing pre-pregnancy BMI categories have been equivocal with regard to the effects on
glucose metabolism and insulin resistance, although none has measured adiponectin concentration.123,161
Following the completion of UPBEAT (1546 women), the influence of the intervention on plasma
adiponectin concentration will therefore be explored.
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To the best of our knowledge, there have been no previous studies of adiponectin concentration and
GDM in an exclusively obese population, but the findings are consistent with other reports in women of all
BMI categories with established disease or prior to the development of GDM.156,162 A recent case–control
study from Brazil of 79 and 129 women of mixed ethnicity with and without GDM, respectively, reported
that GDM was associated with significantly lower serum concentrations of adiponectin in the third
trimester (28–36 weeks) than in the control group (p = 0.0015). GDM and BMI both had an independent
association with adiponectin concentration, with no significant interaction between the two factors (GDM,
p = 0.04; BMI, p = 0.01; and interaction, p = 0.76; using a two-way analysis of variance test).163 In contrast,
although adiponectin concentration was significantly lower in women who developed GDM in our
previous study in women of mixed risk, it did not contribute to the final model, which combined two
factors (HDL cholesterol and tissue plasminogen activator antigen), both recognised to be related to
adiponectin via linked hepatic/circulating triglyceride-mediated pathways.148
Low serum adiponectin concentrations appear to be associated with ethnic groups known to have a higher
risk of developing incident type 2 diabetes mellitus later in life.164 In the present study, women of black
ethnic origin had significantly lower plasma levels of adiponectin than non-black women, consistent
with findings from previous work examining pregnant women of South Asian origin.162 Although we
acknowledge our diverse ethnic population is not representative of the UK population, having a large
proportion of women of black ethnic origin (> 80%) has yielded further insights into the relationship
between adiponectin concentration and ethnicity.
We also observed that adiponectin concentration was significantly related to current smoking status, a
finding previously reported in a non-pregnant population in which the plasma adiponectin concentration
increased in a stepwise fashion with never, past and current smokers.165
The present study has some limitations. The sample size was small and the data obtained should be
considered as a training data set for later validation in UPBEAT. Furthermore, fasting blood samples were
not obtained at randomisation (15+0–17+6 weeks’ gestation), precluding the measurement of the fasting
glucose or insulin concentration and assessment of HOMA2-IR (homeostatic model assessment of insulin
resistance); however, as fasting is not mandatory for antenatal clinic visits, the present study was designed
pragmatically, to be relevant to current clinical practice in obese women. In this high-risk group, it is
possible that some women with GDM may have had undiagnosed type 2 diabetes mellitus; initial
screening with fasting blood glucose or glycated haemoglobin (HbA1c) concentrations was not undertaken
as IADPSG recommendations for universal testing for overt diabetes mellitus at the first antenatal visit have
not been implemented. It is possible, therefore, that low early pregnancy adiponectin concentrations may
have been influenced by type 2 diabetes mellitus in a small minority of women. Nevertheless, others have
shown that low adiponectin concentrations are strongly predictive of GDM in women in whom type 2
diabetes mellitus was excluded antenatally.166 The algorithm developed in the present study was based on
the diagnosis of GDM by IADPSG’s criteria; it follows that it is potentially valid only for this method of
diagnosis. As IADPSG’s guidelines are increasingly being adopted, for example by WHO, it would be
appropriate to evaluate in studies of larger sample size their predictive potential for GDM diagnosis by
other commonly used criteria.
In summary, we have demonstrated that the risk of developing GDM in obese pregnant women may be
predicted in the early second trimester of pregnancy by using an algorithm which incorporates routine
clinical variables as well as the biochemical marker, adiponectin. Our findings extend the work of previous
studies and, collectively, the findings suggest that by additionally measuring adiponectin concentrations in
women at high risk before routine clinical diagnosis of GDM, a potential therapeutic window for intervention
could be created. As GDM is associated with a greater risk of incident type 2 diabetes mellitus and 10-year
cardiovascular risk in mothers,167 as well as with maternal and neonatal pregnancy complications, successful
intervention has the potential to improve both short- and long-term outcomes. We conclude that further
large-scale studies of GDM prediction in obese pregnant women are warranted.
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Relationships between Physical Activity and Pregnancy
Outcomes in Obese Pregnant women from the UK Pregnancies
Better Eating and Activity trial pilot trial
This is a shortened version of a longer review article published as Hayes L, Bell R, Robson S, Poston L on
behalf of the UPBEAT Consortium. Association between Physical Activity in Obese Pregnant Women and
Pregnancy Outcomes: The UPBEAT Pilot Study. Ann Nutr Metab 2014;64:239–46.168 Reproduced by kind
permission of S. Karger AG, Basel, Switzerland.
Abstract
Background: Obesity in pregnancy is associated with fetal macrosomia, a raised neonatal fat mass and an
increased risk of obesity and poor metabolic health in childhood that persists into adulthood. The offspring
of obese women are more likely to be obese than the offspring of lean women when they become
pregnant themselves, perpetuating a cycle of obesity and its associated negative metabolic consequences.
Increasing PA during pregnancy could improve insulin sensitivity and reduce the risk of maternal and
offspring adverse outcomes. UPBEAT is a study of a complex intervention designed to improve pregnancy
outcomes through dietary changes and PA. Data from the pilot trial of 183 women were available for
analysis. The relationship between the time spent at different PA levels and maternal and infant pregnancy
outcomes was examined.
Key messages: Strong evidence exists that PA improves insulin sensitivity in non-pregnant populations, and
lifestyle interventions of proven effectiveness in non-pregnant populations have been developed. Women
who are active in pregnancy demonstrate better glucose control and favourable pregnancy outcomes. There
is a lack of effective interventions to support obese pregnant women to be physically active.
Conclusions: No difference was detected in objectively measured PA between women randomised to the
intervention and the control arms of the UPBEAT pilot trial. Low-intensity PA was lower in early pregnancy
in women who delivered macrosomic infants. Maternal sedentary time at 35–36 weeks’ gestation was
positively associated and moderate-intensity PA was inversely associated with neonatal abdominal
circumference. Maternal PA is associated with infant birthweight and abdominal circumference and is an
appropriate target for intervention to improve infant outcomes. The challenge remains to develop an
effective intervention to support obese pregnant women to be physically active.
Background
The prevalence of obesity in pregnant women is increasing. In the UK, maternal obesity doubled from
7.6% to 15.6% between 1989 and 2007.140 This is of concern because of the well-established association
between maternal obesity (typically defined as a BMI of ≥ 30 kg/m2 at the first antenatal appointment) and
the risk of adverse pregnancy outcomes, including GDM, maternal hypertension, assisted delivery and
macrosomia.169 In addition to the adverse outcomes apparent at birth, it is becoming clear that offspring
born to obese mothers are at an increased risk for obesity and its associated metabolic consequences in
later life. A recent systematic review and meta-analysis of 20 published studies concluded that babies
weighing > 4 kg at birth were more than twice as likely (OR 2.07, 95% CI 1.91 to 2.04) to be obese as
adults as babies weighing ≤ 4 kg at birth.170 In a birth cohort of 1400 individuals followed up at the age of
32 years, maternal pre-pregnancy BMI was associated with a worse cardiometabolic profile (higher BMI,
waist circumference and blood pressure, and lower HDL cholesterol) in the adult offspring.171
Interventions to reduce the impact of maternal obesity on adverse pregnancy outcomes have the potential
to reap positive benefits not only for the offspring of the index pregnancy but also for subsequent
generations born to these offspring. The relative importance of intrauterine exposure for an individual’s
predisposition to obesity compared with the role of genetic factors and shared lifestyles during childhood is
a subject of increasing interest.172,173 It has been reported that the offspring of obese women already
display metabolic disturbances at birth, supporting a role of the intrauterine environment in determining
future metabolic health. An increasing maternal BMI is associated with higher levels of fat deposition in
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the abdomen and liver,174 insulin resistance and raised leptin levels172 at birth. An understanding of
how the intrauterine environment exerts an impact on health that persists through childhood and into
adulthood will help to identify appropriate targets for intervention.
Developmental overnutrition
The concept of developmental overnutrition has been proposed as one explanation for the association
between maternal BMI and obesity and its sequelae in the offspring of obese mothers.173 This hypothesis
suggests that obese mothers who are often insulin resistant have raised levels of circulating glucose and other
nutrients during pregnancy which result in fetal hyperinsulinaemia, stimulating excessive fetal growth. This
sets these offspring on a lifetime course of acquisition of excess adipose tissue and poor metabolic health.173
It has been hypothesised that overnutrition in utero, and particularly the influences of fetal hyperinsulinaemia
and hyperleptinaemia, affects the development of the fetal hypothalamus and related neuroendocrine
organs that play a critical role in appetite regulation.175 This offers a potential mechanism by which maternal
insulin resistance and associated raised circulating glucose impact on offspring health, independently of the
environmental and genetic factors shared by the mother and offspring. Findings from animal models of
maternal obesity support the hypothesis that exposure to raised levels of maternal glucose and insulin are
associated with fetal hyperinsulinaemia, which could be implicated in programming of the development of
obesity, perhaps because offspring exposed to raised insulin levels adapt to store rather than use energy.176
Physical activity and insulin resistance
The role of PA in the prevention and treatment of diabetes mellitus in non-pregnant populations is well
established. It has been suggested that PA helps to prevent diabetes mellitus and to improve glucose
control in individuals with diabetes mellitus because it improves insulin sensitivity.177 For example, in the
European Relationship between Insulin Sensitivity and Cardiovascular risk study, in which PA was measured
objectively in 800 individuals, a strong relationship between total PA and insulin sensitivity was found.177
Lifestyle interventions that include a PA component are effective in reducing the incidence of diabetes mellitus in
high-risk populations. For example, a systematic review of pharmacological and lifestyle interventions to reduce
the incidence of type 2 diabetes mellitus in individuals with impaired glucose tolerance concluded that lifestyle
interventions achieved a reduction in the risk of diabetes mellitus of 49%, compared with a reduction of 30% for
pharmacological interventions.178 When women were randomised to a weight loss intervention in which weight
loss was achieved by either calorie restriction of 500 kcal/day or energy expenditure of 500 kcal/day through
exercise for a 14-week period, a significant improvement in glucose disposal was achieved in the exercise group
but not in the calorie restriction group.179 Both groups achieved a similar weight loss (approximately 8 kg),
suggesting that PA has a role in improving insulin sensitivity that is independent of weight loss.
Physical activity and glucose metabolism in pregnancy
A number of observational studies have reported an association between higher levels of PA in pre-pregnancy
and early pregnancy and a lower prevalence of GDM. A meta-analysis that pooled data from eight studies,
including pre-pregnancy PA data on 34,929 women and early pregnancy PA data on 4401 women,
concluded that being in the highest pre-pregnancy PA category was associated with a greater than 50%
reduction in risk of GDM, and for early pregnancy PA it was associated with a reduction of 25%.88 An acute
effect of PA (treadmill walking) on blood glucose concentrations in pregnancy was observed in 46 women in a
study examining the impact of different intensities and durations of exercise on glucose concentration.180 The
study authors found an interaction between the estimated risk of GDM and the glucose response to exercise
and concluded that walking for 25 minutes at a vigorous intensity (70% of the heart rate reserve) or for
35–40 minutes at a moderate intensity (30% of the heart rate reserve) achieved a substantial decrease
(approximately 1.0 mmol/l) in the glucose concentration in women considered to be at a high risk of GDM
(defined as a history of GDM/polycystic ovary syndrome, a family history of diabetes mellitus, overweight/
obesity, a history of macrosomia or early weight gain in the current pregnancy).
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Evidence is beginning to accumulate that improved insulin sensitivity, achieved through PA during pregnancy,
could translate into favourable outcomes for the offspring. A recent observational study assessed PA in 30
pregnant women at 28–32 weeks’ gestation, using a combined heart rate monitor and accelerometer, and
estimated insulin sensitivity using the Matsuda composite model.25 The body composition of the offspring of
these women was measured at 11–19 weeks post partum using air displacement plethysmography (PeaPod,
COSMED, Rome, Italy). Infant fat-free mass was significantly related to both maternal insulin sensitivity and
maternal PA. The authors of the study concluded that insulin sensitivity at 28–32 weeks’ gestation was
related to a favourable body fat distribution in the offspring and that this relationship appeared to be
influenced by maternal PA.25 This finding, if confirmed in larger studies, provides justification for offering
interventions to support pregnant women to be active and thereby improve the health of their offspring.
Interventions to increase PA in obese women during pregnancy could improve insulin sensitivity and reduce
the exposure of the developing fetus to excess glucose and insulin and thus help to reduce the burden of
obesity and metabolic disturbances among the offspring.
Physical activity during pregnancy
Until relatively recently, pregnant women were discouraged from being physically active. As recently as
1985, the American College of Obstetricians and Gynecologists recommended that pregnant women
‘stringently limit the type, duration and intensity of their exercise to minimize both fetal and maternal risk’.
Current guidance from the American College of Obstetricians and Gynecologists and other national
bodies now recommends that all pregnant women, including those with a raised BMI, be encouraged to
participate in regular moderate-intensity PA for 30 minutes on all or most days of the week. This change in
guidance reflects accumulating evidence that PA during pregnancy confers benefits on both the mother
and the offspring. In the Health Survey for England 2008, only 29% of (non-pregnant) women reported
meeting this guideline, and objective measurement of PA revealed that as few as 4% of women actually
met the guideline.181 Most women, therefore, are insufficiently active at the beginning of pregnancy.
Generally, PA declines with gestation. For example, a recent study found that the number of steps walked
per day, assessed using a pedometer, fell by 1340 (equivalent to walking approximately 1000 m) between
12 and 28 weeks’ gestation in 97 women at high risk of developing GDM.128 There is a need, therefore,
for interventions to support women to be active during pregnancy.
The UK Pregnancies Better Eating and Activity trial
UPBEAT is an ongoing RCT of a combined PA and dietary intervention in > 1500 obese (BMI of ≥ 30 kg/m2)
pregnant women which aims to improve glucose homeostasis and thereby prevent GDM (the primary outcome)
(trial registration number ISRCTN89971375). A pilot RCT in 183 women to determine if the intervention led
to changes in PA and diet was completed in 2011.150 Research Ethics Committee approval was obtained for
the trial (UK IRAS reference number 09/H082/5), and all participants provided written informed consent to
participate in the trial. Details of how PA was measured have been reported previously.150 Briefly, PA was
assessed by an ActiGraph accelerometer worn for 7 consecutive days at baseline (16+0–18+6 weeks’ gestation),
27+0–28+6 weeks’ gestation and 35+0–36+6 weeks’ gestation and via a questionnaire (RPAQ). For accelerometry,
a valid recording day was defined as > 500 minutes of monitored ‘on’ time in 24 hours, and women providing
valid data on at least 3 days were included in the analysis. Recorded activity was categorised as sedentary
(< 100 cpm), light physical activity (LPA; 100–1951 cpm) or moderate or vigorous activity (MVPA; ≥ 1952 cpm).
For the RPAQ, self-reported time spent on activities with a MET of < 1.5 was categorised as sedentary. LPA was
activity of 1.5–3.0 METs and MVPA as activity of > 3.0 METs. No difference in objectively measured PA
between women in the intervention and control groups was detected at 28 or 36 weeks’ gestation, although
women in the intervention group self-reported more minutes of MVPA than women in the control group at
28 weeks (mean difference 34 minutes/day; 95% CI 9 to 59 minutes/day).150
As there was no significant difference between the intervention and control groups in objectively
measured PA, the data from both arms of the pilot trial were combined to examine the relationship
between PA and pregnancy outcomes in the analyses presented here. Forty-six women (29.9%) were
diagnosed with GDM in the UPBEAT pilot trial, as assessed by an OGTT at 27+0–28+6 weeks’ gestation,
using the IADPSG’s criteria for diagnosis.6 Valid objective PA data were available for 37 of these women.
DOI: 10.3310/pgfar05100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Poston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
No statistically significant differences in time spent at different PA levels were identified between women
who developed GDM and those who did not. There was a trend towards a higher baseline sedentary time
and lower LPA and MVPA time in women who developed GDM, but these differences were not statistically
significant (see Table 14). Twenty-nine women gave birth to a macrosomic (> 4000 g) baby, with valid PA
data available in 26 cases. LPA at baseline, but not MVPA, was significantly lower in women who delivered a
macrosomic baby than in those who did not (158 minutes/day compared with 186 minutes/day; p = 0.014).
The correlations between maternal PA and fasting and 2-hour post-75-g OGTT are presented in Table 19.
TABLE 19 Relationship between maternal PA and GDM and macrosomia
PA measure
GDM status
p-valueGDM No GDM
GDM (n = 37) (n = 103)
Time of measurement
Baseline
Sedentary 622 (148) 581 (216) 0.109
LPA 170 (53) 184 (53) 0.168
MVPA 38 (16) 41 (21) 0.354
28 weeks’ gestation
Sedentary 591 (147) 585 (103) 0.860
LPA 155 (60) 173 (73) 0.336
MVPA 35 (19) 33 (16) 0.683
36 weeks’ gestationa
Sedentary 563 (103) 575 (96) 0.698
LPA 145 (44) 186 (59) 0.024
MVPA 21 (9) 29 (16) 0.088
Macrosomia (n = 26) (n = 114)
Time of measurement
Baseline
Sedentary 570 (90) 598 (139) 0.347
LPA 158 (43) 186 (54) 0.014
MVPA 42 (23) 40 (19) 0.741
28 weeks’ gestation
Sedentary 570 (84) 690 (122) 0.606
LPA 143 (31) 173 (76) 0.202
MVPA 37 (23) 33 (15) 0.482
36 weeks’ gestationa
Sedentary 555 (71) 575 (103) 0.587
LPA 153 (31) 180 (61) 0.197
MVPA 24 (13) 28 (16) 0.507
a After a GDM diagnosis.
Notes
Values are presented as mean (SD) minutes/day in each category of PA. GDM was diagnosed based on IADPSG’s criteria.
Macrosomia was defined as an infant weighing > 4000 g. Sedentary time was recorded using an accelerometer at
< 100 cpm. LPA is 100–1951 cpm. MVPA is > 1952 cpm.
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A trend towards baseline sedentary time being weakly positively associated and LPA time being negatively
associated with fasting and post-challenge glucose levels was observed, but the relationships did not reach
statistical significance. LPA at 28 weeks’ gestation was negatively associated with fasting and 2-hour
post-challenge glucose. The relationship between maternal PA and newborn infant abdominal circumference,
as a proxy for abdominal adiposity, was also examined (Table 20). Maternal sedentary time at baseline was
negatively associated with newborn infant abdominal circumference, but at 36 weeks’ gestation the
relationship was positive. LPA and MVPA at 36 weeks’ gestation were negatively associated with newborn
infant abdominal circumference.
Discussion
Maternal obesity is associated with an increased risk of obesity and an unfavourable cardiometabolic
profile in the offspring, which persists into adulthood and, therefore, impacts future generations. Obese
women are more insulin resistant than lean women during pregnancy and thus the offspring of obese
women are exposed to higher levels of glucose and other nutrients in utero. Exposure to intrauterine
overnutrition is associated with a higher birthweight, increased adiposity and indicators of poor
metabolic health.
Physical activity during pregnancy has the potential to increase insulin sensitivity and improve the health of
the offspring. Data presented here from the UPBEAT pilot trial and from other studies180,182,183 demonstrate
that PA during pregnancy is associated with improved maternal glucose control and less macrosomia and
adiposity in the offspring.184 Specifically, in the UPBEAT pilot study, even LPA in obese women was associated
with improved glucose tolerance and a lower infant abdominal circumference. It was of particular interest to
note that more time spent on sedentary activities and less time spent on low- and moderate-intensity PA
at 36 weeks’ gestation were related to an increasing infant abdominal circumference, whereas PA when
measured at 28 weeks showed no such relationships. Should this observation be repeated in the larger
cohort of the full RCT, in fully adjusted regression analyses, it could indicate that PA towards term may have
specific benefits for reducing adiposity in the child.
TABLE 20 Associations between maternal PA and fasting and 2-hour post-OGTT glucose (27+0–28+6 weeks’ gestation)
and between maternal PA and newborn infant abdominal circumference (Pearson product-moment correlation
coefficients)
Variable
Time point
Baseline (n= 61) 28 weeks’ gestation (n= 43) 36 weeks’ gestation (n= 34)
Maternal fasting glucose
Sedentary 0.162 0.090
LPA –0.117 –0.224a
MVPA –0.070 –0.078
Maternal 2-hour glucose
Sedentary 0.101 0.132
LPA –0.169 0.225a
MVPA –0.046 –0.114
Newborn infant abdominal circumference
Sedentary –0.287a –0.920 0.435a
LPA –0.036 0.024 –0.367a
MVPA –0.101 –0.011 –0.466a
a These correlations are statistically significant (p < 0.05).
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Despite the existence of lifestyle interventions of proven effectiveness to increase PA and improve insulin
sensitivity in non-pregnant populations, there is a paucity of interventions with demonstrated effectiveness
for pregnant women. Many intervention studies targeting PA in pregnant women, including the UPBEAT
pilot trial, have failed to impact PA levels.
Despite the difficulty of designing effective interventions to support obese pregnant women to be
physically active on the basis of this and other studies, it is clearly premature to abandon efforts to do
so.185 In the context of the increasing problem of obesity internationally, the potential benefits that could
be achieved if obese pregnant women become sufficiently active are substantial. A better understanding of
the barriers to obese women engaging in PA during pregnancy is needed to inform the development of
interventions. Process evaluation of the UPBEAT pilot trial revealed that the intervention was considered
acceptable and well received by most women, although some reported that the lifestyle information they
received was too basic and that attending group sessions was too time-consuming.150 Refinement of the
protocol for the delivery of the intervention in the UPBEAT has been made in view of these findings,
although the intervention remains the same. Previous work has also found that pregnant women report a
lack of time and childcare, as well as physical discomfort, as barriers to PA.150 The intervention design
needs to address these barriers by considering flexibility in the mode and location of intervention delivery,
and in terms of facilitating engagement in appropriate types of activity.
In summary, it is increasingly acknowledged that efforts to prevent obesity and its associated poor health
should begin in utero174 and should aim to improve maternal glucose control as this reduces the risk of
obesity among offspring.176 PA is an appropriate target for intervention to achieve this. The identification
of methods by which obese pregnant women can best be supported to be sufficiently active remains
a challenge.
PILOT TRIAL: ADDITIONAL ANALYSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Chapter 4 Trial protocol
Phase 1, the development phase, and phase 2, the pilot trial, led to completion of the protocol for phase 3,the RCT of a complex behavioural intervention in obese pregnant women to prevent GDM and LGA
deliveries. This protocol has been published previously as Briley AL, Barr S, Badger S, Bell R, Croker H,
Godfrey KM, Holmes B, Kinninen TI, Nelson SM, Oteng-Ntim O, Patel N, Robson SC, Sandall J, Sanders T,
Sattar N, Wardle L, Poston L. A complex intervention to improve pregnancy outcome in obese women;
the UPBEAT randomised controlled trial. BMC Pregnancy and Childbirth 2014;14:74.186 © Briley et al.;
licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is
an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated. Minor additions and formatting changes have been made to the
published text.
Abstract
Background: Despite the widespread recognition that obesity in pregnant women is associated with
adverse outcomes for mother and child, no intervention has been proven to reduce the risk of these
complications. The primary aim of this RCT is to assess, in obese pregnant women, whether a complex
behavioural intervention, based on changing diet (to foods with a lower GI and lower saturated fat intake)
and PA, will reduce the risk of GDM and delivery of a LGA infant. A secondary aim is to determine
whether or not the intervention lowers the long-term risk of obesity in the offspring.
Methods/design: A multicentre RCT comparing a behavioural intervention designed to prevent GDM at
27+0–28+6 weeks’ gestation and LGA with standard antenatal care in obese pregnant women. Inclusion
criteria: women with a BMI of ≥ 30 kg/m2 and a singleton pregnancy between 15+0 weeks and 18+6 weeks’
gestation.
Exclusion criteria: Predefined, pre-existing diseases and multiple pregnancy. Randomisation is online by a
computer-generated program and is minimised by BMI category, maternal age, ethnicity, parity and centre.
Intervention: This is delivered by a HT over eight sessions. Based on control theory, with elements of
social cognitive theory, the intervention is designed to improve maternal glucose homeostasis. Women
randomised to the control arm receive standard antenatal care until delivery in accordance with local
guidelines. All women have a 75-g OGTT at 27+0–28+6 weeks’ gestation.
Primary outcome: Maternal – diagnosis of GDM, in accordance with the IADPSG’s criteria; neonatal –
LGA, defined as > 90th customised birthweight centile.
Sample size: 1546 women to provide 80% power to detect a 25% reduction in the incidence of GDM
and a 30% reduction in the number of LGA infants.
Discussion: All aspects of this protocol have been evaluated in a pilot RCT, with subsequent optimisation
of the intervention. The findings of this trial will inform whether or not lifestyle-mediated improvement of
glucose homeostasis in obese pregnant women can minimise the risk of pregnancy complications.
Trial registration: Current Controlled Trials ISRCTN89971375.
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Background
The rise in the global incidence of obesity has reached pandemic proportions.187 In 2008, the WHO
estimated that there were 1.5 billion individuals with a BMI of ≥ 25 kg/m2, including nearly 300 million
obese women (BMI of ≥ 30 kg/m2).82 The UK has seen a sharp increase in the proportion of obese women;
as reported in a recent survey, approximately one in five women aged between 16 and 44 years is obese.188
The UK Confidential Enquiry into Maternal and Child Health identified that overweight and obesity were,
either directly or indirectly, the cause of over half of maternal deaths.109 The adverse effects of obesity on
reproductive health and childbearing are manifold. Obesity reduces fertility, and in pregnancy is associated
with a heightened risk of GDM, hypertensive disorders of pregnancy including pre-eclampsia and failure to
progress in labour. Caesarean section rates among obese women are high, and infants of obese mothers
are at greater risk of congenital malformation, of being LGA at delivery (> 90th centile), macrosomia,
shoulder dystocia and stillbirth. Following delivery, obese women are more likely to suffer a postpartum
haemorrhage and have longer hospital stays than women with a normal BMI (18.5–24.9 kg/m2).189,190 The
effects of obesity may extend beyond health in pregnancy; increasing evidence suggests that the children of
obese women or of those whose GWG was excessive may be at greater risk of obesity because of antenatal
exposure to adverse metabolic influences in utero or in the early postnatal period.9,191
In the UK, in contrast to the USA, women are no longer routinely weighed during pregnancy, except at their
first antenatal appointment. The US Institute of Medicine’s guidelines for weight gain during pregnancy
provide recommendations for women according to their pre-pregnancy BMI, which include that obese
women should gain less weight in pregnancy (11–20 lb; 5–9 kg) than those with a lower pre-pregnancy
BMI.192 This advice is based on observational studies suggesting improved outcomes with lower weight gain.
The UK NICE guidelines on weight management in pregnancy concluded that more evidence of improved
outcomes from interventional studies is required before the US or similar guidelines for limitation of GWG
are adopted.93 Although review of the literature suggests that intervention studies designed to limit
GWG may sometimes be effective in achieving a reduction in GWG, there is, at present, no evidence for
improvement of pregnancy outcome among obese women. However, most studies, including those in
overweight and obese pregnant women, have been small, have not been sufficiently powered for clinical
outcomes and have suffered from design limitations.84,193
The role of insulin resistance in obese pregnancies
An alternative approach to restricting GWG is to focus on the adverse clinical outcomes associated with
obesity, and to develop interventions which are directly associated with known underlying mechanisms.
A pre-pregnancy BMI of ≥ 30 kg/m2, irrespective of the amount of weight gained during pregnancy, is the
most important independent determinant of the risk of caesarean section, delivery of a LGA infant and
postpartum weight retention.194 In addition, the evidence linking GWG with GDM, in contrast to the strong
association with pre-pregnancy BMI, is relatively weak.195 This is, at least in part, likely to be a reflection
of the strong association between maternal fat mass and insulin resistance.9 There is a physiological increase
in insulin resistance during normal pregnancy and the obese pregnant woman is at greater risk of
developing GDM. Maternal hyperglycaemia and, more recently, maternal hypertriglyceridaemia are strongly
implicated in the development of fetal macrosomia.196–199 Using the method of continuous blood glucose
monitoring, Harmon et al.198 have shown, as might be expected, that obese pregnant women have an
exaggerated postprandial glucose response. As the magnitude of the postprandial response was directly
implicated in increasing fetal adiposity and birthweight through fetal hyperinsulinaemia, a dietary
intervention focusing on reducing postprandial hyperglycaemia by lowering the dietary GL could improve
maternal glucose control, reduce the incidence of GDM and lower the incidence of delivery of LGA infants.
Similarly, pre-eclampsia is associated with maternal insulin resistance, and improved glucose homeostasis
might lower the risk of pre-eclampsia in obese women.200
Improving glucose homeostasis in pregnancy
Specific dietary advice including intake of low-GI foods and reduction of dietary saturated fats, as well
increased PA, could contribute to improved maternal glucose homeostasis.87,201 In a study of 50 obese
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Danish women designed to limit GWG, Wolff et al.202 found that an intense dietary regime (10 1-hour
sessions with a dietitian) focusing on healthy eating resulted in a reduction in plasma insulin compared
with women in the control arm of the study. Another study reported that a diet and exercise regime led to
a reduction in GWG and a decrease in the incidence of GDM in 126 overweight and obese Australian
women,110 but no difference in infant birthweight (3.5 vs. 3.4 kg). In non-obese women with mild GDM, in
whom improved glucose homeostasis is achieved through a strict regime of dietary intervention and insulin
treatment when required, a reduction in the risk of adverse pregnancy outcome is achievable, as shown
in two RCTs.4,203 Higher levels of PA in normoglycaemic pregnant women and those with GDM have also
been shown to improve insulin sensitivity,9 but few data of adequate power are available for the obese
pregnant population. A recent meta-analysis of eight prenatal PA intervention studies, however, showed
that there is a lack of consistent evidence regarding the benefits of exercise combined or not combined
with dietary advice for improving glucose tolerance in obese pregnant women, which was interpreted to
reflect the limited power of current evidence and poor intervention compliance.204
Systematic review of the literature
Louie et al.7 conducted a systematic review of the influence of lowering dietary GI in pregnancies across
all BMI categories. Of the eight studies included, two suggested that a low-GI diet can reduce the risk of
LGA infants in healthy pregnancies, but one reported an increase in small-for-gestational-age infants. In
the three studies in which pregnancies were complicated by GDM, the evidence supported the overall
advantages of a low-GI diet. This review recommended that, until larger-scale intervention trials are
completed, a low-GI diet should not replace the current dietary recommendations from government and
health agencies, and that further research regarding the optimal time to start a low-GI diet for maximum
protection against adverse pregnancy outcomes is warranted.
In a systematic review of nine randomised trials including 743 overweight and obese pregnant women,
Dodd et al.193 reported that there was no significant effect of interventions designed to limit GWG on
weight gain or on delivery of a LGA infant. In a later systematic review of 13 randomised clinical trials of
lifestyle interventions in overweight and obese pregnant women (n = 1228), we concluded that there was
a modest influence on GWG (–2.21 kg; 95% CI –2.86 to –1.59 kg), but no significant effect on any
relevant clinical outcome.85 We have also reviewed dietary and PA interventions in normal BMI and obese
pregnant women (n = 1656 women) for the purpose of limiting GWG; in a systematic review we assessed
12 trials. Overall, diet and PA change was effective in reducing GWG, but there was considerable
heterogeneity in outcomes.2 The analysis highlighted differences in sample characteristics and aspects of
intervention design, content, delivery and evaluation which might explain variation in effectiveness.
Furthermore, failure to evaluate changes in behaviour or its psychological determinants could have
obscured identification of the processes by which weight change is effective, and limited the ability to
discern active intervention ingredients. We concluded that interventions should be more systematically
designed and built on insights from behavioural science.
More recently, Thangaratinam et al.,84 in a meta-analysis of 44 clinical trials of lifestyle or dietary interventions
or a combination of both during pregnancy across all BMI ranges, found a reduction in GWG (mean reduction
1.42 kg) with any intervention in comparison with the control.84 PA alone was associated with a reduction in
birthweight (mean difference –60 g, 95% CI –120 g to –10 g). Interventions based on diet were the most
effective, being associated with reductions in maternal GWG (mean 3.84 kg, 95% CI 2.45 to 5.22 kg) and a
modest improvement in obstetric outcomes. However, the combination of intervention methods did not result
in a reduction in the incidence of LGA infants between the groups (relative risk 0.85, 95% CI 0.66 to 1.09).
Among obese women, there was no evidence of an improvement in any clinical outcome. In an editorial to
this review, we highlighted that there remains a paucity of information regarding intensity, duration and
compliance of the interventions, all of which could account for the lack of efficacy, as well minimal evidence
for any effect of the intervention on the targeted behaviours. If the intervention does not achieve a change in
behaviour in the expected direction, it follows that there will be no influence on clinical outcomes.185
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The protocol presented here describes a complex behavioural intervention comprising dietary (low GI and
reduced saturated fat intake9) and PA changes that we have developed with the aim of improving glycaemic
control in obese pregnant women. The intervention is based on established control theory with elements of
social cognitive theory.94,95 The primary hypothesis being tested is that an antenatal intervention package
of low-glycaemic dietary advice and reduced saturated fat intake combined with advice on increased PA
will reduce the incidence of maternal GDM and delivery of LGA infants. A secondary hypothesis is that the
intervention will reduce the risk of obesity in the child. Prior to undertaking a trial adequately powered to
investigate clinical outcomes, we completed a pilot study (n = 183 women) to determine whether or not the
intervention changed dietary and physical behaviours as expected.150 This pilot study showed that diet but not
PA (as objectively measured) changed with the intervention and that all aspects of the protocol were feasible.
A process evaluation led to optimisation of intervention delivery. The trial steering committee recommended
continuation with recruitment for the RCT, and it was decided that the PA aspect of the intervention should
remain, as this follows standard guidelines for pregnant women.39
Methods/design
Study design
Multicentre RCT. For participating centres see the UPBEAT website: www.medscinet.net/upbeat/.
Ethics approval
NHS Research Ethics Committee approval was obtained in all centres (UK IRAS, reference number 09/H0802/5).
Inclusion criteria
Women with a singleton pregnancy, 15+0–18+6 weeks’ gestation and a BMI of ≥ 30 kg/m2 at their first
antenatal appointment.
Exclusion criteria
Women unable or unwilling to give informed consent; at < 15+0 weeks or at > 18+6 weeks’ gestation;
essential hypertension requiring treatment either pre-pregnancy or in index pregnancy; (see Erratum below
for omission in error of ‘pre-existing diabetes, type 1 or type 2’), pre-existing renal disease; systemic lupus
erythematosus; antiphospholipid syndrome; sickle cell disease; thalassaemia; coeliac disease; thyroid
disease; current psychosis; multiple pregnancy; or currently prescribed metformin.
The protocol for the study is shown in Figure 6.
Trial entry
Eligible women are identified in antenatal clinics and from GP and midwives referral letters. Verbal and
written information is given. Research midwives contact potential recruits, obtain verbal consent and
arrange the first appointment. Care is taken to search the clinical records for those women screened in
early pregnancy for pre-existing diabetes mellitus (UK recommendations are that all women with pre-GDM
should be screened in early pregnancy). Women with a diagnosis of diabetes mellitus are excluded from
the study (see Exclusion criteria). For those who decline to participate, permission is sought to collect
minimal pregnancy outcome data.
15+0–18+6 weeks’ appointment: baseline and randomisation
At the first appointment, written informed consent is obtained. Baseline demographic information, medical
and family history and current pregnancy information are collected. A short validated FFQ205 is completed
to evaluate dietary GL, dietary GI, saturated fat and total sugar intake and other dietary variables. Women
are weighed, their pulse and blood pressure are checked, anthropometric measurements obtained and
blood and urine samples taken. Behavioural and psychological measures include the EQ-5D,98 the EPDS,99
the IPAQ206 and a binge-eating screening questionnaire.207 Randomisation occurs at this visit via a secure
internet-based data management system (MedSciNet Ltd), which is the repository for all trial data. The
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≈ 14  weeks’ gestation:
Verbal and written explanation of study given, permission sought to proceed
14–15 weeks
Telephone/e-mail contact to answer queries 
and obtain verbal consent
15+0–18+6 weeks
Eligibility confirmed; written informed consent
Randomisation
Data: demography, maternal history, maternal 
family history and current pregnancy health
Questionnaires: dietary assessment (FFQ) and IPAQ
Anthropometry
Samples: non-fasting blood urine samples
DECLINED
Standard ANC
BMI, ethnicity, age and pregnancy
outcome recorded (if agreed) 
CONSENT NOT GIVEN
Standard ANC
Data: BMI, ethnicity, age and 
pregnancy outcome recorded
(if agreed)
Session – week 1
Session – week 2
Session – week 3
Session – week 4
Session – week 5
Session – week 6
Session – week 7
Session – week 8
CONTROL
Standard ANC
27+0–28+6 weeks
Consent confirmed
Consent confirmed
Data: current pregnancy 
health information
Questionnaires: FFQ and IPAQ
Anthropometry
Samples: OGTT, fasting 
blood and urine
34+0–36+6 weeks
Data: current pregnancy health
Questionnaires: FFQ and IPAQ
Anthropometry, samples: blood and urine
Pregnancy, delivery and neonatal
Data: maternal late pregnancy, intrapartum,
newborn, maternal postnatal and neonatal
Neonatal anthropometry: cord blood sample
INTERVENTION
Appointment with
health trainer 
followed by eight
weekly sessions
FIGURE 6 The UPBEAT protocol summary. ANC, antenatal clinic.
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randomisation schedule is minimised according to ethnicity, parity (0 vs. ≥ 1), age, BMI (BMI 30–34 vs.
35–39.9 and > 40 kg/m2) and centre. Randomised women are allocated sequential study numbers,
regardless of allocation to the intervention or standard care group.
Intervention
Women randomised to the intervention group attend a one-to-one interview with the HT, which includes
discussion of the potential benefits of attending the weekly sessions. In the UK, HTs help people to change
their behaviour to achieve personal choices and goals and, generally, do not have prespecified health
professional qualifications, but do have relevant experience. All HTs in this trial receive study-specific training
in all aspects of the intervention and ongoing support throughout the trial. Women in the intervention
group receive a participant handbook, a DVD of an exercise regime safe for pregnancy, a pedometer and a
logbook for recording weekly SMART goals and steps (as assessed by a pedometer). They are invited to
attend eight sessions with the HT on a weekly basis, each lasting 1–1.5 hours. Women are encouraged
to attend all sessions, but are strongly recommended to attend a minimum of five. When the sessions are
not attended in person, the HT covers the session material by telephone or e-mail. Attendance and coverage
of session material are documented in the study database. Following a review of the dietary and physical
intervention, each session is designed to focus on different approaches in achieving the goals set. These
include SMART goals, self-monitoring, and provision of feedback regarding goal attainment, identification
and problem-solving of barriers, enlisting social support and providing opportunities for social comparison.
At each session, a review of the previous week’s goals is undertaken.
The dietary intervention aims to promote a healthier pattern of eating, similar to that used in diabetes
mellitus prevention studies, but does not aim to restrict energy intake. In order to decrease the GL, dietary
advice includes replacing starchy foods with a medium/high GI by foods with a lower dietary GI, and
restricting the consumption of sugar-sweetened beverages (including fruit juice) but not fruit. Participants
are also given dietary advice to reduce SFA intake. No advice was given regarding GWG.
Advice regarding PA focuses on increasing the daily step count incrementally, and being more active in daily
life. Pedometers are used for monitoring and motivation. The emphasis is on walking at a moderate intensity
with additional options included, especially for those who are already engaging in some PA. This degree of
activity accords with that recommended by the UK’s Royal College of Obstetricians and Gynaecologists.39
Standard care
Women randomised to the standard care group attend routine antenatal care in accordance with local
health-care provision. The UK recommendations state that all pregnant women, and particularly those with
a BMI of ≥ 30 kg/m2, should be advised by a health professional at the earliest opportunity of the risks of
obesity in pregnancy and be given advice about a healthy diet and safe levels of PA. Recommendations
for referral to a registered dietitian are infrequently implemented. No specific advice is given about GWG
and women are weighed only at their first antenatal visit.93 Women should also be encouraged to lose
weight after pregnancy.
27+0–28+6 weeks’ appointment
All women in both groups attend for an OGTT at 27+0–28+6 weeks’ gestation (fasting for a minimum of
10 hours, 75-g glucose load). At this visit weight and anthropometric measurements are taken, health in
current pregnancy noted, additional blood and urine samples taken, and dietary FFQ, EQ-5D, EPDS, IPAQ
and questionnaires about binge-eating completed. Early pregnancy data including blood pressure, blood
chemistry and anomaly scan reports are entered from routine clinical records.
34+0–36+0 weeks’ appointment
Women in both arms of the study attend the research appointment at 34+0–36+0 weeks’ gestation.
Current health in pregnancy is recorded, weight and anthropometric measurements taken, blood and
urine samples collected and dietary FFQ, EQ-5D, EPDS, IPAQ and binge-eating questionnaires completed.
Unexpected adverse events are reported in accordance with good clinical practice guidance.
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Pregnancy outcome data
Following delivery, information is collected from maternal medical records regarding health in late
pregnancy, labour onset, mode of delivery, blood loss, antenatal and postnatal inpatient nights. When
possible a cord blood sample is taken.
Neonatal and postnatal outcome data include Apgar scores, admission to special care baby unit and
inpatient nights. To address the influence of the intervention on fetal growth and adiposity, neonatal
anthropometry and length measurements are undertaken within 72 hours of birth.
Six months post partum
To determine whether or not the intervention has led to sustained change in maternal dietary and PA
behaviours, diet is assessed by FFQ and PA by IPAQ. Maternal demographic data, health since pregnancy
and smoking history are obtained. Maternal anthropometric measures are taken. EPDS, Three-Factor Eating
Questionnaire-R18208 and binge-eating questionnaires are completed. To address safety and the influence
of the intervention on the long-term health of the child, details regarding the child’s health from birth are
obtained. If cord blood was not taken, and if the parents provide consent, a buccal cell sample is taken
from the child’s mouth for deoxyribonucleic acid (DNA) extraction (Oragene, DNA Genotek, Ottawa, ON,
Canada). To address the potential influence of the intervention on infant adiposity at 6 months and to
obtain information on known determinants of childhood obesity, infant length and other anthropometric
measures are taken. The mother provides information for an infant feeding and growth questionnaire209
and a validated questionnaire addressing appetite, the Baby Eating and Behaviour Questionnaire.210
Information on activity using questions from the Infant Behaviour Questionnaire-Revised211 and sleep
patterns are obtained212 and information on childcare (kindergarten, other carers) collected.
Paternal data
At any point during the pregnancy or at the 6-month postnatal appointment the father of the baby is
asked to consent to taking part in the study to provide information that may influence the health of the
child. A brief medical history, blood pressure and pulse are checked, anthropometric measurements
are taken and a blood samples collected for the provision for DNA. In the absence of direct paternal
measurement, women are asked to recall their partner’s height and weight and brief medical and
smoking history.
Study end points
Primary maternal outcome
Gestational diabetes mellitus was diagnosed by OGTT at 27+0–28+6 weeks’ gestation in accordance
with the criteria recommended by IADPSG (i.e. fasting blood glucose concentration of ≥ 5.1 mmol/l or
1-hour glucose of ≥ 10.0 mmol/l or 2-hour glucose of ≥ 8.5 mmol/l).
Primary neonatal outcome
A LGA infant is defined as an infant whose adjusted birthweight is > 90th centile for gestational age,
adjusting for maternal height, corrected maternal weight, ethnicity, parity and sex of baby.
Secondary outcomes
Maternal
Pre-eclampsia, severe pre-eclampsia; mode of delivery: caesarean section (elective, emergency, pre labour,
in labour), vaginal delivery, operative vaginal delivery; induction of labour; blood loss at delivery
(> 1000 ml; > 2000 ml); inpatient nights (antenatal, postnatal); GWG, trimester-specific GWG; fasting
plasma glucose, fasting plasma insulin, insulin resistance calculated by homeostatic model assessment 2
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(Homeostatic Model Assessment 2 – Insulin Resistance, HOMA2-IR)213 at 28 weeks’ gestation; diagnosis
of GDM by local criteria; referral to GDM antenatal service following OGTT; requirement for insulin or
metformin during pregnancy; and fetal growth at 28 weeks. Health-related quality of life as assessed by
EQ-5D. At 27+0–28+6 and 34+0–36+0 weeks’ gestation and 6 months post partum; mid-arm, neck, hip,
thigh and wrist circumference and skinfold thickness (subscapular, triceps, biceps, suprailiac); plasma
fructosamine, triglycerides, LDL, very low-density lipoprotein (VLDL) and HDL cholesterol, plasma insulin,
C-reactive protein, other relevant epigenetic and metabolomic biomarkers, and urinary biomarkers; dietary
measures including GL, saturated fat and total sugar intake; dietary feeding patterns; PA scores; measures
of depression; and maternal smoking. At 6 months post partum, postnatal weight retention and existing
maternal morbidity (diabetic status, hypertension, thromboembolism, low mood214).
Neonatal
Gestational age at delivery, delivery at < 37 weeks’ gestation, delivery at < 34 weeks’ gestation; birthweight
> 4000 g; birthweight < 2500 g; birthweight > 95th, < 10th and< 5th customised birthweight centiles,
distribution of birthweight, neonatal death, days in special care baby unit, total inpatient days, need for
mechanical ventilation and duration, discharge home on oxygen, suspected and confirmed infection,
evidence of intraventricular haemorrhage and other complications, (pulmonary haemorrhage, necrotising
enterocolitis), retinopathy of prematurity, hypoglycaemia (blood glucose < 2.6 mmol/l), occipitofrontal
head circumference, abdominal circumference, mid-arm circumference, chest circumference, crown–rump
length and crown–heel length (neonatometer), triceps and subscapular skinfold thicknesses and estimated
fat mass.
And other infrequent adverse outcomes, including shoulder dystocia were recorded as free text.
Key epigenetic and metabolomic biomarkers will be investigated using cord blood or whole blood
(maternal and fetal) and their relation to specific outcomes.
Infant at 6 months
Duration of breastfeeding, choice of formula milk, weaning history (introduction of foods and frequency/
timing of foods), a general measure of appetite, and four specific scales (enjoyment of food, food
responsiveness, slowness in eating, satiety responsiveness); anthropometric measurements (occipitofrontal
circumference, abdominal circumference, mid-arm circumference, chest circumference, crown–rump length
and crown–heel length by infantometer, subscapular and triceps skinfold thicknesses and estimated fat
mass); activity (total number of 14 standard milestones reached) and sleeping patterns (time spent sleeping
morning, afternoon and night); health-care resource use (hospital admissions and medications); and
frequency of use of kindergarten/mother’s help.
Subgroup analysis
Women who are treated for GDM; differences in diagnostic thresholds between centres will be
accommodated by minimisation by centre. Other subgroups likely to be of interest include demographic
and socioeconomic status (as assessed by the Index of Multiple Deprivation), ethnic groups, BMI categories,
groups of different parity and smokers.
Interaction tests will be used to determine whether or not treatment is particularly effective in individual
subgroups. Performance of subgroup analysis will be dependent on sufficient data. Because of the
well-known risk of false positives, both main effects and interaction tests will be performed before
considering results for subgroups.
Sample size
In the pilot RCT,150 30% of women in the standard care arm developed GDM in accordance with the
IADPSG’s criteria.208 A total of 1546 women (including allowance for 20% dropout) (773/arm) will be
recruited to provide 80% power to detect a 25% reduction in the incidence of GDM. Considering LGA
TRIAL PROTOCOL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
deliveries, for a 30% relative risk reduction from an estimated 17.2% of LGA to 12.0% in the intervention
arm, 1546 women would give 80% power.215,216
Analysis
To determine whether the trial participants are representative of the general population, relevant
parameters available from electronic summary patient records will be compared between eligible women
agreeing and declining to take part. Analyses will follow the intention-to-treat principle.
Following CONSORT guidelines, risk ratios and risk differences will be estimated by binary regression for
yes/no outcomes. When measurements are repeated over time, results [mean (SD) or n (%)] will be
presented separately at each time point. Randomised comparisons with 95% CIs will be made using linear
regression with robust standard errors, adjusting for the baseline value when appropriate.
Multiple regression models will be used to address the influence of maternal exposures on neonatal and
infant (6 months) body composition and the role of paternal factors.
Discussion
This RCT will determine whether a complex intervention addressing diet and PA will reduce the incidence
of GDM and delivery of LGA infants in a population of obese pregnant women receiving antenatal care in
the UK. The study will inform guidelines on the management of obesity in pregnancy and, if successful, is
designed to be rapidly transferable to clinical practice. Determination of infant anthropometry at 6 months
of age will assess whether or not the intervention in pregnancy can influence body composition of the
infant. Further studies on childhood body composition at 3 years of age will also be undertaken.
Erratum
An erratum of this protocol has been published as follows:
Briley AL, Barr S, Badger S, Bell R, Croker H, Godfrey KM, et al. Erratum: a complex intervention to
improve pregnancy outcome in obese women; the UPBEAT randomised controlled trial. BMC Pregnancy
Childbirth 2015;15:111. http://dx.doi.org/10.1186/s12884-015-0540-1186
The paragraph describing exclusion criteria should read:
Exclusion criteria
Women unable or unwilling to give informed consent; < 15+ 0 weeks or > 18+ 6 weeks’ gestation; essential
hypertension requiring treatment either pre pregnancy or in index pregnancy; pre-existing diabetes
mellitus (type 1 or type 2); pre-existing renal disease; systemic lupus erythematosus; antiphospholipid
syndrome; sickle cell disease; thalassaemia; coeliac disease; thyroid disease; current psychosis; multiple
pregnancy; currently prescribed metformin.
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Chapter 5 The UK Pregnancies Better Eating and
Activity trial: phase 3 – randomised controlled trial
Following successful completion of phases 1 and 2, the programme continued with a RCT (phase 3)of a complex intervention designed to prevent GDM and LGA in pregnant women with obesity and
their offspring.
Effect of a behavioural intervention in obese pregnant
women (the UK Pregnancies Better Eating and Activity trial):
a multicentre, randomised controlled trial
This study has been published previously as Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L,
et al., on behalf of The UPBEAT Trial Consortium. Effect of a behavioural intervention in obese pregnant
women (the UPBEAT study): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol
2015;3:767–77.217 © Poston et al. Open Access article distributed under the terms of CC BY-NC-ND.
Summary
Background: Behavioural interventions might improve clinical outcomes in pregnant women who are
obese. We aimed to investigate whether a complex intervention addressing diet and physical activity could
reduce the incidence of gestational diabetes and large-for-gestational-age infants.
Methods: The UK Pregnancies Better Eating and Activity Trial (UPBEAT) is a randomised controlled trial done
at antenatal clinics in eight hospitals in multi-ethnic, inner-city locations in the UK. We recruited pregnant
women (15–18 weeks plus 6 days of gestation) older than 16 years who were obese (BMI ≥ 30 kg/m2).
We randomly assigned participants to either a behavioural intervention or standard antenatal care with an
internet-based, computer- generated, randomisation procedure, minimising by age, ethnic origin, centre,
BMI, and parity. The intervention was delivered once a week through eight health trainer-led sessions.
Primary outcomes were gestational diabetes (diagnosed with an oral glucose tolerance test and by criteria
from the International Association of Diabetes in Pregnancy Study Groups) and large-for-gestational-age
infants (≥ 90th customised birthweight centile). Analysis was by intention to treat. This trial is registered
with Current Controlled Trials, ISCRTN89971375. Recruitment and pregnancy outcomes are complete but
childhood follow-up is ongoing.
Findings: Between March 31, 2009, and June 2, 2014, we assessed 8820 women for eligibility and
recruited 1555, with a mean BMI of 36.3 kg/m2 (SD 4.8). 772 were randomly assigned to standard
antenatal care and 783 were allocated the behavioural intervention, of which 651 and 629 women,
respectively, completed an oral glucose tolerance test. Gestational diabetes was reported in 172 (26%)
women in the standard care group compared with 160 (25%) in the intervention group (risk ratio 0.96,
95% CI 0.79–1.16; p = 0.68). 61 (8%) of 751 babies in the standard care group were large for gestational
age compared with 71 (9%) of 761 in the intervention group (1.15, 0.83–1.59; p = 0.40). Thus, the
primary outcomes did not differ between groups, despite improvements in some maternal secondary
outcomes in the intervention group, including reduced dietary glycaemic load, gestational weight gain,
and maternal sum-of-skinfold thicknesses, and increased physical activity. Adverse events included
neonatal death (two in the standard care group and three in the intervention group) and fetal death in
utero (ten in the standard care group and six in the intervention group). No maternal deaths were
reported. Incidence of miscarriage (2% in the standard care group vs. 2% in the intervention group),
major obstetric haemorrhage (1% vs. 3%), and small-for-gestational-age infants (≤ 5th customised
birthweight centile; 6% vs. 5%) did not differ between groups.
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Interpretation: A behavioural intervention addressing diet and physical activity in women with obesity
during pregnancy is not adequate to prevent gestational diabetes, or to reduce the incidence of large-for-
gestational-age infants.
Funding: National Institute for Health Research, Guys and St Thomas’ Charity, Chief Scientist Office
Scotland, Tommy’s Charity.
Introduction
In 2013, an estimated one in five women in the world aged 20 years or older was obese (BMI of ≥ 30 kg/m2).218
Obesity in women was most widespread in high-income countries, with a prevalence of 25% in the UK and
34% in the USA.218 Pregnant women with obesity are at risk of many complications, with insulin resistance and
gestational diabetes being major concerns because they beget important adverse outcomes. These include
stillbirth, large-for-gestational-age infants, and associated complications at birth.9 Children born to women with
gestational diabetes could themselves be at risk of metabolic disease in later life.219
The increasing global problem of obesity in maternity care has led to national guideline recommendations
for the development of interventions to improve pregnancy outcomes.83,93 This advice stimulated many
clinical trials, predominantly of behavioural interventions addressing diet and physical activity. However,
most trials have been underpowered for clinical outcomes such as gestational diabetes, focusing instead
on restriction of gestational weight gain.84 Nonetheless, systematic reviews of these mostly small trials
suggest the potential for prevention of gestational diabetes in women with obesity by behaviour change
interventions in pregnancy.85,220
Methods
Study design
We did this multicentre, randomised controlled trial at antenatal clinics in eight inner-city NHS Trust
Hospitals in the UK – London (three centres), Bradford, Glasgow, Manchester, Newcastle, and Sunderland.
The detailed study design and protocol have been published elsewhere.186 A flow chart of the protocol is
shown in the appendix (Figure 7). We did the study according to the UK’s National Institute for Health
and Care Excellence (NICE) guidelines for diabetes in pregnancy, in which early pregnancy biochemistry
screening for glucose intolerance and risk of gestational diabetes is not recommended.221 The NHS
research ethics committee approved the study protocol for all centres (UK integrated research application
system, reference 09/H0802/5). The trial steering committee approved the protocol and the analysis plan
and provided oversight of all aspects of the trial, including safety.
Participants
We recruited women older than 16 years with a BMI of 30 kg/m2 or higher and a singleton pregnancy
between 15 weeks and 18 weeks plus 6 days of gestation. We excluded individuals if they were unwilling
or unable to give informed consent; if they had underlying disorders, including a pre-pregnancy diagnosis
of essential hypertension, diabetes, renal disease, systemic lupus erythematosus, antiphospholipid
syndrome, sickle-cell disease, thalassaemia, coeliac disease, thyroid disease, and current psychosis; or if
they were currently being prescribed metformin. All participants provided written informed consent.
For women who declined to participate, we recorded age, BMI, ethnic origin, socioeconomic status, and
outcome data if permission was granted.
Randomisation and masking
We randomly allocated participants to either standard antenatal care or the behavioural intervention plus
standard antenatal care. We used a computer-generated randomisation procedure via a password-protected
website. Allocation to study groups was done by the centre’s UPBEAT trial midwife. We used minimisation,
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according to ethnic origin (black, white, Asian, other), parity (primiparous, multiparous), age (≤ 24, 25–29,
30–34, ≥ 35 years), BMI (30.0–34.9, 35.0–39.9, ≥ 40 kg/m2), and centre. In view of the nature of the
intervention, participants and staff were aware of allocations.
Procedures
Within 1 week of randomisation, women in the intervention group attended an individual interview at
their trial centre with a health trainer (a person with skills in assisting behavioural change, but not
necessarily a health professional) who received coaching in all aspects of the intervention and ongoing
support throughout the study period.186 The intervention, which was informed by control theory and
elements of social cognitive theory, consisted of eight further health trainer-led group or individual sessions
BOX 3 Research in context
Evidence before this study
Obesity is a risk factor for complications in pregnancy particularly gestational diabetes, large-for-gestational-age
babies, and associated adverse outcomes. In a systematic review of 44 randomised controlled trials of
behavioural interventions in pregnant women, irrespective of BMI, lifestyle interventions were shown to possibly
improve clinical outcomes for both mother and baby. We and others have undertaken systematic reviews
restricted to behavioural interventions in women with obesity, suggesting the potential for prevention of
gestational diabetes. The contributing trials were mostly small scale and not powered for robust detection of
differences in clinical outcomes. In the LIMIT trial of more than 2000 overweight and obese women, no
reduction in gestational diabetes was recorded in individuals who took part in a lifestyle intervention, although
gestational diabetes was not the primary endpoint of the trial.
Added value of this study
Our study compared a theory-based and intensive behavioural intervention with standard antenatal care for
obese pregnant women from communities of ethnic diversity and high levels of socioeconomic deprivation.
The intervention improved diet and physical activity, and modest reductions were noted in maternal weight
gain and fat mass, but it had no effect on the incidence of gestational diabetes or large-for-gestational-age
infants. Use of an oral glucose tolerance test and diagnosis of gestational diabetes with the stringent IADPSG
diagnostic criteria (also used by WHO) was associated with a lower than anticipated incidence of large-for-
gestational-age infants in the trial population.
Interpretation
An intervention addressing diet and physical activity in high-risk women with obesity does not prevent
gestational diabetes or reduce the incidence of large-for-gestational-age infants. We recommend a shift in
research focus towards improved screening for and treatment of gestational diabetes, in addition to renewed
efforts towards effective public health measures that prevent obesity in women of reproductive age.
Here, we report the results of the UK Pregnancies Better Eating and Activity Trial (UPBEAT), a randomised
controlled trial of a complex behavioural intervention addressing diet and physical activity versus standard
antenatal care. The behavioural intervention was designed to prevent maternal gestational diabetes and reduce
the incidence of large-for-gestational-age infants. By contrast with interventions tested in many previous small-
scale studies,84 the intervention was more intensive in design. Findings of a pilot study have shown feasibility,
acceptability, and efficacy of the intervention to change lifestyle behaviours.150
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≈ 14  weeks’ gestation:
Verbal and written explanation of study given, permission sought to proceed
14–15 weeks
Telephone/e-mail contact to answer queries 
and obtain verbal consent
15+0–18+6 weeks
Eligibility confirmed; written informed consent
Randomisation
Data: demography, maternal history, maternal 
family history and current pregnancy health
Questionnaires: dietary assessment (FFQ) and IPAQ
Anthropometry
Samples: non-fasting blood urine samples
DECLINED
Standard ANC
BMI, ethnicity, age and pregnancy
outcome recorded (if agreed) 
CONSENT NOT GIVEN
Standard ANC
Data: BMI, ethnicity, age and 
pregnancy outcome recorded
(if agreed)
Session – week 1
Session – week 2
Session – week 3
Session – week 4
Session – week 5
Session – week 6
Session – week 7
Session – week 8
CONTROL
Standard ANC
27+0–28+6 weeks
Consent confirmed
Consent confirmed
Data: current pregnancy 
health information
Questionnaires: FFQ and IPAQ
Anthropometry
Samples: OGTT, fasting 
blood and urine
34+0–36+6 weeks
Data: current pregnancy health
Questionnaires: FFQ and IPAQ
Anthropometry, samples: blood and urine
Pregnancy, delivery and neonatal
Data: maternal late pregnancy, intrapartum,
newborn, maternal postnatal and neonatal
Neonatal anthropometry: cord blood sample
INTERVENTION
Appointment with
health trainer 
followed by eight
weekly sessions
FIGURE 7 Trial protocol summary. ANC; antenatal care.
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of 1 h duration once a week for 8 weeks.186 If a participant could not attend a session in person, the
material was covered by telephone or e-mail, providing flexibility in intervention delivery. Every session
addressed approaches to achieving SMART goals (i.e. specific, measurable, achievable, relevant,
time-specific) and reviewed the previous week’s goals. Women assigned to the intervention received
advice on self-monitoring, identification and problem-solving of barriers to behaviour change; enlisting
social support; and providing opportunities for social comparison. We encouraged participants to attend all
sessions and provided them with a handbook in which information was included about the intervention
and the theory behind it, with recommended foods and recipes, and suggestions for physical activity.
We also gave the women a DVD of an exercise regimen that was safe for pregnancy, a pedometer, and
a log book for recording their weekly SMART goals. The intention of the intervention was to improve
glucose tolerance through dietary and physical activity behaviour change. With the dietary intervention we
aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake. We tailored
recommendations to the woman’s habitual diet and cultural preference, and suggested exchanging
carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index
to reduce the glycaemic load, and restricting dietary intake of saturated fat. With respect to advice on
physical activity, we focused on incremental increases in walking from a pedometer- assessed baseline,
tailored to pre-existing activities. The emphasis of the exercise intervention was on walking at a moderate
intensity, with additional options included, particularly for women already engaging in some physical
activity. Further details are available in the protocol.186 Women in the intervention group continued with
their routine antenatal care appointments.
Women who were allocated to the standard antenatal care group continued to attend routine antenatal
appointments at their trial centre, according to local practice. Typically, women would attend nine
appointments. Recommendations of UK guidelines are for women with obesity to be advised, at first
contact with a health professional, and at no other time, about a healthy diet and the benefits of physical
activity.93,221 We did not provide any additional information, including any details of the nature of the
intervention.
For diagnosis of gestational diabetes, we gave all participants an oral glucose tolerance test (75-g load)
between 27 weeks and 28 weeks plus 6 days of gestation. We used diagnostic criteria recommended by
the International Association of Diabetes and Pregnancy Study Groups (IADPSG) (i.e., fasting venous
glucose of 5.1 mmol/l or higher, 1 h venous glucose of 10.0 mmol/l or higher, 2 h venous glucose of
8.5 mmol/l or higher, or a combination of these).6 We used these criteria not only because of their
increasing adoption globally (and by WHO) but also because of differences in routine diagnostic criteria
used by trial centres. We referred women who were diagnosed with gestational diabetes for antenatal
diabetic services, according to local practice at every centre.
To assess the efficacy of the behavioural intervention, we gathered maternal dietary data and physical
activity scores, calculated gestational weight gain and took maternal anthropometric measurements. We
used standard laboratory methods to measure biochemical outcomes between 27 weeks and 28 weeks
plus 6 days of gestation.
We used a food frequency questionnaire186,222 to assess the diet of participants for the month before
randomisation and for the month before the study visit at between 27 weeks and 28 weeks plus 6 days
of gestation. We adapted this questionnaire from one used in the UK arm of the European Prospective
Investigation into Cancer Study.222 We used WISP 3.0 (Tinuviel Software, Llanfechell, Anglesey, UK) to
calculate nutritional composition and glycaemic load per 100 g of food and beverage items. We excluded
from the analysis data for participants who we estimated were under-reporting (≤ 4.5 MJ/day) and
over-reporting.223
We measured physical activity at randomisation and at the study visit between 27 weeks and 28 weeks
plus 6 days of gestation. We used the International Physical Activity Questionnaire (IPAQ) and summarised
data according to established methods.186 We calculated physical activity (minutes/week) as metabolic
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equivalents (METs) – i.e., the ratio of energy expenditure for an activity to energy expenditure at rest – with
the formula 8.0 × vigorous activity + 4.0 × moderate activity + 3.3 × light activity (walking).
At delivery of the infant, we measured and weighed the baby. We calculated customised birthweight
centiles with Gestation Related Optimal Weight (GROW) software, version 6.7.5.1 (Gestation Network,
Perinatal Institute, Birmingham, UK).
Outcomes
The primary maternal outcome was gestational diabetes. Pre-specified secondary outcomes included
dietary measures, physical activity scores, gestational weight gain, maternal anthropometric measurements
(mid-arm and thigh circumference and subscapular, triceps, biceps, and suprailiac skinfold thicknesses),
and biochemical outcomes (maternal fasting plasma glucose, fasting plasma insulin, insulin resistance
[calculated by homoeostatic model assessment, HOMA2-IR]213, fasting triglycerides, LDL cholesterol, HDL
cholesterol, and VLDL cholesterol). We pre-specified several other secondary clinical maternal outcomes:
pre-eclampsia (defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or
both, on at least two occasions 4 h apart, with proteinuria ≥ 300 mg/24 h or spot urine protein to
creatinine ratio ≥ 30 mg/mmol creatinine, or urine dipstick protein ≥ 2+); severe pre-eclampsia (defined as
systolic blood pressure ≥ 170 mmHg, diastolic blood pressure ≥ 110 mmHg, or both, with proteinuria
≥ 500 mg/24 h or spot urine protein to creatinine ratio ≥ 50 mg/mmol creatinine, or urine dipstick protein
≥ 3+); mode of delivery (elective or emergency caesarean section, vaginal delivery, or operative vaginal
delivery); induction of labour; blood loss at delivery (> 1000 ml or > 2000 ml); inpatient nights (antenatal
and postnatal); referral to diabetic antenatal service after oral glucose tolerance test; and a requirement for
insulin or metformin during pregnancy. Prespecified maternal secondary outcomes not reported here are
listed in the Supplementary text below.
The primary neonatal outcome was delivery of a large-for-gestational-age infant, which we defined as
the 90th or higher customised birthweight centile for gestational age, adjusting for maternal height and
weight, ethnic origin, parity, and sex of the baby. We pre-specified several secondary neonatal outcomes:
gestational age at delivery; delivery at less than 37 weeks and less than 34 weeks; birthweight; birthweight
4.0 kg or heavier, 2.5 kg or lighter, or 1.5 kg or lighter; customised birthweight centile (≥ 95th, ≤ 10th, and
≤ 5th); neonatal death; days in special care baby unit; total inpatient days; discharge home on oxygen;
confirmed infection; retinopathy of prematurity; neonatal hypoglycaemia; intraventricular haemorrhage;
need for mechanical ventilation and duration; necrotising enterocolitis; pulmonary haemorrhage, skinfold
thicknesses and circumferences; and birthweight centiles as population centiles (≥ 90th, ≥ 95th, ≤ 10th, and
≤ 5th). Pre-specified neonatal secondary outcomes not reported here are listed in the Supplementary text.
Adverse events other than those prespecified as secondary outcomes included miscarriage, late termination
of pregnancy, maternal accident, placental abruption, antenatal and postnatal sepsis, iatrogenic premature
birth, intrauterine complications (fetal cardiac, renal, respiratory, and neurological), fetal death in utero,
unspecified neonatal complications at birth, and confirmed neonatal sepsis.
Statistical analysis
We calculated that a sample size of 1546 women (allowing for 20% dropout) would provide at least 80%
power to detect a clinically important 25% reduction in the incidence of gestational diabetes, from 30%
(observed in the pilot study of 183 women)150 to 23%. From a review of published population birthweight
centiles in obese UK women,16 1546 infants provided 80% power to detect a 30% relative risk reduction
for large-for-gestational-age infants (17.2% to 12.0%).215
Our analysis was by intention to treat. We expressed treatment effects for binary endpoints as risk ratios
(relative risk) with 95% CIs, using binomial regression and adjusting for maternal BMI, ethnic origin, and
parity (i.e. minimisation variables for intervention allocation). We calculated risk differences and did
significance tests for both primary endpoints. For continuous measurements, we used linear regression with
robust SEs, adjusting for baseline data or the variables used for minimisation. For physical activity data,
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we did median regression. For biochemical data, we did log transformations for normality, as appropriate.
To check for the potential of a variable response to the intervention, we did subgroup analyses with
interaction tests for BMI, ethnic origin, socioeconomic status, parity, and smoking. Moreover, to ascertain
whether attendance at intervention sessions affected outcome, we did further interaction tests.
For the main analysis, we followed the missing-at-random assumption. Predictors of missingness, which we
included to ensure an unbiased measure of treatment effect, were maternal BMI, ethnic origin and parity.
To test the possibility of undetectable bias attributable to missing data, we did a series of analyses under
different missing-not-at-random assumptions for the primary maternal and neonatal endpoints, with the
Stata command rctmiss. We tested the assumptions that the odds of disease in participants with missing
data were variously half or double that for women with complete data, in both study groups or in one
group only. We did all analyses with Stata version 13.1.
This trial is registered with Current Controlled Trials, ISCRTN89971375.
Role of the funding source
The funders had no role in study design, data collection, data analysis, data interpretation or writing of the
report. The corresponding author had full access to all data in the study and had final responsibility for the
decision to submit for publication.
Results
From 31 March 2009 to 2 June 2014, 8820 pregnant women with a BMI of 30 kg/m2 or higher were
assessed for inclusion. Of 8259 eligible individuals, 1555 (19%) gave informed consent to participate and
were randomly allocated to either standard antenatal care (n = 772) or the behavioural intervention
(n = 783; Figure 8). The mean BMI of participants was 36.3 kg/m2 (SD 4.8); three-quarters of women were in
the two highest quintiles of the index of multiple deprivation (Table 21). Compared with 3711 individuals
who declined to participate but agreed to use of routine data, participants were on average 10 months
older and had a BMI that was 0.7 kg/m2 higher (Table 22).
On average, women who were assigned the intervention attended seven (SD 3) of eight health trainer-led
sessions, including four in person, and a further three by telephone or e-mail. For sessions attended in
person, 30% of women attended only one session, and 46% attended fewer than four. For sessions
delivered by any method, 10% of women received only one session and 17% had fewer than four.
A total of 629 (80%) women in the intervention group and 651 (84%) in the standard care group had an
oral glucose tolerance test and could be assessed for the primary maternal outcome. Demographic
variables were similar between groups for women with primary outcome data (Table 23). The main reason
for missing outcome data was that participants declined to attend further study visits (see Figure 8).
129 (16%) women in the intervention group failed to complete the oral glucose tolerance test compared
with 92 (12%) in the standard care group (p = 0.02).
The incidence of gestational diabetes was similar between groups (Table 24). Of women who had an oral
glucose tolerance test, 10 women in the intervention group and eight in the standard care group had their
test done outside the predefined period. A sensitivity analysis excluding all data obtained outside this
period gave similar results to the main analysis [intervention 150 (25%) of 589 vs standard care 164 (27%)
of 618; risk ratio 0.96, 95% CI 0.79–1.16; p = 0.67].
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8820 women assessed 
at 15+0 to 18+6 weeks’ gestation, BMI of > 30 kg/m2
7265 Excluded
• 438 Not eligible when reassessed
• 6704 Declined to participate
• 123 Termination/miscarriage
3712 agreed to use of routine data
1 excluded after enrolment
in another trial
1555 randomised
154 without oral-glucose-tolerance-test 
results:
• 11 test outside dates
• 19 did not attend
• 110 declined further visits
• 14 loss of pregnancy
629 completed oral glucose tolerance
tests; 589 at 27+0 – 28+6 weeks;
40 within 6 days, (mean 3.0)
• 6 lost to follow up
• 3 withdrew permission to use data
• 6 miscarriages
• 2 fetal death in utero (unweighed)
• 1 termination
765 infants with known birthweight
18 without birthweight
• 4 fetal deaths in utero excluded
629 Primary maternal outcomes
761 Primary neonatal outcomes
783 allocated to intervention
120 without oral-glucose-tolerance-test 
results:
• 14 test outside dates
• 23 did not attend
• 69 declined further visits
• 14 loss of pregnancy
651 completed oral glucose tolerance
tests; 618 at 27+0 – 28+6 weeks;
33 within 6 days, (mean 3.0)
• 2 lost to follow up
• 3 withdrew permission to use data
• 2 miscarriages
• 4 fetal death in utero (unweighed)
• 3 terminations
757 infants with known birthweight
14 without birthweight
• 6 fetal deaths in utero excluded
651 Primary maternal outcomes
751 Primary neonatal outcomes
772 allocated to control
FIGURE 8 Trial profile.
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Compared with women assigned standard antenatal care, glycaemic index was reduced in participants
assigned the intervention, as was mean intake of total energy, carbohydrate, saturated fat, and total fat;
protein and fibre intake was increased (Table 25). Physical activity was higher at 27–28 weeks plus 6 days
of gestation in women in the intervention group versus the standard care group, which was attributable to
more time spent walking (see Table 25).
Women in the intervention group had less gestational weight gain than did those in the standard care
group at the time of the oral glucose tolerance test, and over the entire pregnancy (see Table 24). The
sum of maternal skinfold thicknesses was also lower with the intervention at 27–28 weeks plus 6 days of
gestation and at 34–36 weeks’ gestation (see Table 24). Mode of delivery, postpartum haemorrhage, or
treatment of gestational diabetes did not differ between groups; likewise, no differences were noted
between groups in fasting glucose, fasting insulin, or HOMA2-IR, or in any other biochemical variables
measured at 27–28 weeks plus 6 days of gestation (see Table 24).
TABLE 21 Baseline characteristics of women
Standard care (n= 772) Intervention (n= 783)
Age (years) 30.4 (5.6) 30.5 (5.5)
BMI (kg/m2) 36.3 (4.6) 36.3 (5.0)
Ethnic origin
White 483 (63%) 490 (63%)
Black 200 (26%) 202 (26%)
Asian 48 (6%) 47 (6%)
Other 41 (5%) 44 (6%)
Parity
Primiparous 338 (44%) 336 (42%)
Multiparous 434 (56%) 447 (57%)
Current smoker 60 (8%) 48 (6%)
Previous history of gestational diabetes (multiparous only) 13/434 (3%) 19/447 (4%)
Family history of type 2 diabetes mellitus 181/767 (24%) 194/772 (25%)
Family history of gestational diabetes 20/742 (3%) 38/760 (5%)
Index of multiple deprivationa
1 (least deprived fifth) 36 (5%) 29 (4%)
2 44 (6%) 59 (8%)
3 84 (11%) 93 (12%)
4 289 (37%) 245 (31%)
5 (most deprived fifth) 318 (41%) 352 (45%)
Data are mean (SD) or number of women/total (%).
a Scores were calculated for the region of residence, by fifths of the population. UK-wide scores were developed from
English and Scottish data relating to employment and income domains.
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TABLE 22 Maternal outcomes
Standard care Intervention
Effect of intervention (95% CI)
pRisk ratio (95% CI)
Mean difference
(95% CI)
Gestational diabetes 172/651 (26%) 160/629 (25%) 0.96 (0.79 to 1.16) –1.2% (–5.8 to 3.8)a 0.68
Fasting blood glucose
(mmol/l)
4.71 (0.6), n= 651 4.68 (0.6), n = 629 –0.02 (–0.09 to 0.04) 0.49
1 h blood glucose
(mmol/l)
8.02 (2.1), n= 605 7.91 (2.1), n = 584 –0.10 (–0.33 to 0.14) 0.43
2 h blood glucose
(mmol/l)
5.94 (1.5), n= 650 5.96 (1.5), n = 628 0.02 (–0.15 to 0.19) 0.81
Treatment of gestational diabetesb
Dietary advice 69/146 (47%) 62/127 (49%) 1.03 (0.81 to 1.32) 0.80
Metformin 35/146 (24%) 34/127 (27%) 1.12 (0.74 to 1.68) 0.60
Metformin and insulin 16/146 (11%) 14/127 (11%) 1.01 (0.51 to 1.98) 0.99
Insulin 26/146 (18%) 17/127 (13%) 0.75 (0.43 to 1.32) 0.32
All pre-eclampsia 27/752 (4%) 27/753 (4%) 1.00 (0.59 to 1.69) > 0.99
Severe pre-eclampsia 10/752 (1.3%) 6/753 (0.8%) 1.64 (0.60 to 4.49) 0.33
Labour and delivery
Induction of labour 275/757 (36%) 251/765 (33%) 0.90 (0.79 to 1.04) 0.15
Unassisted vaginal 399/757 (52%) 400/765 (52%) 0.99 (0.90 to 1.09) 0.87
Operative vaginal 84/757 (11%) 94/765 (12%) 1.11 (0.84 to 1.46) 0.47
Caesarean section 274/757 (36%) 271/765 (35%) 0.98 (0.86 to 1.12) 0.75
Elective caesarean
section
136/757 (18%) 160/765 (21%) 1.16 (0.95 to 1.43) 0.15
Emergency caesarean
section
138/757 (18%) 111/765 (14%) 0.80 (0.63 to 1.00) 0.051
Postpartum haemorrhage
≥ 1000ml 91/747 (12%) 109/755 (14%) 1.19 (0.91 to 1.54) 0.20
≥ 2000ml 10/747 (1%) 20/755 (3%) 1.98 (0.93 to 4.20) 0.075
Inpatient nights (n) 2.3 (1.8), n = 691 2.4 (2), n = 691 0.14 (–0.06 to 0.34) 0.16
Antenatal 2.9 (2.5), n = 65 2.9 (3), n = 74 –0.02 (–0.98 to 0.95) 0.98
Postnatal 2.2 (1.7), n = 685 2.3 (2), n = 684 0.08 (–0.09 to 0.25) 0.37
Gestational weight gain (kg)c
Total 7.76 (4.6), n= 567 7.19 (4.6), n = 526 –0.55 (–1.08 to –0.02) 0.041
Before pregnancy to
27–28 weeks+ 6 days
5.40 (3.3), n= 664 4.97 (2.9), n = 637 –0.42 (–0.75 to –0.09) 0.013
Mid-arm circumference (cm)
15–18 weeks+ 6 days 36.8 (4.0), n= 766 36.7 (4.1), n = 775
27–28 weeks+ 6 days 36.9 (4.2), n= 663 36.6 (4.0), n = 634 –0.19 (–0.39 to 0.01) 0.063
34–36 weeks+ 0 days 36.6 (4.1), n= 567 36.5 (3.9), n = 526 –0.10 (–0.32 to 0.13) 0.40
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TABLE 22 Maternal outcomes (continued )
Standard care Intervention
Effect of intervention (95% CI)
pRisk ratio (95% CI)
Mean difference
(95% CI)
Thigh circumference (cm)
15–18 weeks+ 6 days 68.6 (6.5), n= 766 68.6 (6.8), n = 775
27–28 weeks+ 6 days 69.2 (6.8), n= 662 68.9 (6.6), n = 635 –0.10 (–0.54 to 0.33) 0.64
34–36 weeks+ 0 days 69.3 (6.7), n= 566 68.9 (7.0), n = 526 –0.48 (–1.01 to 0.05) 0.078
Sum of skinfold thicknesses (mm)d
15–18 weeks+ 6 days 123 (27), n= 763 123 (29), n= 771
27–28 weeks+ 6 days 127 (26), n= 661 124 (27), n= 632 –2.3 (–4.3 to –0.3) 0.022
34–36 weeks+ 0 days 25 (27), n= 561 122 (26), n= 520 –3.2 (–5.6 to –0.8) 0.0081
Plasma fasting insulin
(mU/l)
23.2 (2.4), n= 510 22.48 (2.3), n= 480 0.97 (0.87 to 1.08)e 0.57
HOMA2-IR (units) 3.04 (2.1), n= 496 2.99 (2.1), n = 471 0.98 (0.89 to 1.07)e 0.60
Plasma triglycerides (mmol/l)
27–28 weeks+ 6 days 1.98 (1.41), n= 505 1.92 (1.40), n= 478 0.99 (0.96 to 1.02)e 0.39
Plasma LDL cholesterol (mmol/l)
27–28 weeks+ 6 days 3.66 (1.31), n= 509 3.66 (1.35), n= 479 1.01 (0.99 to 1.04)e 0.27
Plasma HDL cholesterol (mmol/l)
27–28 weeks+ 6 days 1.80 (1.29), n= 509 1.80 (1.28), n= 479 1.00 (0.98 to 1.02)e 0.93
Plasma VLDL cholesterol (mmol/l)f
27–28 weeks+ 6 days 0.40 (1.41), n= 505 0.38 (1.40), n= 478 0.99 (0.96 to 1.02)e 0.39
HOMA2-IR, homeostatic model assessment.
a For the primary maternal outcome, the risk difference (95%CI) is presented.
b Treatment was recorded in women with gestational diabetes diagnosed according to predefined study criteria.
c Gestational weight gain calculated using estimated weight before pregnancy.
d Calculated by addition of biceps, triceps, suprailiac and subscapular skinfold thicknesses.
e For biochemistry data, the ratio of means (95% CI) is presented.
f Calculated by Friedewald formula (triglycerides/5).
Data are number of women /total (%) or mean (SD), number of women.
TABLE 23 Maternal nutritional and physical activity outcomes, by period of gestation
Standard care Intervention Mean difference (95%CI) p-value
Nutrition
Total energy (MJ/day)
15–18 weeks+ 6 days 7.8 (2.6) 7.6 (2.5)
27–28 weeks+ 6 days 7.5 (2.3) 6.8 (1.9) –0.70 (–0.96 to –0.45) < 0.0001
Glycaemic index
15–18 weeks+ 6 days 56.9 (4.1) 56.8 (3.9)
27–28 weeks+ 6 days 57.0 (3.9) 54.3 (3.9) –2.6 (–3.0 to –2.1) < 0.0001
continued
DOI: 10.3310/pgfar05100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Poston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
TABLE 23 Maternal nutritional and physical activity outcomes, by period of gestation (continued )
Standard care Intervention Mean difference (95%CI) p-value
Glycaemic load
15–18 weeks+ 6 days 141 (56) 135 (51)
27–28 weeks+ 6 days 133 (47) 112 (38) –21 (–26 to –16) < 0.0001
Carbohydrate (% energy)
15–18 weeks+ 6 days 49.4 (7.4) 49.0 (7.4)
27–28 weeks+ 6 days 48.6 (6.6) 47.2 (7.2) –1.4 (–2.2 to –0.58) 0.0011
Protein (% energy)
15–18 weeks+ 6 days 19.7 (4.4) 20.1 (4.5)
27–28 weeks+ 6 days 20.1 (4.0) 22.3 (4.6) 2.05 (1.5 to 2.5) < 0.0001
Total fat (% energy)
15–18 weeks+ 6 days 31.0 (5.5) 31.0 (5.3)
27–28 weeks+ 6 days 31.5 (5.1) 30.5 (5.2) –0.88 (–1.49 to –0.26) 0.0011
Saturated fat (g/day)
15–18 weeks+ 6 days 26.5 (11.5) 25.4 (11.0)
27–28 weeks+ 6 days 26.4 (10.9) 22.0 (8.3) –4.3 (–5.4 to –3.1) < 0.0001
Saturated fat (% energy)
15–18 weeks+ 6 days 12.7 (3.0) 12.5 (2.9)
27–28 weeks+ 6 days 13.1 (3.0) 12.1 (2.8) –0.85 (–1.2 to –0.51) < 0.0001
Fibre (g/day)
15–18 weeks+ 6 days 13.6 (6.0) 13.1 (5.3)
27–28 weeks+ 6 days 12.6 (5.3) 13.4 (5.3) 0.83 (0.17 to 1.48) 0.013
Physical activity
MET (minutes per week)
15–18 weeks+ 6 days 1386 (660–3052) 1386 (594–2982)
27–28 weeks+ 6 days 1386 (639–3363) 1836 (792–4158) 295 (105 to 485)a 0.0015
Moderate or vigorous activity (minutes/week)
15–18 weeks+ 6 days 0.0 (0.0–180) 0.0 (0–180)
27–28 weeks+ 6 days 0.0 (0.0–240) 30 (0.0–240) 0.0 (–18 to 18) > 0.99
Walking (minutes/week)
15–18 weeks+ 6 days 280 (140–600) 280 (140–540)
27–28 weeks+ 6 days 300 (132–630) 420 (180–840) 77 (28 to 126) 0.0018
MET, metabolic equivalent of task.
a Median difference (95%CI).
Data are mean (SD) or median (IQR). Women with reported energy intake ≤ 4.5 MJ/day or ≥ 20MJ/day at 15–18 weeks
+ 6 days of gestation were excluded from analyses of diet. Thus, in the standard care group, 571 women were assessed at
15–18 weeks + 6 days of gestation and 511 were assessed at 27–28 weeks + 6 days of gestation; corresponding figures in
the intervention group were 574 and 435. Dietary intervention estimates were calculated by multiple regression and
adjusted for pretrial values. For analyses of physical activity, in the standard care group, 678 women were included at
15–18 weeks + 6 days of gestation and 588 were assessed at 27–28 weeks + 6 days of gestation; in the intervention
group, 683 and 559 women, respectively, were analysed. Physical activity estimates were calculated by bootstrapped
(1000 replications) median regression, adjusting for pretrial values. MET is defined as the energy expenditure ratio of
activity to rest; one MET is roughly equal to an individual’s resting energy expenditure. MET, vigorous activity, moderate or
vigorous activity, and walking were not prespecified end points.
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TABLE 24 Neonatal outcomes
Standard care Intervention
Effect of intervention
(95% confidence interval)
pRisk ratio
Mean difference
(95% CI)
Large for gestational age (customised birth weight centiles)
≥ 90th 61/751 (8%) 71/761 (9%) 1.15 (0.83–1.59) 1.2% (–1.6 to 4.1)a 0.40
≥ 95th 32/751 (4%) 39/761 (5%) 1.20 (0.76–1.90) 0.43
≤ 10th 76/751 (10%) 95/761 (13%) 1.24 (0.93–1.64) 0.15
≤ 5th 43/751 (6%) 36/761 (5%) 0.83 (0.54–1.27) 0.39
Population birthweight centiles
≥ 90th 83/750 (11%) 96/761 (13%) 1.14 (0.87–1.50) 0.35
≥ 95th 42/750 (6%) 51/761 (7%) 1.20 (0.81–1.78) 0.37
≤ 10th 38/750 (5%) 53/761 (7%) 1.38 (0.92–2.06) 0.12
≤ 5th 19/750 (3%) 22/761 (3%) 1.14 (0.62–2.09) 0.67
Birthweight (kg) 3450 (580),
n= 751
3420 (580),
n = 761
–27 (–85 to 31) 0.37
≥ 4 105/751 (14%) 105/761 (14%) 0.99 (0.77–1.27) 0.93
≤ 2.5 36/751 (5%) 31/761 (4%) 0.85 (0.53–1.36) 0.50
≤ 1.5 9/751 (1%) 7/761 (1%) 0.77 (0.29–2.05) 0.60
Gestational age at birth
(weeks)
39.5 (2.4),
n= 751
39.5 (2.0),
n = 761
0.02 (–0.2 to 0.2) 0.89
Delivery ≤ 37 weeks 48/751 (6%) 45/761 (7%) 0.93 (0.62–1.37) 0.70
Delivery ≤ 34 weeks 16/751 (2%) 15/761 (2%) 0.93 (0.46–1.86) 0.83
Hospital admission
Admission to neonatal unit 57/751 (8%) 65/761 (9%) 1.13 (0.80–1.58) 0.49
Time spent in neonatal
unit, if admitted (days)
16.8 (30.2),
n= 52
11.6 (23.5),
n = 61
–0.26 (–9.65 to 9.13) 0.96
Time spent in hospital after
birth, if admitted (days)
3.0 (9.0),
n= 733
2.8 (7.3),
n = 743
–0.06 (–0.86 to 0.74) 0.88
Neonatal death 2/771 (< 1%) 3/783 (< 1%) 0.98 (0.14–6.97) 0.99
Intraventricular haemorrhage
grade 3–4
2/751 (< 1%) 0/760
Retinopathy of prematurity 1/751 (< 1%) 1/760 (< 1%) 0.99 (0.06–15.7) 0.99
Discharged home on oxygen 4/751 (1%) 2/760 (< 1%) 0.49 (0.09–2.69) 0.41
Neonatal hypoglycaemia 12/751 (2%) 27/760 (4%) 2.22 (1.13–4.36) 0.020
Confirmed infection 14/751 (2%) 7/760 (1%) 0.49 (0.20–1.22) 0.13
Congenital abnormalities 6/751 (1%) 5/760 (1%) 0.82 (0.25–2.69) 0.75
continued
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A total of 761 infants born to women allocated the intervention and 751 infants born to mothers in the
standard care group had a known birthweight and could be assessed for the primary neonatal outcome
(≥ 90th customised birthweight centile; Table 26). The incidence of large-for-gestational-age infants did
not differ between groups. Similar results were recorded in a sensitivity analysis allowing for possible
selective bias in missing data (odds ratio 0.95, 95% CI 0.72–1.25, assuming a halving of the odds of large-
for-gestational-age infants in the intervention group with missing data).
By population birthweight centiles (secondary outcome), 12% of infants were in the 90th centile or higher,
and there was no difference between groups. Similarly, other neonatal secondary outcomes did not differ
between groups, with the exception of neonatal hypoglycaemia, which was increased in the intervention
group (see Table 26). As neonatal hypoglycaemia is treatable, it is not judged a severe adverse event.
TABLE 24 Neonatal outcomes (continued )
Standard care Intervention
Effect of intervention
(95% confidence interval)
pRisk ratio
Mean difference
(95% CI)
Mechanical ventilation 21/751 (3%) 19/760 (3%) 0.89 (0.48–1.65) 0.72
Duration of mechanical
ventilation (h)
500 (885),
n= 20
330 (573),
n = 16
–170 (–667 to 327) 0.49
Necrotising enterocolitis 2/751 (< 1%) 0/760
Pulmonary haemorrhage 2/751 (< 1%) 1/760 (< 1%) 0.49 (0.04–5.43) 0.56
a For the primary neonatal, the risk difference (95% CI) is presented.
Data are number of children/total (%) or mean (SD), number of children. Population centiles were calculated with
WHO centiles.
TABLE 25 Adverse events not prespecified as secondary outcomes
Standard care
(n= 772)
Intervention
(n= 783) Pa
All miscarriage 14 18 0.50
Late termination of pregnancy 3 1
Maternal accident 1 0
Placental abruption 0 1
Maternal antenatal sepsis 1 0
Maternal postnatal sepsis 1 0
Iatrogenic preterm birth 2 2
Intrauterine complications (cardiac, neurological, renal,
respiratory)
2 3
Fetal death in utero 10 6 0.30
Unspecified neonatal complications at birth 2 1
Neonatal sepsis 1 0
a p-values were calculated only if data were sufficient.
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Neonatal anthropometric measures were evaluated in a subgroup of infants and did not differ between
groups (Table 27).
Table 28 shows adverse events that were not pre-specified as secondary outcomes. Adverse events did not
differ between intervention and standard care groups.
Interaction tests for prespecified maternal demographic variables (BMI, ethnic origin, socioeconomic status,
parity, and smoking) did not differ between standard care and intervention groups for the primary
maternal or neonatal outcomes (Tables 29 and 30). Furthermore, no differences were recorded in maternal
and neonatal primary outcomes with respect to whether the intervention had been delivered mainly in
person or by telephone or e-mail (maternal p = 0.39; neonatal p = 0.54), nor for women who attended
more versus less than half the health trainer-led sessions (maternal p = 0.56; neonatal p = 0.59).
Discussion
Our findings suggest that a complex intervention addressing diet and physical activity in pregnant women
with obesity is effective at improving diet quality and physical activity, reducing gestational weight gain,
and decreasing surrogate measures of maternal body fatness. However, the intervention does not prevent
the development of gestational diabetes nor change the incidence of large-for-gestational-age infants in this
population. Neither was evidence noted of a benefit on other pregnancy outcomes, including pre-eclampsia,
which is associated with raised BMI.
TABLE 26 Maternal characteristics of women who participated and those who declined, but gave consent to use of
routine data
Declined
randomisation
(n= 3711)
Randomised
(n= 1555) Risk ratio (95% CI)
Mean difference
(95% CI) p-value
Age (years) 29.7 (5.7) 30.5 (5.5) 0.82 (0.49 to 1.15) < 0.0001
Body mass index (kg/m2)
(n = 3269; 1555)
35.1 (4.5) 35.7 (4.8) 0.67 (0.38 to 0.96) < 0.0001
Ethnicity (n = 3569, 1555)
White 2055 (58%) 973 (63%) 1.09 (1.04 to 1.14) 0.001
Black 1117 (31%) 402 (26%) 0.83 (0.75 to 0.91) 0.0001
Asian 212 (6%) 95 (6%) 1.03 (0.81 to 1.30) 0.81
Other 185 (5%) 85 (5%) 1.05 (0.82 to 1.35) 0.68
Index of multiple deprivation (n = 3493; 1549)a
1 (Least deprived) 115 (3%) 65 (4%) 1.27 (0.95 to 1.72) 0.11
2 186 (5%) 103 (7%) 1.25 (0.99 to 1.58) 0.06
3 377 (11%) 177 (11%) 1.06 (0.89 to 1.25) 0.51
4 1222 (35%) 534 (35%) 0.99 (0.91 to 1.07) 0.73
5 (Most deprived) 1593 (46%) 670 (44%) 0.95 (0.89 to 1.01) 0.13
a The UK-wide Index of Multiple Deprivation score is developed on English and Scottish data relating to employment and
income domains.
Data are mean (SD) or n (%).
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TABLE 27 Maternal demographics of randomised participants with oral glucose tolerance test for the diagnosis of
gestational diabetes
Standard care
(n= 651)
Intervention
(n= 629) Risk ratio (95% CI) Mean difference (95% CI)
Age (years) 30.7 (5.5) 30.9 (5.3) 0.26 (–0.33 to 0.86)
Body mass index (kg/m2) 36.3 (4.6) 36.2 (4.9) –0.13 (–0.65 to 0.40)
Ethnicity
White 422 (65%) 401 (64%) 0.98 (0.91 to 1.07)
Black 156 (24%) 155 (25%) 1.03 (0.85 to 1.25)
Asian 41 (65) 38 (6%) 0.96 (0.63 to 1.47)
Other 32 (5%) 35 (6%) 1.13 (0.71 to 1.81)
Current smoker 50 (8%) 36 (6%) 0.75 (0.49 to 1.13)
Previous history of
gestational diabetes
(multiparous only)
10/362 (3%) 15/351 (4%) 1.55 (0.70 to 3.40)
Family history of type 2
diabetes
152/647 (24%) 152/621 (25%) 1.04 (0.86 to 1.27)
Family history of
gestational diabetes
18/631 (3%) 26/624 (4%) 0.85 (0.51 to 1.40)
Index of multiple deprivation (n = 650, 624)a
1 (Least deprived) 32 (5%) 26 (4%)
2 42 (6%) 47 (8%) 1.17 (0.78 to 1.74)
3 74 (11%) 75 (12%) 1.06 (0.78 to 1.43)
4 243 (37%) 200 (32%) 0.86 (0.74 to 1.00)
5 (Most deprived) 259 (40%) 276 (44%) 1.11 (0.98 to 1.26)
a The UK-wide Index of Multiple Deprivation score is developed on English and Scottish data relating to employment and
income domains.
Data are mean (SD) or n (%). Treatment allocation is balanced by minimisation on maternal age, centre, ethnicity and
parity. Family history is defined as first degree relatives.
TABLE 28 Neonatal anthropometry at birth
Standard care Intervention Mean difference p-value
Head circumference (cm) N= 695; 34.7 (1.8) N = 708; 34.7 (1.8); –0.05 (–0.23 to 0.14) 0.63
Abdominal circumference (cm) N= 311; 32.6 (2.1) N = 285; 32.6 (2.5); –0.01 (–0.39 to 0.36) 0.95
Crown rump (cm) N= 177; 33.5 (2.2) N = 155; 33.5 (2.0) 0.02 (–0.44 to 0.48) 0.93
Triceps skinfold thickness (mm) N= 268; 5.3 (1.6) N = 249; 5.3 (1.4) 0.05 (–0.21 to 0.31) 0.72
Subscapular skinfold thickness (mm) N= 258; 5.6 (1.4) N = 244; 5.7 (1.4) 0.06 (–0.20 to 0.31) 0.66
Sum of skinfold thickness (mm) N= 258; 10.9 (2.7) N = 244; 11.0 (2.6) 0.13 (–0.34 to 0.59) 0.59
Data are mean (SD). Sum of neonatal skinfold thickness calculated as a sum of triceps and subscapular skinfold thickness.
THE UK PREGNANCIES BETTER EATING AND ACTIVITY TRIAL: PHASE 3 – RANDOMISED CONTROLLED TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
TABLE 29 Interaction tests for primary maternal outcome (GDM at 27+0 to 28+6 weeks’ gestation) according to
predefined maternal demographic characteristics
Standard care
N (%)
Intervention
N (%) Risk ratio (95% CI)
Wald test for
interaction
BMI (kg/m2) 30–34.9 294 62 (21.1) 300 56 (18.7) 0.89 (0.64 to 1.22) 0.249
35–39.9 210 59 (28.1) 180 60 (33.3) 1.19 (0.88 to 1.60)
≥ 40 109 34 (31.2) 114 43 (37.7) 0.83 (0.57 to 1.19)
Ethnicity Asian 13 37 (35.1) 35 11 (31.4) 0.89 (0.46 to 1.72) 0.434
Black 148 41 (27.7) 146 36 (24.7) 0.89 (0.61 to 1.31)
Other 33 13 (39.4) 32 7 (21.9) 1.80 (0.83 to 3.93)
White 375 90 (24.0) 401 103 (25.7) 0.93 (0.73 to 1.19)
Index of multiple
deprivation
1 (Least deprived) 31 4 (12.9) 23 5 (21.7) 1.68 (0.51 to 5.59) 0.163
2 42 13 (31.0) 43 4 (9.3) 0.30 (0.11 to 0.85)
3 69 20 (29.0) 72 17 (23.6) 0.81 (0.47 to 1.42)
4 227 56 (24.7) 183 48 (26.2) 1.06 (0.76 to 1.48)
5 (Most deprived) 248 70 (28.2) 263 76 (28.9) 1.02 (0.78 to 1.35)
Parity Nullip 273 70 (25.6) 260 61 (23.5) 0.92 (0.68 to 1.23) 0.680
Multip 345 94 (27.2) 329 89 (27.1) 0.99 (0.78 to 1.27)
Current smoking Non-smoker 570 149 (26.1) 554 139 (25.1) 0.96 (0.79 to 1.17) 0.892
Smoker 48 15 (31.3) 35 11 (31.4) 1.01 (0.53 to 1.92)
TABLE 30 Subgroup analysis for primary neonatal outcome (large for gestational age infant ≥ 90th centile)
according to predefined maternal demographic characteristics
Standard care
n (%)
Intervention
n (%) Risk ratio (95% CI)
Wald test for
interaction
BMI (kg/m2) 30–34.9 367 24 (6.5) 381 38 (10.0) 1.53 (0.93 to 2.49) 0.167
35–39.9 250 17 (6.8) 238 18 (7.6) 1.11 (0.59 to 2.11)
≥ 40 134 20 (14.9) 142 15 (10.6) 0.71 (0.38 to 1.32)
Ethnicity Asian 47 5 (10.6) 43 5 (11.6) 1.09 (0.34 to 3.52) 0.987
Black 193 16 (8.3) 194 18 (9.3) 1.12 (0.59 to 2.13)
Other 40 3 (7.5) 44 3 (6.8) 0.91 (0.19 to 4.25)
White 471 37 (7.9) 480 45 (9.4) 1.19 (0.79 to 1.81)
Index of multiple
deprivation
1 (Least deprived) 33 2 (6.1) 29 4 (13.8) 2.28 (0.45 to 11.53) 0.460
2 43 4 (9.3) 57 7 (12.3) 1.32 (0.41 to 4.22)
3 84 5 (6.0) 86 10 (11.6) 1.95 (0.70 to 5.47)
4 277 19 (6.9) 241 21 (8.7) 1.27 (0.70 to 2.31)
5 (Most deprived) 313 31 (9.9) 343 28 (8.2) 0.82 (0.51 to 1.34)
Parity Nullip 332 19 (5.7) 325 29 (8.9) 1.56 (0.89 to 2.72) 0.169
Multip 419 42 (10.0) 436 42 (9.6) 0.96 (0.64 to 1.44)
Current smoking Non-smoker 693 56 (8.1) 714 66 (9.2) 1.14 (0.81 to 1.61) 0.904
Smoker 58 5 (8.6) 47 5 (10.6) 1.23 (0.38 to 4.01)
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By contrast with previous systematic reviews and meta-analyses of studies on a smaller scale to ours,85,220
our null finding extends some observations. In particular, in two Danish studies of lifestyle interventions,224,225
more than 350 obese pregnant women in each study were screened with an oral glucose tolerance test.
Although analysis was not by intention-to-treat, a reduction in the primary outcome of gestational weight
gain of around 1.5 kg was recorded in both studies, but gestational diabetes was not decreased. In the
Australian LIMIT randomised controlled trial in 2212 overweight and obese pregnant women,226 a lifestyle
intervention less intense than ours (in terms of frequency and personal contact) had no effect on gestational
diabetes (a secondary outcome). Furthermore, no difference was noted in the proportion of large-for-
gestational-age infants (the primary outcome) or in gestational weight gain, but the proportion of babies
4 kg or heavier at birth was lower in the intervention group.226 The inference from systematic reviews that
pregnancy lifestyle interventions might be an effective means to prevent gestational diabetes in women with
obesity seems to have been biased by small-scale studies and methodological limitations.84
On average, seven of the eight intervention sessions were attended by women assigned to the intervention,
whether in person or by telephone or e-mail. There was no indication that failure of adherence, mode of
session delivery, ethnic origin, or socioeconomic status of the women affected the primary outcomes.
Further planned analyses will ascertain whether coverage of sessions affected specific elements of dietary
and physical activity behavioural change. Measurement of several biomarkers of glucose intolerance and
insulin resistance, as well as the metabolome, at study entry and after the intervention will also establish
whether early risk stratification can identify a subgroup of women in whom the intervention could show
clinical benefit.
Our study was set in UK inner-city settings of ethnic diversity and high socioeconomic deprivation. Black
women were the predominant minority ethnic subgroup (26%); individuals of this ethnic origin have a
high risk of obesity in pregnancy in the UK,140 which, as elsewhere, is strongly related to socioeconomic
deprivation. Similar to previous studies,224–226 large numbers of women had to be approached to meet our
recruitment target, and the drop-out rate in our study for oral glucose tolerance testing was similar to
previous studies.224,225 The reluctance of pregnant women with obesity to take part in a complex behavioural
intervention suggests that lifestyle interventions can improve healthy behaviours, but only in a subgroup of
motivated individuals. Likewise, the 5% higher proportion of women who dropped out of the study from
the intervention group than the standard care group, although a limitation, was not unexpected. Despite
small numerical differences, participants were similar to individuals who declined participation with
respect to demographic characteristics, suggesting generalisability of outcomes to populations of this
demographic complexity.220
The self-reported reduction in glycaemic load in the intervention group was larger than that noted in
previous similar pregnancy intervention studies,115,226 a potential reflection of the intensity of our
intervention, which included motivational interviewing every week for 8 weeks, goal-setting, and
behavioural self-monitoring.227 Together with reduced intake of saturated fat and total energy in the
intervention group, these outcomes could be the reasons for the modest lowering of gestational weight
gain and measures of fat mass noted in our study. Although we acknowledge the limitations of dietary
assessment by self-report, the size of the improvement was similar to that recorded in the pilot trial,150 in
which a more rigorous assessment method was used. Thus, we conclude that the behavioural intervention
increases healthy dietary behaviours, but that the modest size of the effect is inadequate to reduce the risk
of gestational diabetes or improve insulin sensitivity in women who are obese at the time of conception.
The incremental rise in physical activity achieved with the intervention was also inadequate to improve
glucose tolerance. A minimum of 16 MET h/week of physical activity has been suggested to be needed to
reduce the risk of gestational diabetes,228 which equates to 41 minutes/day of walking; this amount is well
above the 12- to 13-minute increase (or < 1 mile) reported by women in our study, which was similar to the
increase in physical activity reported in the LIMIT trial intervention group.226 Again, we are aware of the
limitations in accuracy of self-report; indeed, in the pilot trial, physical activity was assessed by accelerometry,
and no increase in exercise levels was reported in the intervention group compared with women in the
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standard care group.212 However, this method of objective assessment is recognised to be ineffective at
measuring low-intensity activity that, as we report here, was increased by self-report.
Although not the primary maternal outcome of this study, the 0.55 kg lower gestational weight gain in the
intervention group compared with the standard care group adds to growing evidence from other studies
that a substantial reduction in gestational weight gain is unlikely to be achievable in women with obesity
through interventions addressing diet, physical activity, or both.224,225 The reduction achieved was less than
that reported in a meta-analysis of previous studies (–2.41 kg),7 which could reflect our rigorous trial
method (i.e., intention-to-treat analysis), the high mean BMI, ethnic diversity, and low socioeconomic
status of the UPBEAT participants, or that gestational weight gain was not the main focus of this study.
Ongoing follow-up of mothers and their children in the UPBEAT study will ascertain whether the changes
recorded in diet, physical activity, and maternal anthropometric measures are sustained or extended and
can benefit maternal and child health in the longer term. Although gestational diabetes was not prevented,
the behavioural intervention has the potential to reduce the risk of obesity and adverse metabolic risk in
the child, because excessive gestational weight gain, high maternal fat mass, and increased glycaemic load
are all associated independently with greater adiposity in the offspring, potentially through epigenetic
pathways.219,229,230
We had anticipated that 17% of babies in our study would be in the 90th centile or higher, whereas the
recorded incidence was 9% and 12% by customised and population centiles, respectively. This incidence is
well below the 16% reported in UK women with similar BMI (range 35.0–39.9 kg/m2),231 and roughly half
of that noted in the LIMIT trial (20%), which included women who had a lower BMI.226 Our use of IADPSG
criteria for diagnosis of gestational diabetes could partly explain the low incidence of large-for-gestational-
age babies in our study. To our knowledge, no previous study of women with obesity has diagnosed
gestational diabetes with these criteria, and a quarter of women in both groups in our trial had gestational
diabetes. Only 9% would have had a diagnosis of gestational diabetes had we used the previous WHO
guidelines.221 Diagnosis and treatment of more women with gestational diabetes in this study compared
with current clinical practice in the UK could, therefore, account for the lower incidence of large-for-
gestational-age infants to roughly population levels (10%). In line with this notion, a 50% reduction in
large-for-gestational-age infants was reported after treatment of women with mild gestational diabetes5
that fell below conventional diagnostic thresholds but would have been treated by the new criteria.
Women were treated according to local practice at trial centres, 83% receiving treatment after a diagnosis
of gestational diabetes. Although local practice might have differed, randomisation was minimised to
centre, and variable practice is unlikely to have affected primary trial outcomes. Indeed, had all women
been treated, as recommended by the IADPSG, the incidence of large-for-gestational-age infants might
have been reduced further. Universal testing of all participants in our study for gestational diabetes,
independent of the diagnostic criteria, might have contributed to the difference between trial and
population incidences of large-for-gestational-age infants because, despite NICE recommendations,
universal testing of women with obesity is not adopted across the UK.221
Several neonatal outcomes, including birthweight and inpatient days, were lower than UK outcomes for
women with obesity,231 although caesarean section rates were similar, potentially a reflection of current
management of women with a diagnosis of gestational diabetes. Participation in a clinical trial is in itself
unlikely to be a cause of lower than anticipated incidence of large-for-gestational-age infants because no
evidence for such an effect was noted in the LIMIT trial, in which the incidence of large-for-gestational-age
infants was 20%.226 Comparison of the incidence of large-for-gestational-age infants with eligible women
who declined participation was precluded because those with available birthweight data had a significantly
lower BMI than did the group as a whole.
Our study highlights the need for randomised controlled trials in women with obesity that do universal
testing and formally compare IADPSG and older diagnostic criteria for gestational diabetes. In the UK,
comparison should be made with the most recent NICE criteria, which do not align with IADPSG.221
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More infants born to mothers in the intervention group developed neonatal hypoglycaemia than did those
in the standard care group, but statistical power for this outcome was low. This finding contrasts with that
of a meta-analysis of smaller lifestyle intervention studies, which showed no effect.82 Ten infants in the
intervention group with hypoglycaemia were fed formula milk from birth, compared with two in the
standard care group (37% vs. 16%; p = 0.04). Since early introduction of formula feeding has been
associated with neonatal hypoglycaemia,232 this factor could be contributory. The rates of exclusive
breastfeeding (p = 0.73) or formula feeding (p = 0.63) did not differ at neonatal discharge between the
two study groups; therefore, this finding is likely to be attributable to chance.
The behavioural intervention we assessed in this study could provide a means to improve healthy
behaviours in obese pregnant women. It offers an alternative to current UK NICE guidelines,93 which
recommend general healthy eating and physical activity for pregnant women with obesity with little
evidence for proven change in behaviours. The potential benefit of the intervention on post-pregnancy
infant health and on maternal and infant long-term health needs further investigation, which is under way.
Increasing the intensity and duration of the intervention, which is already greater than that adopted in
previous studies,84,224,226,227 is likely to be impractical for most women with obesity.
The current focus on behavioural interventions to prevent gestational diabetes would seem to be
misplaced. The intervention we assessed could be used as an evidence-based method to encourage
healthy dietary and physical activity behaviours in women with obesity. However, efforts to prevent
gestational diabetes should be diverted towards not only trials of targeted interventions, including
pharmacotherapy but also establishing optimum diagnostic criteria for gestational diabetes to reduce risk
of adverse outcomes. Importantly, renewed efforts are needed at the population level to prevent obesity in
women of reproductive age.
Supplementary text
Pre-specified outcomes; as in published protocol
Prespecified secondary outcomes not included in the manuscript include:
Maternal
Trimester specific gestational weight gain, diagnosis of GDM by local criteria; fetal growth at 28 weeks,
health related quality of life as assessed by EQ-5D. Neck, hip and wrist circumferences, plasma
fructosamine, C-reactive protein and other relevant epigenetic and metabolomics biomarkers and urinary
biomarkers, dietary feeding patterns and measures of depression. Data for these outcomes are available
and will be included in preplanned further data analyses. Metabolomic and epigenetic biomarkers in blood
also prespecified outcomes will be undertaken in future analyses for publication.
Neonatal
Estimated body fat and crown–heel length also included will be reported in detailed analyses of
anthropometry. Metabolomic and epigenetic biomarkers in cord blood, also prespecified outcomes, will be
undertaken in future analyses for publication.
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Chapter 6 Economic evaluation methods
and results
Overview
A within-trial cost–utility analysis was undertaken to estimate the cost-effectiveness of the health training
(intervention) over and above routine care (control). Costs were estimated from the perspective of the NHS
acute care provider. QALYs were used to measure health outcomes and were derived from participant-
completed EQ-5D questionnaires. Participants were randomised to treatment groups between 15 and
18 weeks’ gestation and baseline data were collected at this point (see Chapter 4). Participants were
followed up at 20 weeks’ gestation and 36 weeks’ gestation.
Methods
The aim of this economic evaluation is to examine the cost-effectiveness of an intensive complex
intervention combining dietary and PA to the NHS health system compared with routine care over the time
horizon of the trial.
Resource utilisation was recorded using trial management software (MedSciNet Ltd) that provided
information on the intensity of resources required to deliver the intervention (health training), as well as
consequences to health care of intervention (primarily observation of perinatal care).
The following items of resource use were assessed:
l contacts to provide the health training intervention
l antenatal admissions
l cessation of pregnancy
l postnatal admissions.
Consequences of the intervention were captured electronically for each participant and her infant during
the period between randomisation and delivery, including the duration and intensity of antenatal,
intrapartum and neonatal care. Data were also collected on the mode of birth: unassisted vaginal birth,
instrumental vaginal birth or caesarean section.
Valuation of resource use
For standard NHS health care, UK unit costs are applied from national sources including NHS reference
costs233 and Personal Social Services Research Unit’s Unit Costs of Health and Social Care 2014.234
All costs were valued in pounds sterling, according to a price year representing the mid-point of the trial.
Costs occurring in prior price years will be inflated using the Hospital and Community Health Services pay
and prices index234 and costs from later price years will be discounted at a rate of 3.5%, as recommended by
the NICE.235 As the trial follow-up was less than 1 year post randomisation, no discounting was required.
Resource use profiles were constructed for each patient in the trial multiplying quantities of resource
utilisation by the relevant unit costs to estimate cost profiles for women in the trial.
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Outcome measures
The EQ-5D81 questionnaires were collected at baseline (15–18 weeks’ gestation), at 27–28 weeks’
gestation and at 34–36 weeks’ gestation in UPBEAT and form the primary cost-effectiveness end point
following NICE guidance.236 Responses were then converted into a utility score (a scale where death is
equal to 0 and full health 1) using population-based valuation tariff237 and each participant was assigned
their utility (U) for each time point (t). As intended time points varied, exact dates on which data were
collected were used and the date of each time point is denoted as Dt. To enable cost–utility analysis to be
undertaken, an area under the curve method was then used to estimate the QALY score over the available
follow-up period,238 such that an individual QALYs can be expressed as:
QALY = ∑
t = n
t = 1
Ut + Ut +1
Dt + Dt +1
. (1)
Analysis
Participants received programme health training and fidelity to the programme was recorded during
sessions. This information allows for an accurate examination of intervention uptake and the related
potential variation in direct costs of intervention. Over the course of treatment, for each contact with the
participants, the HT recorded information on whether or not the participant attended, whether or not
dietary and PA were set and, in situations when participants did not attend face-to-face training, whether or
not a follow-up contact (either by telephone or e-mail) successfully agreed at least one of the two goals. This
information was used to estimate the expected cost of intervention.
As recommended by NICE in 2008, base case analysis was explored from a NHS and personal social
services perspective, including direct health effects (QALYs) and costs (or cost savings) to the NHS. The
base case analysis takes the form of an incremental cost-effectiveness analysis following the NICE guidance
for health-care evaluations.236 An incremental approach allows for meaningful comparisons between
the treatments, as it compares the additional costs of one treatment with those of the other, as well as
the additional benefits. The primary cost-effectiveness outcome of the study is the cost per QALY. The
incremental cost-effectiveness ratio (ICER) calculates the mean cost of the intervention group over and
above the control and divides by the mean difference in health benefits.
Equation 2 is used to calculate the ICER, where Δ represents change, C represents the costs, E represents
the effects and subscripts I and C refer to the intervention and control, respectively:
ICER =
ΔC
ΔE
=
CI− CC
EI−EC
. (2)
All analyses are conducted on an intention-to-treat basis, including all randomised participants in the
groups to which they were randomised. Analyses were conducted using Stata version 13. Results are
reported as means and 95% CIs.
Economic data often demonstrate skewness creating difficulties for analysis using traditional parametric
tests. In such cases the bootstrap method can be used to account for this expected skewness. Bootstrapping
samples observations with replacement a fixed number of times in order to generate a new population of
sample means with an approximate normal distribution. This allows for statistical analysis and the derivation
of CIs. Bootstrapping will resample the data using 10,000 replications with Stata software.
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To estimate the joint distributions of cost and QALYs, non-parametric bootstrapping was conducted on the
observed data.239 This non-parametric bootstrap resampling technique allows us to assess uncertainty in the
ICER.26 First, results of the bootstrapped cost and QALYs are presented on the cost-effectiveness plane.
To further evaluate the joint distributions of costs and benefits, a cost-effectiveness acceptability curve
(CEAC) was generated.240 The CEAC illustrates the probability that the health training intervention will be
cost-effective as decision-makers’ willingness to pay increases. According to NICE, the willingness to pay
for an additional QALY ranges between £20,000 and £30,000; the CEAC indicates the probability that
antenatal behavioural intervention is within this range.
Results
Resource utilisation and costs
The trial protocol was based on the delivery of eight sessions of health training to participants. Figure 9
presents patterns of engagement with sessions and how successful trainers were at setting goals. The
most common outcome is that participants received all eight sessions and, therefore, worked towards a
series of eight training goals. The second most common pattern represents early withdrawal. Overall, the
pattern suggests that the more face-to-face sessions received, the more likely that the participant would be
to receive eight training goals via either face to face or follow-up contacts.
Table 31 presents resource utilisation (by study group) in four main categories. The first category presents
average resources of the intervention (health training) and indicates the total number of patient contacts
in which at least one goal was set. The second component examines antenatal admissions and type of
admission (day case admission or overnight) and the related reason for admission. Third, resources related
to pregnancy cessation present either mode of birth or rate of miscarriage or termination. Finally, postnatal
admissions provide information on length of maternal admissions, rates of neonatal admission and neonatal
length of stay. All resource use data are presented either for the full sample (all available information) or
for complete cases (which informs the subsequent cost-effectiveness analysis).
Health training aimed to provide weekly 1.5-hour sessions for 8 weeks during the intervention period of
the study. Participants received an average of 5.37 contacts, in which at least one goal was set, of which
4.10 contacts occurred face to face and 1.27 were follow-ups (telephone or e-mail).
The most commonly reported reason for an overnight prenatal hospital admission was for ‘hyperemesis/
vaginal bleeding’. The most common day case was reported as related to trauma. Overall, the mean
number of inpatient nights was 2.754 (SD 2.398) in the control group and 2.824 (SD 3.462) in the
intervention group.
Pregnancy cessation was used in Healthcare Resource Groups (HRGs) categories; HRGs are commonly used to
inform reimbursement of hospital trusts and as such form the subsequent basis for cost-effectiveness analysis.
The most commonly recorded HRG mode of birth was normal delivery [comorbidities or complications (CC)
score = 0] (intervention, 24.3%; control, 23.9%), followed by emergency caesarean section (CC score 0–1)
(intervention, 16.1%; control, 19.4%). Rates of miscarriage (between 15 and 24 weeks) were low
(intervention, 1.3%; control, 0.9%) and likewise observed terminations (between 15 and 24 weeks) were
rare (intervention, 0.1%; control, 0.3%). Responses to EQ-5D questionnaires (required for complete case
analysis) are missing in all cases of miscarriage and termination; therefore, the figure was drawn from the
‘full sample’. No data about the end of pregnancy were missing in the intervention group (complete case
analysis); however, 0.5% of data were missing in the control group.
On average, maternal length of stay was similar to the national averages (intervention group, 2.123 days;
control group, 1.996 days). Mean rates of neonatal admissions demonstrate some differences between
groups (intervention 7.6% vs. control 4.1%); however, when compared in the full sample the difference
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diminishes (intervention 8.5% vs. control 7.5%), suggesting that this difference may be an artefact of
sample attrition. Mean neonatal length of stay displays similarities between groups (intervention 2.235
nights vs. control 2.096 nights), although inspection of conditional means (i.e. mean given a neonatal
admission) demonstrates interesting differences [intervention 12.951 nights (n = 61) vs. control 18.058
nights (n = 52)].
Table 32 presents unit cost data for each item of resource use. All unit costs are based on the NHS price
year 2012–13 to represent the halfway time point of randomisation into UPBEAT. The HTs providing
intervention were valued at the same rate as ‘clinical support worker (hospital)’. Specific costs were applied
for all antenatal admissions. The numbers of CCs used to inform specific to modes of birth were based on
either the presence of systemic comorbidities [pre-eclampsia, pre-existing hypertension, gestational
hypertension, cardiovascular disease, pre-existing diabetes mellitus, GDM (previous history or currently
diagnosed), genitourinary or general infection or existing mental health disorder] or labour complications
[preterm labour (< 37 weeks’ gestation), long labour (i.e. second stage > 4 hours) or postpartum
haemorrhage (blood loss of > 500 ml)]. Average bed stay post partum generally depends on mode of
delivery; however, the cost for ‘non-elective inpatient – long-stay excess bed-days’ is applied when the
maternal length of stay exceeds 2 days. Neonatal stay is incorporated into the cost of the mode of delivery;
however, neonatal admissions are treated separately. In the absence of further information from the trial,
all neonatal nights are assumed to be neonatal critical care, normal care.
Table 33 presents the total costs by study group, and subtotal costs (by item groups) and costs by specific
item. Again, to aid consideration of the implications of missing data, the results are further subdivided into
those drawn from the full sample and those available to inform the complete case cost-effectiveness analysis.
The mean cost of health training was £485 based on complete cases (n = 510). This is lower than would
have been expected based on the protocol description of the intended intervention (i.e. ‘eight group
sessions with the HT on a weekly basis, each lasting 1.5 hours’ equating to £624). However, when
compared with the intervention cost based on the full sample (£390) the complete case estimate is higher
and may be attributed to several potential factors (e.g. consumer preferences, attrition during intervention
due to the loss of the pregnancy, etc.).
Overall, aggregated costs of all antenatal admissions would seem significantly higher in the intervention
group (intervention £251 vs. control £177), although again, compared with results from the full sample
(intervention £189 vs. control £168), any difference may be related to underlying patterns of missing data.
As complete case data are contingent on the completion of the EQ-5D, the cost of pregnancy cessation
(for complete case analysis) excludes costs related to pregnancy loss and is solely based on the HRG mode
TABLE 32 Unit costs
Resource category
Unit
cost (£) Price year Reference
Health training
Clinical support worker (hospital) 52 2012–13 Personal Social Services Research
Unit’s Unit Costs of Health and
Social Care 2014, p. 249234
Antenatal hospital admissions
Asthma (per night) 709 2012–13 NHS Reference Costs 2012–13233
Asthma (day case) 407 2012–13 NHS Reference Costs 2012–13233
Hyperemesis/vaginal bleeding (per night) 659 2012–13 NHS Reference Costs 2012–13233
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TABLE 32 Unit costs (continued )
Resource category
Unit
cost (£) Price year Reference
Hyperemesis/vaginal bleeding (day case) 440 2012–13 NHS Reference Costs 2012–13233
Other (per night) 480 2012–13 NHS Reference Costs 2012–13233
Other (day case) 383 2012–13 NHS Reference Costs 2012–13233
Other medical (per night) 791 2012–13 NHS Reference Costs 2012–13233
Other medical (day case) 359 2012–13 NHS Reference Costs 2012–13233
Other obstetric (per night) 804 2012–13 NHS Reference Costs 2012–13233
Other obstetric (day case) 464 2012–13 NHS Reference Costs 2012–13233
Surgical (per night) 1613 2012–13 NHS Reference Costs 2012–13233
Surgical (day case) 229 2012–13 NHS Reference Costs 2012–13233
Trauma (per night) 2537 2012–13 NHS Reference Costs 2012–13233
Trauma (day case) 437 2012–13 NHS Reference Costs 2012–13233
Pregnancy cessation
Normal delivery with a CC score of 2+ 1804 2012–13 NHS Reference Costs 2012–13233
Normal delivery with a CC score of 1 1529 2012–13 NHS Reference Costs 2012–13233
Normal delivery with a CC score of 0 1325 2012–13 NHS Reference Costs 2012–13233
Normal delivery with induction, with a CC score of 2+ 2413 2012–13 NHS Reference Costs 2012–13233
Normal delivery with induction, with a CC score of 1 1987 2012–13 NHS Reference Costs 2012–13233
Normal delivery with induction, with a CC score of 0 1728 2012–13 NHS Reference Costs 2012–13233
Assisted delivery with a CC score of 2+ 2407 2012–13 NHS Reference Costs 2012–13233
Assisted delivery with a CC score of 1 2063 2012–13 NHS Reference Costs 2012–13233
Assisted delivery with a CC score of 0 1802 2012–13 NHS Reference Costs 2012–13233
Assisted delivery with epidural or induction, with a CC
score of 2+
2982 2012–13 NHS Reference Costs 2012–13233
Assisted delivery with epidural or induction, with a CC
score of 1
2449 2012–13 NHS Reference Costs 2012–13233
Assisted delivery with epidural or induction, with a CC
score of 0
2170 2012–13 NHS Reference Costs 2012–13233
Planned caesarean section, with a CC score of 4+ 4161 2012–13 NHS Reference Costs 2012–13233
Planned caesarean section, with a CC score of 2–3 3288 2012–13 NHS Reference Costs 2012–13233
Planned caesarean section, with a CC score of 0–1 2684 2012–13 NHS Reference Costs 2012–13233
Emergency caesarean section, with a CC score of 4+ 5302 2012–13 NHS Reference Costs 2012–13233
Emergency caesarean section, with a CC score of 2–3 4243 2012–13 NHS Reference Costs 2012–13233
Emergency caesarean section, with a CC score of 0–1 3414 2012–13 NHS Reference Costs 2012–13233
Miscarriage < 23+6 weeks of gestation 1708 2012–13 NHS Reference Costs 2012–13233
Termination for anomaly < 23+6 weeks of gestation 1282 2012–13 NHS Reference Costs 2012–13233
Postnatal hospital admissions
Non-elective inpatient – long-stay excess bed-days 450 2012–13 NHS Reference Costs 2012–13233
Neonatal critical care, normal care 471 2012–13 NHS Reference Costs 2012–13233
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of birth. Over all the varying modes of birth, the averaged cost is found to be identical (intervention £2177
vs. control £2177).
Costs associated with longer stays (i.e. more than two nights) are slightly higher in the intervention group
than in the control group (intervention £536 vs. control £432).
The cost related to neonatal stay was higher in the intervention group than in the control group
(intervention £187 vs. control £128). This may initially seem counterintuitive when considering that the
conditional mean length of stay was higher in the control group; however, the rate of neonatal admissions
in the intervention group was almost double that in the control group (7.6% vs. 4.1%, respectively),
meaning that over the entire observed sample costs were higher.
Outcomes
The EuroQol-5 Dimensions, three-level (EQ-5D-3L), scores at baseline, 20 weeks’ and 36 weeks’ gestation
are presented in Table 34. Comparing the two groups, scores are displayed as similarities across time
points and as an aggregated QALY.
Cost-effectiveness analysis
Table 35 presents the results of a seemingly unrelated regression. The model tests the joint distribution of
the effect of treatment (health training) on the incremental total costs and QALY, whether or not the
effects are significantly different from those in the control group and whether or not the cost and QALYs
are significantly correlated.
The results suggest that health training results in a non-significant mean increase in QALYs of 0.002 (95%
–0.004 to 0.009) and a significant increase in mean total costs of £722 (95% CI £473 to £970). The ICER
is £331,630/QALY.
To further explore uncertainty surrounding the ICER, Figure 10 presents results of the non-parametric
bootstrap (10,000 replications) on a cost-effectiveness plane.
TABLE 35 Results of the seemingly unrelated regression testing the effect of treatment (health training) on total
cost and QALYs
Variables Total costs (NHS perspective, £) (95% CI) QALY (95% CI)
Treatment 722 (473 to 970)*** 0.002 (–0.004 to 0.009)
Constant 2191 (1804 to 2578)*** 0.280 (0.267 to 0.290)***
***p< 0.001.
Notes
Correlation of QALYs and costs = –0.0669.
Breusch–Pagan χ2 = 4.794.
TABLE 34 The EQ-5D utility scores by group
Intervention group Baseline
Weeks’ gestation
QALY20 36
Intervention, mean (SD) 0.883 (0.169) 0.828 (0.185) 0.76 (0.222) 0.284 (0.054)
Control, mean (SD) 0.868 (0.17) 0.813 (0.19) 0.76 (0.207) 0.282 (0.056)
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To illustrate implications of uncertainty within the context of health care decision-making, the results of the
bootstrap analyis are further expressed on a CEAC (Figure 11). This suggests that, based on the available
information from UPBEAT, the probability that health training would be below NICE’s stated upper
threshold of willingness to pay (£30,000/QALY) is only 1%.
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FIGURE 10 Cost-effectiveness plane (10,000 replications).
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FIGURE 11 Cost-effectiveness acceptability curve illustrating the probability that the intervention is cost-effective at
increasing values of willingness to pay for an additional QALY.
DOI: 10.3310/pgfar05100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Poston et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
Summary of within-trial cost-effectiveness findings
The programme of care was estimated to cost, on average, £485 more per participant (based solely on
health training time) than routine care.
Participants allocated to the intervention group displayed a non-significant mean increase in QALYs of
0.002 (95% CI –0.004 to 0.009; p = 0.52).
Base case cost-effectiveness analysis found that the ICER was £331,630 per QALY. Accounting for
uncertainty in the ICER on a CEAC suggests that the probability that antenatal behavioural intervention is
below the £30,000/QALY willingness-to-pay threshold is 1%.
Based on total cost to the NHS provider and health gains (of the expectant mother), from randomisation
up until 36 weeks’ gestation, UPBEAT provides no supporting evidence to suggest that the intervention
represents value for money based on NICE benchmarks of cost-effectiveness.
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Chapter 7 Conclusions
This study developed a complex behavioural intervention through a three-phase approach; the conclusionsfrom the different phases and how each contributed to the final outcome are summarised below.
Phase 1: development phase
The programme commenced at a time of intense research activity in this field, a response to the growing
clinical burden of obesity and excessive GWG among pregnant women in developed countries. One of
the first activities was to review the current, expanding, literature in order to inform development of the
intervention, particularly in regard to successful approaches to behavioural change in previous studies of
healthy lifestyle interventions in pregnant women. We found a common issue to be the failure of prior
studies to evaluate changes in behaviour or its psychological determinants, as well as the provision of
inadequate detail of the intervention content. The conclusion that little could be learnt from previous studies
in terms of effective approaches reinforced our intention to systematically develop an evidenced-based
intervention based on known theory, and to pilot the intervention to evaluate all components and effects,
particularly change in behaviour, acceptability and its psychological determinants. To provide new insight
into means whereby we would target dietary behaviours, we asked 103 pregnant women, 38% of whom
were overweight or obese, to complete a questionnaire to identify determinants of gestational dietary
behaviour relating to the intended dietary components of the intervention. We were encouraged to find that
women whose diet was the least healthy had the strongest intentions to make the proposed changes in
their diet. Furthermore, and in contrast to the general population, we found no evidence of barriers to
dietary change, and that perceived benefits for the health of the mother and baby were the most likely
determinants of change. We also carried out semistructured qualitative interviews with obese pregnant
women that identified significant barriers to change in PA, particularly in relation to physical discomfort.
These also highlighted the already well-recognised issues around stigmatisation of obesity, and the
overarching importance of care to avoid inadvertently offending women when approaching them to take
part in the programme and throughout their involvement. Concern over the lack of any standardised
method of objective assessment of PA led us to address optimal methods for assessment of PA in pregnant
women. At the time, the most accurate validated devices were accelerometers worn on the waist, but the
cost of these was prohibitive for a large trial. We therefore undertook a study of 93 women comparing the
GT1M accelerometer, one of the most validated devices at the time, and the most accurate pedometer
available (CW701 Digi-Walker™ Pedometer) to determine whether or not the pedometer could be an
inexpensive option. This did not prove to be the case as the pedometer was insufficiently accurate in the
sample of overweight and obese pregnant women. For the purposes of the pilot trial it was concluded that
the accelerometer was the best option, and for the RCT we would need to revert to validated self-report
questionnaires, with the pedometers serving only as motivational devices for women in the intervention arm.
On the basis of the studies in phase 1, and the relevant literature on diet and PA to target insulin
resistance, we were well positioned to develop all components of the intervention, then evaluated in the
pilot trial.
Phase 2: pilot trial
As recommended by the MRC, any complex intervention should include a feasibility study, and the NIHR
understandably insisted that we show effectiveness of behaviour change before releasing funding for
phase 3. Our experience confirmed the pilot trial to be an essential prelude to the main trial. As elaborated
in Chapter 2, the most important conclusion drawn was that the intervention, delivered by HTs, led to a
change in all the dietary targets of the intervention – a reduction in GL and a reduction in free sugar
intake, and lower saturated fat intake. The reduction in GL achieved was similar to that which had been
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shown previously to improve glycaemic control in pregnant women with type 2 diabetes mellitus. Although
evaluated by self-report, the method, triple-pass 24-hour recall, was rigorous but also time-consuming,
and a shorter questionnaire was also used for the purposes of validation for the main trial. The objective
measure of PA failed to show any increase, although women self-reported an increase in walking. Since
pregnant women should be encouraged to adhere to the PA recommended in clinical guidelines, the PA
element of the intervention was not dropped. Other conclusions drawn from elements of the process
evaluation were that although most women found the intervention acceptable, some preferred one-to-one
sessions with the HT and that the time of day of delivery of the intervention should be made more amenable
to the daily lives of the women. We therefore accommodated these needs in revision of delivery of the
intervention. Although we had expected that recruitment to the study would not be easy, we had
underestimated the number of women who would refuse to take part. This had repercussions for funding
but, recognising during the pilot study that the trial recruitment period would need extending, additional
NIHR funding was secured ahead of need.
Phase 3: randomised controlled trial
This phase of the programme demonstrated that the UPBEAT intervention, a theoretically based intensive
complex intervention combining dietary and PA advice designed to reduce insulin resistance and achieve
changes in diet and PA in obese pregnant women and a modest reduction in GWG, was not associated
with a reduction in GDM or the delivery rate of LGA infants.
The lack of effect of the intervention on the primary maternal and neonatal outcomes was disappointing but
when viewed in association with the many other smaller trials84 and more recent large trials218 it is becoming
clear that behavioural interventions in unselected obese pregnant women may be ineffective in improving
clinically important outcomes. The health economic evaluation reinforced this conclusion. UPBEAT, being
the largest study in the world of a behavioural intervention in obese pregnant women, may thus provide a
turning point in research focus, with more emphasis being placed on preventing obesity/reducing the BMI of
women of reproductive age. The negative effect of the intervention runs the risk, however, of diet and PA
advice being sidelined. This is not our intention; the UPBEAT intervention, being successful in establishing
improved diet in obese pregnant women, could be a component of a combined intervention or of a different
approach. We know that women who have a diagnosis of GDM make rigorous changes to their diet which
improve their glycaemic control and clinical outcomes. The lack of effective prevention of GDM in this study
is likely to relate to an inadequate change of diet, as the effectiveness of a low-GI diet in the non-pregnant
population to improve glycaemic control is frequently reported. Much effort, including that of the UPBEAT
team, is now focused on early pregnancy risk assessment of obese women, to develop a screening test
which will identify, with better accuracy than current risk assessment, which women will develop GDM in
later pregnancy. This was the basis of the study reported in Chapter 3, in which we identified early second-
trimester clinical and biochemical markers from pregnant women who had taken part in the pilot trial that
showed good predictive potential for later development of GDM. This focus on risk assessment has now
been extended to the whole trial population, with the addition of measurement of the metabolome.241 On
the basis that knowledge of diagnosis leads to effective dietary change, we hypothesise that women who
are informed in the first weeks of pregnancy that they have a very high risk of GDM will be more likely to
make clinically effective dietary change. In this setting the UPBEAT intervention might lead to improved
outcomes or could be used in combination with a pharmacological intervention, such as metformin. In the
light of the failure of this and other behavioural studies to prevent adverse outcomes in obese women,84,193
and because of the cost which would be incurred by introduction of an intervention in all obese pregnant
women, we recommend that more focus should be placed on risk stratification in early pregnancy and
delivery of interventions to those most at risk.
Another important outcome of this study arose from our decision to standardise GDM diagnosis and adopt
the internationally accepted (IADPSG’s) criteria. These criteria are rigorous, as evidenced by the high rate
(25%) of GDM in the trial population. Using these criteria, there were many fewer LGA infants than
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expected from population estimates, which may relate to the number of women who received treatment
for GDM; this was more than twice that expected had the diagnosis been made on the basis of the
previous WHO criteria. While not confirmatory, this contributes to the growing need to formally evaluate
the IADPSG’s criteria in UK obese women, and to determine whether or not national adoption would
reduce the burden of disease. Again, health economic benefit could potentially be improved by screening
for diabetes mellitus using these criteria only among women designated as high risk in early pregnancy.
Changes in the diet of the mothers may have lasting effects on maternal health. Analyses of data from the
mothers at 36 months and from the mothers and infants at 6 months post partum has shown, for the first
time in any intervention study in obese women, continued improvement in diet and reduction in infant
measures of body fat at 6 months.242 The ongoing follow-up of the UPBEAT mothers and children will
determine whether or not the improvements in maternal diet and PA are maintained, and whether or not
the risk of obesity in the children is affected by improved health behaviours in the mother during and
after pregnancy.
The strengths of this study included the phased design, in accordance with national (MRC) recommendations
for complex interventions. The pilot study enabled very detailed assessment of diet and objective assessment
of PA, at a level which would have been feasible in the setting of a large-scale randomised trial, and also
determined the practical feasibility of every aspect of the trial. The delivery and content of the intervention
were based on a sound evidence base drawn from the behavioural intervention and clinical literature
with advice from a multidisciplinary team including obstetricians, a consultant midwife, a social scientist,
psychologists and a psychiatrist. In relation to the population studied, our deliberate focus was on women
from inner-city deprived populations who, worldwide, demonstrate a high prevalence of obesity and an
associated burden to health-care resources.
Cost-effectiveness findings
Health economic analysis
Provision of the intervention was estimated to cost, per participant, an average of £485 more than routine
care. Allocation to the intervention was associated with a non-significant increase in QALYs (0.002, 95% CI
–0.004 to 0.009; p = 0.52). Base case cost-effectiveness analysis found that the ICER was £331,630 per
QALY. Based on the total cost to the NHS provider and health gains from randomisation to 36 weeks’
gestation, UPBEAT provided no supporting evidence to suggest the intervention represented value for
money based on NICE’s benchmarks for cost-effectiveness.
Limitations of the study
There were some limitations. In phase 1, the study of dietary behaviours by questionnaire was carried out
mainly in women of higher socioeconomic status than the trial population, and the structured interviews
included some women with underlying pathologies who were not included in the trial population. A common
issue was the estimation of diet, which as in all large studies had to be by self-report. With the caveats of
self-report in mind, in the pilot study, phase 2, we undertook a rigorous but time-consuming evaluation using
triple-pass 24-hour recall. Data from the main trial confirmed similar changes using a more practical shorter
method. Because of the expense and practical issues of using accelerometers and downloading data for
objective measurement, PA was also by self-report. Another limitation was the number of women who
had to be approached in order to recruit the trial sample in phase 3. Although those women showed no
important demographic difference from the trial participants, this highlights reluctance of individuals who are
obese to take part in intervention trials or indeed in established health-care lifestyle programmes. It also
implies that the women who took part were the more motivated among the obese population to improve
their health. Once recruited, compliance was good, suggesting, as identified by our process evaluation, that
obese pregnant women will engage in a well-designed intervention.
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